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Abstract
Hypoxic-ischaemic encephalopathy (HIE) is a relatively common and potentially devastating form of
perinatal brain injury, associated with neurodevelopmental problems and mortality. HIE is an evolving
process and so there is a need for real-time, in-vivo measurements of brain oxygenation and metabolism
for clinical assessment in the first days of life, to detect those at risk of further brain injury who may
benefit from redirection of care.
This thesis describes the development of a broadband near-infrared spectroscopy (NIRS) system to
monitor changes in metabolism and haemodynamics in HIE infants at the cotside. This system uses
multiple wavelengths (λ = 136, 770-905nm) to monitor changes in concentration of the oxidation state
of cytochrome-c-oxidase (CCO) as well as haemoglobin oxygenation. Changes in the oxidation state of
CCO (oxCCO) are indicative of CCO redox state changes within mitochondria and therefore represent
oxygen utilisation. The 2-channel system incorporates a broadband source, optical fibres, spectrograph
and CCD. This set-up is flexible and robustly monitors changes in haemoglobin and oxCCO.
The system was developed specifically for the neonatal intensive care unit (NICU) and has been
demonstrated on 38 brain-injured newborn infants (28 with HIE). NIRS data were continuously collected
over the frontal lobe simultaneously with systemic data for multimodal analysis. This allows the study of
cerebral changes in response to global pathophysiological events. HIE was assessed by magnetic resonance
spectroscopy measurement of lactate to NAA ratio (Lac/NAA), the gold standard for neurodevelopmental
outcome.
Initially the analysis focussed on spontaneous hypoxias. The relationship between haemoglobin oxy-
genation and oxCCO during hypoxic events was significantly associated with Lac/NAA (n=22, r=0.51,
p=0.02). Further investigation of the dynamics of the cerebral changes during hypoxias found oxCCO
differences with injury severity that was not observed in haemoglobins (n=17). Finally, the relationship
between cerebral signals and systemic physiology was investigated with a multivariate statistical tech-
nique. A strong relationship between oxCCO and systemic changes indicated severe brain injury (n=11,
p=0.04).
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Chapter 1
Introduction
This chapter introduces the motivations behind this thesis and outlines its key aspects. The main clinical
motivation emerges from a severe disorder in newborn babies called hypoxic-ischaemic encephalopathy
(HIE) and the need for a brain tissue physiological monitor to assess the illness and its progression
to guide treatment. This chapter gives an overview of HIE and outlines the key specifications of a
monitoring instrument that uses broadband near infrared spectroscopy (NIRS) to quantify a unique
marker of cellular metabolism, cytochrome-c-oxidase (CCO). The final sections give a summary of the
subsequent chapters in this thesis and outlines my part in the work.
1.1 Motivation and Aims
This thesis is part of a collaboration between two teams at University College London (UCL): the
Multimodal Spectroscopy Group based in the Biomedical Optics Research Laboratory (BORL) and
researchers from the Institute of Women’s Health who are part of the Baby Brain Study based at
University College London Hospitals (UCLH). The Baby Brain Study was set-up to assess the relation
between magnetic resonance (MR) measurements of brain intracellular pH and brain perfusion, and
NIRS derived measurement of CCO in infants with acute brain injury, in particular those with neonatal
encephalopathy at term. The goal of the Multimodal Spectroscopy Group, led by Dr Ilias Tachtsidis, is
to develop clinically useful brain monitors, in particular focussed on the measurement of CCO to inform
on cellular metabolism. The ethos of the group is that the combination of physiological monitors will
paint a more accurate picture and give a better assessment of brain health.
In recent years, a collaboration between Professor Nikki Robertson at the Institute of Women’s Health
and the Multimodal Spectroscopy Group has led to the use of NIRS in a piglet model of HIE. Striking
results have found that the CCO signal has a strong relationship with MR spectroscopy (MRS) measured
biomarkers of cellular metabolism, and have also found that the CCO signal is significantly related to
subject survival [12].
There is a long history of NIRS research in the UCLH neonatal intensive care unit (NICU). As early
as 1988, Edwards et al. [69] used NIRS to monitor critically ill babies, and over the next 27 years this
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research has continued, for example on HIE babies [70, 71], as well as preterm infants [72].
This PhD thesis brings together and expands these previous works with the use of a broadband NIRS
system to measure CCO in the NICU for the first time. The focus of this PhD is to develop a novel
NIRS system capable of measuring CCO within a clinical environment on infants suffering from HIE; and
further, to investigate the hypothesis that the relation of the CCO signal to other physiological changes
will identify the severity of injury, which will aid clinical diagnosis and treatment in the first days of life.
More specifically, the objectives of this PhD are:
• To design and build a broadband NIRS system with the capability to monitor changes in the
oxidation state of CCO specifically for neonates.
• To demonstrate the use of the system in the NICU on babies with brain injury.
• To assess the capacity of the system to measure accurately the changes in metabolic CCO inde-
pendently of the haemoglobin signals.
• To develop and test analysis techniques to assess the ability of CCO to provide information on
neonatal brain injury.
• To gain insight into the potential of CCO as a useful biomarker of brain injury.
1.2 Clinical Introduction
Hypoxic-ischaemic (HI) injury occurs around the time of birth, however the injury can progress and evolve
for days afterwards. The best outcome biomarker following HIE is currently from magnetic resonance
spectroscopy (MRS) but this is only available after five days or longer following the acute brain injury,
and gives only a snapshot of the cerebral injury at a particular time and location. However, MRS
technology is only available in high-end clinics as it is very expensive to run. Electroencephalography
(EEG) is the most commonly used monitor to assess HIE, and it is a reliable predictor of outcome 6
hours of age, however there is a reduction in its predictive ability at 48 hours [5]. Therefore there is
an urgent need for an early biomarker of brain tissue injury severity in the first days of life, to fill the
gap between EEG and MRS. Chapter 2 gives more detail on the injury, its progression, treatment and
current clinical monitors.
1.3 Near-Infrared Spectroscopy Introduction
In 1977, Franz Jobsis discovered an optical window into living tissue in the near-infrared (NIR) spectrum;
light in the region of 650-1000nm travels through tissue and therefore it is possible to interrogate absorb-
ing compounds within the tissue. The strongest absorbers in this region are also clinically interesting;
haemoglobin in both oxygenated and deoxygenated (HbO2 and HHb) forms, and CCO.
NIRS systems are relatively simple: they essentially consist of a light source, which illuminates tissue,
and a detector, to record light that has travelled through and exits the tissue (the light can either travel
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through back-reflection or transmission across the tissue). The monitored changes in light attenuation
from the tissue are related to the changes in concentration of the absorbers within the tissue. It is
possible to calculate these changes by comparing them to the known absorption spectra of the absorbers,
this is done using the modified Beer-Lambert law (which is discussed in section 3.1). This technique
allows real insight into the haemodynamic and metabolic changes within tissue, such as the brain and
muscle, in a non-invasive, non-ionising, relatively inexpensive, portable manner.
Most commercial NIRS systems use 2-4 wavelengths of light to interrogate the tissue and resolve
changes in the concentrations of HbO2 and HHb. However, in order to accurately measure changes in
CCO, a compound that exists in much lower concentrations in-vivo, many more wavelengths are needed.
Broadband NIRS, which is defined here as a NIRS system using more than 100 wavelengths of light, has
therefore been used to record changes in this metabolic marker. Broadband NIRS requires a broadband
light source and spectrometer to detect the changes in attenuation across the entire NIR spectrum. A
clinical broadband NIRS system to monitor CCO has yet to be developed commercially and, although
many in-house systems exist, has never been used to monitor infants within an intensive care unit. This
challenge is addressed by this PhD.
Terminology
Note that in this thesis the term ‘NIRS’ will be used to describe the technique when HbO2 and HHb
are derived from 2-4 discrete wavelengths of light and ‘broadband NIRS’ will be used to describe the
measurement of HbO2, HHb and CCO using over one hundred wavelengths of light.
1.4 Cytochrome-C-Oxidase Introduction
NIRS measurements of CCO have the potential to yield crucial information about cerebral metabolism
and tissue oxygenation at the baby’s cotside. CCO is the terminal electron acceptor in the electron
transport chain, the final stage of oxidative metabolism. The CCO signal does not arise from changes in
concentration of CCO itself (the concentration of CCO is stable over a measurement period) but rather
from changes in its oxidation state. A unique copper dimer in the enzyme has an absorption peak around
835nm in its oxidised form, but not in its reduced state. Therefore broadband NIRS is able to resolve
changes in the oxidation state using the difference spectrum between the oxidised and reduced species
to obtain an indicator of the changes in the CCO redox state. A change in the redox state represents
a change in oxidative cellular metabolism which is dependent on tissue oxygen and glucose availability,
along with other factors such as cellular injury. Therefore monitoring the CCO redox state changes gives
an indication of changes in tissue oxygenation and metabolism at a cellular level.
A full literature review summarising the state of the art clinical measurements of CCO using NIRS
is provided in Chapter 4.
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Terminology
Previous publications, both pre-clinical and clinical, have referred to this signal as CytOx, aa3, CuA,
CCO and oxCCO. For clarity, in this thesis the term oxCCO is used to describe the NIRS measurement
of changes in the concentration of the oxidation state of cytochrome-c-oxidase, which arise from the
redox state-dependent changes in the NIR spectrum. Although the dominant chromophore in the NIR is
the CuA centre, other cytochrome redox centres and oxygen intermediates can contribute to this signal.
1.5 Thesis Overview
The thesis has eleven subsequent chapters. Briefly, the next three chapters cover the background to the
work, followed by two chapters which describe the instrumentation development and the experimental
design, then there are four results chapters and the thesis finishes with a discussion of further work and
a conclusion.
For the background chapters, Chapter 2 contains a medical background including an introduction to
the brain, its circulation, metabolism, and development, and HIE, from the aetiology to the treatment
and monitoring of the illness. In Chapter 3, a summary of NIRS is presented, including the fundamentals
of the technique, and the instrumentation and measurements involved. This chapter concludes with a
literature review of NIRS studies of HIE. A full literature review of the clinical NIRS-measured CCO
signal is given in Chapter 4. This covers the history of the measurement and the methods used to obtain
the signal, an evaluation of these methods and a full review of the neonatal and adult studies to date.
Chapter 5 covers the development of the new broadband NIRS system called CYRIL (CYtochrome-
c-oxidase Research Instrument and appLication), from the design considerations to the hardware and
software. The specification of the system is presented with some preliminary testing. Chapter 6 describes
the use of the CYRIL system in the NICU and the experimental design considerations. Also presented
in this chapter are details of the patients included in the studies.
The results chapters begin with Chapter 7 in which analysis of the broadband NIRS data recorded
in the NICU is performed to ensure a robust oxCCO signal. The depth sensitivity of the signal is
investigated. Assessment of the capacity of the multi-distance measurements possible with CYRIL is
also performed. Chapters 8 and 9 investigate the effect of spontaneous hypoxia on the cerebral NIRS
signals. This is done firstly by looking at the magnitude of the change of the signals for many events,
and then by assessing the physiology behind the dynamics of the changes. The final results chapter,
Chapter 10, looks at the relationship between each cerebral NIRS signal and the systemic physiology as
a whole, using a multivariate statistical technique.
The thesis closes with a brief overview of work currently in progress, and a discussion of the future
for this work in Chapter 11, and Chapter 12, which comprises a summary of the thesis and a discussion
of the results.
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1.6 Personal Statement
The work presented in this thesis can be separated into three parts:
1. The development of a broadband NIRS system to monitor changes in CCO in a clinical environment.
2. The demonstration of this system combined with multimodal monitors in the NICU to monitor
infants with acute brain injury.
3. The analysis of multimodal data using (three) different approaches to understand the CCO signal
in relation to brain injury severity.
Some of the work involved in this project is a collaboration by a number of individuals, therefore it
is important to acknowledge those involved and to highlight the work I carried out.
The first part was mainly carried out by myself, with the guidance of my colleagues in BORL. This
involved the selection and modification of optical components, bringing together the components to form
a system suitable for the clinic, the design of optical fibres and holders, the development of LabVIEW
software and preliminary testing and characterisation of the system.
The data collection in the neonatal intensive care unit (NICU) was mostly carried out by myself and
Dr Subhabrata Mitra, a neonatal registrar undertaking a PhD. Dr Mitra and I, with guidance from our
supervisors (Dr Ilias Tachtsidis, Dr Judith Meek and Professor Nikki Robertson), designed and set-up
the experiments, which involved integrating the NIRS system into the NICU environment, and collecting
systemic data. This work was supported by staff in NICU, particularly Dr Cristina Uria, Dr Giles
Kendall and Mary Dinan, who were involved in approaching parents for informed consent and helping
with the data collection. As well as data collection, I was responsible for maintenance and updates of
the system, ensuring good quality optical data collection, evaluation of optical data, synchronising the
NIRS and systemic data, creating a data processing procedure, and saving back-ups of the data securely.
I also provided technical support for other analysis, mainly involving designing Matlab programmes
to be used by other members of the team. My analysis initially focussed on spontaneous hypoxia events
and the CCO response to them (Chapters 8 and 9). The analysis was then expanded to examine the effect
of all systemic changes on the cerebral NIRS signals simultaneously using multidimensional statistical
analysis (Chapter 10). The entire team was involved in the discussion of the physiological implication of
our results.
Some of this thesis has been published in peer-reviewed journals. I have written three papers from
work directly produced for this thesis, and another which was carried out during this PhD, but is not
relevant here; this paper covers the analysis of data from a piglet study which was performed to assess
cerebral autoregulation impairment during anaesthesia. These publications are shown in Appendix B.
Dr Mitra is first author on another three papers from the neonatal data recorded.
Chapter 2
The Neonatal Brain and
Hypoxic-Ischaemic Encephalopathy
In order to understand neonatal brain injury one must first understand the brain under normal conditions,
in particular, its energy supply and energy usage. Then it is possible to understand the brain in context
of neonatal development and finally, neonatal brain injury. Accordingly, this chapter begins with an
overview of cerebral anatomy and, importantly, the cerebral circulation and cell metabolism. Finally,
we will look at brain development in-utero and perinatal brain injury; specifically hypoxic-ischaemic
encephalopathy, its causes, treatment and assessment.
2.1 Anatomy and Physiology of the Brain
2.1.1 The Nervous System
The human nervous system is the most complex achievement of the process of evolution. The anatomy
and physiology of some aspects of neural function are well understood, while others are the subject of
research in both the basic and clinical sciences.
The basic structural and functional unit of the nervous system is the neuron (or nerve cell or neurone)
and the human nervous system is estimated to contain 1010 neurons [73]. The function of the neuron to
respond to stimuli, transmit the resulting excitations to neurons or effector organs (e.g. muscle cells or
glandular cells) with the goal of conveying and receiving information. Neuron shape and size is diverse
but all neuron cells have a few characteristics in common: a cell body; with branching receptors known
as dendrites; a long nerve fibre, or axon; which carries information away from the cell body and which
may split into several branches, collaterals; and at the end of the axon specialisations called terminal
boutons occur, which transfer information to the dendrites of other neurons [73]. Figure 2.1 shows a
schematic representation of the basic structure of the neuron.
Neurons code information through changes in electrical energy. The neuron possesses a resting
potential across its membrane (between 60 and 70mV), the inside is negative with respect to the outside.
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Figure 2.1: Schematic of neuron structure (Pearson Education, 2012).
When a neuron is stimulated above a certain threshold level, there is a brief reversal of polarity, known
as the action potential. Action potentials propagate down the axon into the terminals. Transmission
of the potential between two neurons is chemical rather than electrical; the action potential releases
neurotransmitters from synaptic vesicles in the terminals, the neurotransmitters travel across the synapse
to bind to receptors on the dendrites of the next neuron. When the neurotransmitters bind to the
receptors they bring about a change in membrane potential which will either depolarise, to move towards
the action potential, or hyperpolarise to stabilise the cell.
The other major cellular components of the nervous system are neuroglia (or glial) cells which out-
number neurons by an order of magnitude. Neuroglia perform a range of different ancillary functions
essential for the functioning of neurons. The three main types of glial cells are:
• Oligodendrocytes which form the myelin sheath that surrounds many neuronal axons to increase
the conduction rate of action potentials.
• Astrocytes are involved with the neuronal connection to the cerebral vasculature. Some astrocytes
form ‘perivascular feet’ upon the walls of capillaries and mediate the transfer of chemicals between
the circulatory and nervous systems.
• Microglia which have a protective role in response to nervous system damage.
The nervous system is divided into the central nervous system (CNS), comprising the brain encapsu-
lated by the skull, and the spinal cord at the centre of the vertebral column, and the peripheral nervous
system (PNS), which consists of the nerves connecting the CNS to the rest of the body. The CNS is a
heterogeneous structure in terms of the distribution of nerve cell bodies and their processes. In the brain,
the grey matter (GM) is enriched with neuronal cell bodies while the white matter (WM) contains mostly
axons (which are myelinated, hence the term white matter) [73]. The nerve cell bodies are grouped by
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their anatomical connections and functions (e.g. motor neurons connected to a group of related muscles)
and hence share common pathways or tracts.
2.1.2 Anatomy of the Brain
The brain is divided into the cerebrum, brain stem and cerebellum. The cerebrum is split into two cerebral
hemispheres and the diencephalon; the brain stem comprises the mid-brain, pons and the medulla (see
Figure 2.2).
Figure 2.2: Major subdivisons of the brain viewed in sagittal section [1].
The brain stem sits on top of the spinal cord and, although it forms a small proportion of the
entire brain, it is crucially important [73]. Its centres control vital functions such as respiration, the
cardiovascular system and the level of consciousness.
The cerebellum is attached behind the brain stem by a large mass of fibres that connect the two parts
together. It has an outer cortex of grey matter with inner white matter. The cerebellum is primarily
concerned with the coordination of movement and operates at an entirely unconscious level.
The cerebrum (or forebrain) dominates the brain and is divided into two hemispheres which are, to
a large extent physically separate, although cross-connections do exist. The diencephalon lies above the
brain stem and comprises four parts, of which the thalumus is the largest. The thalumus plays a large
part in sensory, motor and cognitive functions and is connected extensively with the cerebral cortex.
Another important part of the diencephalon is the hypothalamus which is involved with the autonomic
nervous system, the limbic system and the neuro-endocrine system.
The large cerebral hemispheres have an outer cortex made of grey matter with underlying regions of
white matter like the cerebellum [1]. In addition to the cortex, buried in the white matter are several
subcortical masses of cell bodies (i.e. grey matter) collectively referred to as the basal ganglia. The two
halves of the cortex are separated by a deep midline cleft referred to as the great longitudinal fissure. The
outer cortex is folded into a complex series of ridges and fissures, known as gyri and sulci respectively,
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which increase the cerebral surface area. Some sulci are used as landmarks that divide each hemisphere
in four lobes; the frontal lobe, the parietal lobe, the occipital lobe and the temporal lobe (see Figure 2.3).
Certain areas of the cortex perform specific sensory or motor functions, for example: in the frontal lobe,
the gyrus immediately in front of the central sulcus contains the primary motor cortex which controls
movement at the highest level; on the other side of the central sulcus in the parietal lobe lies the primary
somatosensory cortex which is the terminal site for pathways carrying modalities of touch, pain and
temperature; the visual cortex is located in the occipital lobe; in the temporal lobe lies the auditory
cortex; and in the prefrontal cortex (at the front of the frontal lobe) cognitive functions of a high order
such as judgement and intellect are situated.
Figure 2.3: Diagram showing the functional regions of the brain (Pearson Education, 2011).
2.1.3 Extracerebral Tissue
Covering the brain are supportive and protective layers of bone and membrane. The brain lies within the
cranial cavity of the skull which provides protection from physical injury. The floor of the cranial cavity
consists of three fossae (holes) which accommodate particular parts of the brain and contains foramina
(small holes or channels) through which cranial nerves and blood vessels enter and leave [73].
Within the skull, the brain is covered with three layers of concentric membranes, the meninges, which
are (from outer to inner): dura mater, arachnoid mater and pia mater. Between the arachnoid and pia
mater exists the subarachnoid space through which cerebrospinal fluid (CSF) circulates. Figure 2.4 shows
an illustration of a section through the extracerebral tissue and the brain.
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Figure 2.4: Section through the skull, meninges and brain (Pearson Education, 2011).
2.1.4 Ventricular System
The brain contains an elaborate system of ventricles through which CSF flows; the brain is submerged
in this fluid [73]. It is produced in the chlorid plexus, which hangs from the roof of each ventricle, and
flows through the ventricles and finally into the subarachnoid space where it is absorbed into the venous
system. The CSF has a similar composition to blood plasma. It has many functions:
• The CSF allows the brain to exist in neutral buoyancy, which allows the brain to maintain a
high density without being impaired by its own weight (which would cut off blood supply and kill
neurons in the lower sections).
• The CSF cushions the brain and provides protection from sudden movements.
• The CSF is continually being produced and absorbed into the blood supply so it is able to carry
waste products from metabolism out of the brain. Recently, it has been discovered that the CSF
also penetrates along the blood vessels of the brain in order to remove the metabolic waste, this
has been coined the ‘glymphatic system’ in reference to its similarity to the lymphatic system and
the involvement of glia cells [74].
2.2 Cerebral Circulation
The brain is always active and therefore requires a large and reliable blood supply. Although accounting
for only ∼2% of the body’s weight, the brain receives ∼20% of arterial blood from the heart and generates
∼20% of bodily energy [1]. A constant flow of blood is needed as the brain does not store much oxygen
or glucose; it derives its energy almost entirely from the aerobic metabolism of glucose delivered by the
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blood.
2.2.1 Cerebral Vasculature
Arteries transport blood away from the heart, veins carry blood back to the heart and capillaries take
the blood to and from the exchange sites in the tissue. Blood is supplied to the brain through the pairs
of internal carotid and vertebral arteries, which are the sources for the anterior and posterior circulations
respectively. The anterior and posterior cerebral circulations are interconnected via the Circle of Willis
which acts as a safety valve to ensure blood supply to the entire brain if one of the arteries is occluded
(see Figure 2.5). Tree-like arteries that branch off the Circle of Willis deliver blood to the surrounding
tissues.
Figure 2.5: Major arterial supply to the brain viewed from below. The anterior circulation is shown in
dark red and the posterior circulation in light red. The Circle of Willis comprises the anterior communi-
cating artery (a.), the paired anterior cerebral, internal carotid, posterior communicating and posterior
cerebral arteries. Taken from [1].
The venous drainage of the brain stem and cerebellum roughly follows the arterial pattern to these
structures and can be separated into the superficial and deep subdivisions. The superficial system is
composed of dural venous sinuses, which have walls composed of dura mater as opposed to a vein.
Therefore the dural sinuses are located on the surface of the cerebrum. The deep venous drainage
is primarily composed of traditional veins inside the deep structures of the brain. Most of the blood
ultimately leaves the brain via the internal jugular veins at the base of the skull.
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2.2.2 Blood-Brain Barrier
Neural signalling within the central nervous system (CNS) requires a highly controlled environment [75].
The blood-brain barrier (BBB) protects the brain from harmful substances in the blood via a specialised
system of capillary endothelial cells. Unlike peripheral capillaries that allow relatively free exchange of
substance across the cell wall, the BBB strictly limits transport into the brain. The BBB ensures that the
brain is supplied with the required nutrients for proper function; glucose, essential amino acids, and some
electrolytes move passively through the endothelial cell membranes. Blood-borne metabolic wastes, such
as urea and creatinine, as well as proteins, certain toxins and most drugs are prevented from entering
brain tissue. The barrier is ineffective against fats, fatty acids, oxygen, carbon dioxide, and other fat
soluble molecules that diffuse easily through all plasma membranes; this explains why alcohol, nicotine,
and anaesthetics can affect the brain. The BBB can be disrupted in cases of brain injury such as HIE,
during sepsis or in prematurity [76].
2.2.3 Cerebral Autoregulation
In order to maintain a constant supply of essential nutrients to the brain at all times, autoregulation, the
ability to maintain its required blood flow despite fluctuations in blood pressure, is tightly controlled in
the brain. While all organs perform some degree of autoregulation, the brain is particularly sensitive to
over- and under-perfusion. Cerebral autoregulation is a homoeostatic mechanism that minimises devia-
tions in cerebral blood flow (CBF) when cerebral perfusion pressure changes [77]. Cerebral autoregulation
acts through vasomotor effectors that control cerebrovascular resistance. There is controversy over the
mechanisms governing cerebral autoregulation; the three main hypotheses regarding the mechanism are:
• The myogenic hypothesis suggests that the smooth muscle cells of cerebral vessels detect changes
in pressure across the inside and outside of the vessel walls, and respond by contracting or dilating
the vessel wall [78].
• The metabolic hypothesis is that the high neuronal activity causing variations in concentrations of
oxygen, carbon dioxide and other metabolites (such as adenosine) induce an increase in CBF [79].
• The neurogenic hypothesis states that blood vessel walls are controlled by nerves connected to
them [78].
Cerebral autoregulation can be assessed by comparing measurements of arterial blood pressure and
CBF. This has informed research in brain injuries, including those resulting from hypoxic-ischaemia (see
section 2.5), which have been shown to impair cerebral autoregulation [2, 72]. The normal autoregulatory
range will vary between infants and adults, healthy and injured brains [80]; Figure 2.6 depicts the
autoregulatory range in a preterm infant.
CHAPTER 2. THE NEONATAL BRAIN AND HIE 43
Figure 2.6: A schematic drawing of the CBF against the mean arterial blood pressure in the normal
cerebral circulation in the preterm newborn baby. The flat portion represents the autoregulatory plateau
where the slope is near zero. Below the lower threshold, blood flow falls more than in proportion to
pressure. The critical closing pressure (CrCP) depends on the intracranial pressure and on arterial
elasticity. The lower threshold is 30mmHg or less. There are no good estimates of the upper threshold.
It is reasonable to assume that the ischaemic threshold is around 50% of resting blood flow. Taken from
[2].
2.2.4 Blood Gases and Cerebral Blood Flow
Carbon Dioxide
Carbon dioxide (CO2) has a profound effect on CBF; hypercapnoea causes dilation of cerebral arteries
and arterioles and increases CBF, whereas hypocapnoea causes constriction and decreases CBF [81].
It has been demonstrated that in humans 5% CO2 inhalation causes a CBF increase of 50%, and 7%
CO2 inhalation causes a 100% increase in CBF [81]. Although several mechanisms involved in hyper-
capnic vasodilation have been proposed, the major mechanism appears to be related to a direct effect of
extracellular protons on vascular smooth muscle [82].
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Oxygen
The brain has the highest metabolic demand of all the organs and so acute hypoxia is a dilator of
blood vessels that produces marked increases in CBF [83]. Acute hypoxia causes an increase in CBF
via direct effects on vascular cells of cerebral arteries and arterioles. Hypoxia-induced drop in adenosine
triphosphate (ATP) levels causes hyperpolarisation and vasodilation [84]. In addition, hypoxia rapidly
increases nitric oxide and adenosine production locally, also promoting vasodilation [85].
2.3 Cell Metabolism
Cells produce and consume ATP for energy in the mitochondria which is the cell’s energy ‘powerhouse’.
Respiration is the production of ATP from glucose and oxygen, with carbon dioxide and water as by-
products. The cell produces energy when ATP is converted to adenosine diphosphate (ADP), releasing
energy. The entire process of respiration is carried out in three major states: glycolysis, the tricarboxylic
acid cycle (TCA, also known as the Kreb’s cycle or citric acid cycle) and oxidative phosphorylation (of
which the electron transport chain (ETC) is a part). The entire process is illustrated in Figure 2.7.
A mitochondrion is a double-membraned organelle that exists within most cells to produce ATP.
The organelle is composed of compartments that carry out specialised functions. These compartments
include the outer membrane, the intermembrane space, the inner membrane, the cristae and the matrix
(see Figure 2.7 for an illustration). The number of mitochondria within a cell varies between species
and cell type, for example red blood cells have no mitochondria whereas a neuron has a high density of
mitochondria as it requires a lot more energy.
2.3.1 Glycolysis
Glycolysis literally means the breaking down of glucose. Over a series of several steps, glycolysis breaks
down one molecule of glucose into two molecules of pyruvate. These reactions occur in the cytosol within
the cell cytoplasm.
glucose+ 2Pi+ 2ADP + 2NAD+ → 2pyruvate+ 2ATP + 2NADH (2.1)
where Pi is inorganic phosphate, and NAD+ and NADH are the oxidised and reduced forms of
nicotinamide adenine dinucleotide, respectively. During the sequence of reactions, some of the free
energy released is conserved in the form of ATP and NADH which is used in the subsequent processess.
2.3.2 Tricarboxylic Acid Cycle
There is a short step in between glycolysis and the TCA cycle: pyruvate is transformed into acetyl CoA:
pyruvate+NAD+ → acetylCoA+ CO2 +NADH. (2.2)
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Figure 2.7: Schematic of cellular metabolism with the electron transport chain and CCO expanded. CCO
is represented as complex IV. This diagram is limited to the carbohydrate metabolism (from glucose);
fat metabolism, also aerobic, is ignored. Chromophores that are measured by NIRS are highlighted in
yellow boxes.
The purpose of the TCA cycle is to release the energy shuttle molecules, NADH and FADH2 (the
hydroquinone form of flavin adenine dinucleotide (FAD)), from the free energy of pyruvate. The energy
shuttles can transport high energy electrons to the electron transport chain. To start the cycle, acetyl
CoA fuses with oxaloacetate to form citric acid. There is a series of further reactions, catalysed by
enzymes, that rearrange the carbon atoms in citric acid until oxaloacetate is formed again (hence cycle).
During these reactions energy is released to produce the electron shuttles, NADH and FADH2.
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The overall reaction that occurs during the TCA cycle is:
pyruvate+ 4NAD+ + FAD +GDP + Pi→ 3CO2 + 4NADH + FADH2 +GTP (2.3)
where GTP is guanosine triphosphate and GDP is guanosine diphosphate.
2.3.3 Oxidative Phosphorylation
Oxidative phosphorylation is the process where energy is harnessed through a series of protein complexes
(known as complexes I - V) embedded in the inner-membrane of mitochondria to create ATP. Figure
2.7 shows the position of these complexes within the inner-membrane. Oxidative phosphorylation can
be broken down into two parts: oxidation of NADH and FADH2 via complexes I - IV, known as the
electron transport chain (ETC), and phosphorylation, the production of ATP, at complex V.
Oxidative phosphorylation begins with the arrival of free electron carriers, NAD and FADH2, from
the TCA cycle which transfer electrons to Complex I and II. These electrons are passed to another
membrane-bound electron carrier called ubiquinol (Q) producing ubiquinone (QH2). QH2 is oxidised by
complex III and then to another electron carrier, cytochrome c (not to be confused with cytochrome-c-
oxidase which is also known as complex IV), which takes electrons to complex IV. Complex IV interacts
with oxygen, the final electron acceptor, and water is formed as oxygen receives the electrons. In other
words, cytochrome-c-oxidase is the enzyme that oxidises the substrate, cytochrome c, to complete the
electron transport chain:
4cyt c(Fe2+) + 4H+ +O2 → 4cyt c(Fe3+) + 2H2O. (2.4)
The process of oxidation at each of the complexes I, III and IV results in the pumping of protons
across the membrane from the matrix to the inner-membrane space. This creates a high concentration
of protons outside of the matrix and therefore an electrochemical gradient across the membrane. When
the concentration of protons is high then the protons are pushed through complex V, also called ATP
synthase, which causes ATP synthase to bind ADP to Pi, producing ATP.
2.3.4 Anaerobic Respiration
The processes described above depend on oxygen being present to oxidise pyruvate and receive electrons
from complex IV. If oxygen is not present then fermentation occurs. Fermentation starts after glycolysis,
replacing the TCA cycle and oxidative phosphorylation. The pyruvate is converted to lactate which forms
lactic acid. This is less efficient than aerobic respiration, in which 32 molecules of ATP are produced
from a single glucose molecule, as only 2 molecules of ATP are formed during glycolysis and before
fermentation. Further, the lactic acid needs to be removed from the cells and broken down which is
inefficient.
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2.3.5 Cerebral Metabolic Rate of Oxygen
The rate of cerebral oxygen metabolism (CMRO2) can be quantified by the difference between the rate
of flow of oxygen into the brain and out of the brain. This give a relationship with CBF which is derived
from Fick’s law:
CMRO2 = CBF ([O2]a − [O2]v) (2.5)
where [O2]a and [O2]v are the oxygen concentrations within the arteries and veins entering and leaving
the brain, respectively [86].
2.4 Brain Development
In order to understand injury in the neonatal brain, one must first understand the state of the brain
at birth. Brain maturation involves a complex sequence of functional, morphological and organisational
changes. In the period between 24 weeks gestation and full-term (between 37 and 42 weeks gestational
age(GA)) there are dramatic changes in the structure and physiology in the brain [3]. Therefore a baby
born preterm, or prematurely, between 24 to 37 weeks GA, will be at a very different state of neurode-
velopment to a term baby, and this will affect how the brain responds to both injury and treatment.
The largest and most obvious change in the brain between 24 and 37 weeks is the overall increase in
size [3]. The cortical layers form from the inside of brain moving outwards. The layers are formed by
neuronal migration along radial glial cells; this process is typically completed by 24 weeks GA. Between
29 weeks GA and term, the grey matter volume increases from approximately 60ml to 160ml [87]. As
well as the increase in size, there is also an increase in the number of cortical folds which eventually make
up the gyri and sulci (as can be seen in Figure 2.8); initially the brain is smooth in appearance but as
growth proceeds the folding pattern of the cortex develops allowing a considerable increase in the surface
area of the brain [3]. At 24 and 25 weeks GA white matter can be found; the origins of myelination of
the white matter cannot be observed until 35 weeks GA.
The cerebral circulation develops alongside these structural changes. The blood vessel density in-
creases with GA from 16 to 40 weeks with the most rapid increase between 28 to 36 weeks [88]. At 36-40
weeks GA, the grey matter has a similar vessel density to that of an adult brain which suggests that
cerebral vasculature in term infants is approaching maturity. Low vascularity in the preterm infant may
increase the propensity for brain injury.
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Figure 2.8: Magnetic resonance imaging (MRI) picture of cortical folding at 26 weeks GA (above) and
term (below) in the transverse (left) and sagittal (right) planes. Taken from [3].
2.5 Neonatal Brain Injury: Hypoxic-Ischaemic Encephalopathy
Neurological injury can be caused by many different disorders, including extrinsic disorders caused by
pressure on a part of the nervous system, intrinsic disorders which are primarily disorders of the nervous
system, systemic disorders that originate at another organ, and vascular disorders resulting from damage
to brain circulation. The damage from vascular disorders is usually caused by infarction (death of tissue)
due to a restriction in the blood supply, or haemorrhage (bleeding into nervous tissue). This section
discusses a form of acute neonatal brain injury that is the clinical focus of this thesis: hypoxic-ischaemic
encephalopathy (HIE).
2.5.1 Definition and Incidence
Neonatal brain injury caused by a HI event (perinatal asphyxia) is known as HIE. It is the result of
events during or before birth causing a reduction of oxygenation (hypoxia) and/or perfusion (ischaemia)
in the brain.
It is difficult to establish the incidence of HIE as different definitions are used in the literature. In
developed countries the incidence of HIE has been estimated to be 1.5 per 1000 live births [89]. A single
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centre study in UK revealed a fall in the incidence of HIE in term infants (1.9 vs. 4.6 per 1000 total
live births) over a 21 year study period alongside the fall in neonatal mortality rate (NMR) [90]. The
incidence in preterm infants is much higher [91] as is the incidence in developing countries [92].
HIE can lead to severe neurodevelopmental problems or to death. It accounts for 15-28% of cases of
cerebral palsy [93] and is responsible for a quarter of global infant mortality [92].
2.5.2 Aetiology
A baby in-utero has oxygen, necessary nutrition and life support from the mother delivered from the
placenta via the blood vessels in the umbilical cord. Waste products and CO2 from the foetus are sent
back through the umbilical cord to the mother’s circulation to be disposed of. The foetal circulation is
different to that of a newborn; blood does not need to flow through the liver or lungs for oxygenation
and metabolism as the mother provides these functions. The foetal heart acts as a one-way pump with
shunts called the foramen ovale and ductus arteriosus that bypass the lungs, and another shunt called the
ductus venosus to bypass the liver (see Figure 2.9). After birth, the neonate no longer receives oxygen
or nutrients from the umbilical cord. As the baby takes its first breaths, the lungs begin to expand and
clear of fluid. This creates changes in blood pressure that close the shunts which are no longer needed
and the heart becomes a two-way pump.
Figure 2.9: Schematic of foetal circulation. Taken from [1].
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During labour and the huge subsequent physiological changes, problems can occur that lead to as-
phyxia. During normal labour, uterine contractions will apply some degree of pressure to the umbilical
cord resulting in reduced blood flow to the foetus. Other factors during childbirth such as maternal
hyper- or hypoventilation, dehydration and a higher oxygen consumption from both mother and baby
can lead to a reduced oxygen delivery to the brain. If the mother has a pre-existing condition, such as
pre-eclampsia, or there is a complication during the birth, a cord accident for example, then dangerous
levels of asphyxia can be reached [94].
Ninety percent of asphyxia insults occur just before or during birth due to placental insufficiency; the
remainder happen postpartum, usually secondary to pulmonary, cardiovascular or neurological insuffi-
ciency. Intrauterine growth restriction and breech presentation are both associated with increased inci-
dence of asphyxia [94]. In the term infant, the most common mechanism of hypoxic injury is intrauterine
asphyxia brought on by circulatory problems, such as clotting of placental arteries or placental abruption,
or inflammatory processes. These result in perinatal depression leading to diminished exchange of O2
and CO2, and severe lactic acidosis [91].
During a hypoxic-ischaemic insult the brain is more easily damaged than other organs; neurons are
so specialised that most are incapable of reproducing themselves and they lose viability if in a hypoxic
environment for more than a few minutes [1]. Neurons do not build an oxygen debt like other cells
so cannot survive anaerobically. The brain will lose functionality if the oxygen supply is cut off for
more than a few minutes. The most susceptible sites for injury are: basal ganglia, thalamus, cortex,
subcortical white matter and the brain stem. These areas have increased metabolic rates, increased
glutamate receptors and are actively myelinating which increases their propensity to damage [3]. The
effects of hypoxia and ischaemia are not identical but they are difficult to separate clinically [95].
2.5.3 Clinical Presentation
All of the following must be present for the designation of perinatal asphyxia severe enough to result in
acute neurological injury (guidelines from the American Academy of Paediatrics and American College
of Obstetrics and Gynaecology, 1996):
• Profound metabolic or mixed acidemia (pH<7) in an umbilical artery blood sample.
• Persistence of an Apgar score (a scale determined by evaluating the newborn baby on five simple
criteria on a scale from zero to two, then summing up the five values) of 0-3 for longer than 5
minutes.
• Neonatal neurological sequelae (e.g. seizures, coma, hypotonia).
• Multiple organ involvement (e.g. kidney, lungs, liver, heart, intestines).
HIE can be categorised into three severities of injury, these are outlined in Table 2.1.
HIE is commonly presented with multi-organ dysfunction including heart, lungs, renal, liver and
haematologic.
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Mild HIE Moderate HIE Severe HIE
Muscle tone may be
slightly increased and
deep tendon reflexes may
be brisk during the first
few days.
The infant is lethargic,
with significant hypotonia
and diminished deep ten-
don reflexes.
Stupor or coma is typi-
cal. The infant may not
respond to any physical
stimulus.
Transient behavioural ab-
normalities, such as poor
feeding, irritability, or ex-
cessive crying or sleepiness
may be observed.
The grasping, Moro (re-
sponse to a sudden loss of
support), and sucking re-
flexes may be sluggish or
absent.
Breathing may be irregu-
lar, and the infant often
requires ventilatory sup-
port.
Typically resolves in less
than 24 hours.
The infant may experience
occasional periods of ap-
noea.
Generalised hypotonia
and depressed deep ten-
don reflexes are common.
Seizures typically occur
early within the first 24
hours after birth.
Neonatal reflexes (eg,
sucking, swallowing,
grasping, Moro) are
absent.
An initial period of well-
being or mild HIE may be
followed by sudden deteri-
oration, suggesting ongo-
ing brain cell dysfunction,
injury, and death during
this period, seizure inten-
sity might increase.
Disturbances of ocular
motion may be revealed
by cranial nerve examina-
tion.
Pupils may be dilated,
fixed, or poorly reactive to
light.
Seizures are delayed, can
be severe and may be ini-
tially resistant to conven-
tional treatments. The
seizures are usually gen-
eralised, and their fre-
quency may increase dur-
ing the 24-48 hours after
onset, correlating with the
phase of reperfusion in-
jury. As the injury pro-
gresses, seizures subside
and the EEG becomes iso-
electric (flat) or shows a
burst suppression pattern.
At that time, wakefulness
may deteriorate further,
and the fontanelle may
bulge, suggesting increas-
ing cerebral edema.
Irregularities of heart rate
and blood pressure are
common during the period
of reperfusion injury, as is
death from cardiorespira-
tory failure.
Table 2.1: The clinical presentation of HIE split into three injury severities. The definitions of HIE
injury severity are taken from [67].
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2.5.4 Progression
HIE is not a single event; it is an evolving process. There is an evolution of a delayed cascade of molecular
events triggered by the initial insult which is reflected in the clinical signs. Magnetic resonance imaging
(MRI) studies have shown progression of lesion size over the first few days after injury [91]; typically
starting as small lesions, and usually progressing over the days to involve larger portions of the brain.
Magnetic resonance spectroscopy (MRS) shows a similar pattern of progression, with an increase in lactic
acid (Lac), produced in anerobic metabolism, and a reduction of N-acetyl-aspartate (NAA), suggesting
neuronal loss, over the first few days after initial insult.
Research suggests the concept of a brief ‘therapeutic window’ between the time of insult and the
occurrence of cell death due to a cascade of molecular events [94]. (However, it is difficult to recognise
the onset of cerebral insult, and the diagnosis of asphyxia can be delayed; these problems restrict this
window of time.) HIE presents a biphasic pattern of cerebral energy failure; the first phase occurs during
the insult, primary energy failure, which is followed by re-perfusion and a period of cerebral recovery.
After a latent period of up to 24 hours, a secondary energy failure may occur which can cause severe cell
death and injury. Figure 2.10 shows a schematic of this process. During this latent phase there is the
potential for clinical intervention, however it is difficult to assess the severity of the initial injury.
Figure 2.10: Schematic of theorised changes in cerebral energy metabolism during HIE. Taken from [4].
The cascade of metabolic events during the initial phase of HI begins with a rapid depletion of ATP
leading to the failure of the cell ion pump and depolarisation of the cell. This causes severe cell swelling
and cytoplasmic calcium ion accumulation, leading to necrosis and activation of multiple cascades that
eventually lead to more cell death. In general, the form of cell death depends on the severity of ischaemic
injury. Necrosis predominates in more severe cases, whereas apoptosis occurs in areas with milder
ischaemic injury, often days after the initial insult [91].
Injury from HI is usually localised to particular regions or groups of structures within the brain as
opposed to manifesting as a global injury to cerebral tissue [96]. Predominant neural patterns of injury
have been discovered through analysis from primate studies and post-mortem neonatal studies. These
include: basal ganglia and thalamic injury, with possible hippocampal and brain stem involvement;
watershed predominant pattern of injury, affecting cortical regions related to anteriormiddle cerebral
artery and posteriormiddle cerebral artery (the vascular watershed zones); and less commonly, injury to
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the subcortical white matter and cortex [97]. There are several other patterns each relating to the original
localisation of brain injury. It is more likely that the pattern of regional cerebral injury is governed by
intrinsic properties of vulnerable neurones due to their positioning within the maturing excitatory neural
circuitry, rather than the pattern of vascular supply in the brain or cerebral blood flow [98].
2.5.5 Management
After identification of HIE from the presentation, the severity of the injury will be graded as mild,
moderate or severe with the Sarnat score (a staging system used to classify severity of HIE) which
combines clinical and EEG findings (although not necessarily EEG). There is an urgent need for a
clinical biomarker of brain injury to identify not only infants at risk, but also infants with an injury that
might evolve and thus might benefit from additional treatment [99].
A newborn presenting with HIE will be cared for in a Neonatal Intensive Care Unit (NICU). The man-
agement of HIE focuses on maintaining homoeostasis with respect to temperature, perfusion, ventilation,
glucose levels, fluids, etc. in order to maintain a normal metabolic state, brain pH and cerebral blood
flow [95]. Oxygen levels should be kept within a normal range by monitoring arterial partial pressure
of oxygen (PaO2) or oxygen saturation (SpO2) by pulse oximetry and treating hypoxia with oxygen or
ventilation. Likewise, CO2 should be kept to normal levels by continuous monitoring to prevent vasodila-
tion or vasoconstriction from hypercapnoea or hypocapneoa respectively. In order to maintain a constant
cerebral perfusion pressure (CPP), the arterial blood pressure (BP) needs to be tightly controlled, this
is usually measured with an arterial line. In HIE infants it is likely that the cerebral autoregulatory
mechanisms have been impaired so CPP will entirely reflect arterial BP. A CPP that is too high can
cause haemorrhage in areas of damaged blood vessels and a low CPP can lead to ischaemic injury. Blood
glucose levels should be controlled to provide adequate substrate for brain metabolism. High levels may
lead to elevation of brain lactate and hypoglycemia can lead to seizures.
If the baby is experiencing seizures, anticonvulsants (such as phenobarbitone) must be given as
seizures may cause further damage so need to be controlled effectively [95]. Seizures may be associated
with increased cerebral metabolic rate. A rise in BP during seizures may contribute towards cerebral
haemorrhage. Continuous EEG is used to monitor electrical activity.
Clinical trials are under way to test new treatments, such as inhaled xenon gas, and preclinical
studies are under-way looking at future neuroprotective agents. Currently the only treatment that has
been proved to be successful is therapeutic hypothermia (TH) which involves cooling the infant to 33.5◦C
for the first 72 hours after birth. This has been shown to reduce adverse outcome so is now standard
practice in the UK [100]. TH must be administered within 6 hours of birth to be effective; clinical trails
have shown that the earlier the cooling is commenced, the better the outcome. TH reduces cerebral
metabolism and protects mitochondrial function [101].
Premature infants have different neuroanatomy and neurophysiology which will affect how the infant
responds to injury and treatment. Most brain injury in the preterm infant occurs in the postnatal period
which can make detection of the insult difficult [94]. Logitharajah et al. [102] found that the outcome
for preterm infants with HIE is poorer than that expected for term HIE with only one-third of seventy
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infants studied having normal outcomes at two years of age. Therapies used in the term population need
to be evaluated thoroughly before being suggested for preterm HIE. TH is not currently used to treat
preterm infants with HIE.
2.5.6 Monitors
The techniques currently used to monitor the injured neonatal brain during the first days of life in the
NICU include EEG, cranial ultrasound and MRS. Here the benefits and limitations of these technologies
are discussed.
Magnetic Resonance Scanning
MR monitoring has become the gold standard for the study of neonates with encephalopathy or suspected
brain injury. The development of MR-compatible monitoring tools and incubators allow hospitals with
MR scanners to study sick infants that need continuous intensive care. Additionally, dedicated neonatal
coils have increased signal-to-noise ratio in these patients, producing high quality images and spectro-
scopic traces [103]. There are many different scan sequences and methods to study the newborn brain;
those which are relevant to neonatal encephalopathy are discussed here. Movement artefacts are the
biggest problem with this imaging modality and can render data uninterpretable [3].
In most clinical environments the MR scan will take place after the therapeutic hypothermia has been
completed (from day 4 of life onwards) and before the second week of life. This is the major drawback
of the technology as it only gives a snapshot of the injury at one time and it is not possible to monitor
the brain in the crucial early days post-partum. Furthermore, the MR equipment is expensive both to
purchase and operate.
Magnetic Resonance Imaging
Conventional anatomical T1 and T2 (so called due to the different relaxation times of protons)
weighted MRI sequences performed between 5 and 8 days after birth can help identify the pattern of the
injury which can predict outcome [3]. These sequences can show some of the causes of encephalopathy
such as haemorrhage, infarction, or congenital malformations. HI injury to grey and white matter can
be detected through T1 and T2 imaging depending on the time of imaging, the location of the injury,
and the underlying cause of the injury.
From 24 hours onwards diffusion tensor imaging is the most sensitive sequence to detect early is-
chaemic lesions [3]. Diffusion tensor imaging exploits the random motion of water in the tissue; the
diffusivity of the tissue is reduced in acute infarction. The localisation of the injury is best diagnosed
using diffusion weighted MRI [97].
Magnetic Resonance Spectroscopy
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Proton MRS (1H MRS) is the most sensitive technique to identify brain injury in the first 24 hours
of life [103]. In an injured brain, Lac levels will be elevated and NAA levels may be reduced (see
Figure 2.11); a high Lac/NAA ratio indicates predicted poor outcome at 18 months (i.e. death or severe
neurodevelopmental problems). The 1H MRS Lac/NAA is currently the gold standard for predicting
outcome as shown by the meta-analysis from Thayyil et al. [104]. The biggest drawback of MRS is that
it is limited to a single voxel in the brain and so the spectroscopy result may not reflect the location of
the greatest damage. MRS requires a dedicated team of physicists to collect and interpret the data, and
as such, many NICUs do not have access to MRS gold standard measurements.
Figure 2.11: MRS Lac/NAA is the gold standard for identifying poor outcome after HIE.
Other MR Techniques
Recent advances in scan sequences have resulted in a technique called arterial spin labelling (ASL)
which is able to measure CBF. ASL applies a magnetic label to the water molecules in flowing blood,
as the magnetic label enters the imaging slice it exchanges with tissue water and slightly alters the
image contrast. This gives a picture of the cerebral perfusion [105]. The Baby Brain Study is currently
investigating the ASL technique to assess if CBF is related to brain injury severity.
Electroencephalography
EEG is used clinically to grade the severity of injury. EEG monitoring is performed from the first day
of life after suspected brain injury. EEG uses multiple electrodes to record the brain’s spontaneous
electrical activity from the scalp. Serial EEG is a good indicator of outcome in the first 24 hours of life.
A very inactive or depressed EEG beyond 8-12 hours indicates poor outcome. An active EEG, or an
inactive EEG that recovers within the first 8 hours, are associated with good outcome [106] (see Figure
2.12).
Amplitude-integrated EEG (aEEG) is a valuable EEG technique for predicting long-term neurode-
velopmental outcome [107]. It gives a quick assessment of the brain’s function by displaying the cerebral
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function monitor (CFM) trace. The CFM is created by filtering and compressing EEG to reflect the
maximum and minimum EEG variations which shows long-term changes and trends in electrocortical
background activity. aEEG is used clinically to predict outcome as it is available in most hospitals. It is
more widely used than serial EEG as it is easier to apply (only 4 electrodes are required) and easier to
interpret the data.
Figure 2.12: Example of EEG in an infant with mild HIE. Taken from [5]. A: Recording at 6 hours from
birth with markedly suppressed amplitude and continuous discontinuity. B: Recording at 24 hours when
EEG findings have recovered, discontinuity seen only during quiet sleep.
Cranial Ultrasound
Cranial ultrasound is a readily available bedside tool for the assessment of cerebral structures and can be
repeated regularly as the HI injury evolves with time. It is a useful tool to exclude congenital anomalies
and other causes of encephalopathy, and to determine the timing of insult. The different patterns of
injury, whether the injury is specific to GM or WM, can also be identified using ultrasound and can
contribute to outcome prediction [108]. The initial scan following HI can be normal but the cortical
appearance can change as injury develops. It is relatively inexpensive, non-invasive, easy to operate and
can be used repeatedly at the cotside, however it cannot assess cerebral oxygenation, metabolism or
energetic state.
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Doppler ultrasound measurements of resistive index (RI) of the middle cerebral arteries can add more
information regarding the severity of HIE; severe HIE results in the loss of autoregulation resulting in
haemodynamic disturbance, which can be monitored with RI [109].
Near-Infrared Spectroscopy
NIRS has the potential to monitor cerebral changes in haemodynamics and metabolism at the cotside,
with an application process that is similar to EEG. This technique is non-ionising, easy to use, relatively
inexpensive and does not require dedicated physicists for operation or interpretation of results. A full
description of NIRS is covered in Chapter (3), including a literature review of the use of NIRS in HIE.
2.6 Summary
The brain is a very complex organ with high energy demand that needs to be constantly maintained;
disturbance to the energy supply can cause irreversible injury. Energy is produced through metabolism
which predominantly depends on a supply of glucose and oxygen which are delivered by the extensive
vascular network. Perinatal HI injury can lead to HIE which is a relatively common and severe injury
that can lead to death or life-long neurodevelopmental impairment, such as cerebral palsy. The injury
develops over the first days of life. There is a clinical need for a viable monitor of cerebral metabolism
and oxygenation during these crucial days to inform diagnosis and treatment.
Chapter 3
Broadband Near-Infrared
Spectroscopy
NIRS was first demonstrated on human tissue by Jobsis almost 40 years ago [110] when he discovered the
NIR translucency of tissue. It is a non-invasive, non-ionizing, portable medical technique that exploits
the high penetration of NIR light through biological tissue to interrogate its components. The technique
uses changes in the intensity of diffusely scattered NIR light through tissue to estimate the changes in
its optical properties. A change of the concentration of optical absorbers, or chromophores, within the
tissue results in a change of the optical properties of tissue. Thus it is possible to monitor changes in
the concentrations of such compounds in the NIR spectrum; the most physiologically interesting are
oxygenated- and deoxygenated-haemoglobin (HbO2 and HHb) and cytochrome-c-oxidase (CCO). The
fundamentals of the technique and its use in neonatal monitoring, in particular on infants with HIE, are
discussed in this chapter.
3.1 Fundamentals of NIRS
3.1.1 Light Transport in Tissue
When light travels through tissue it is attenuated due to a combination of scattering and absorption.
These effects depend upon the wavelength of light used, the absorbing compounds, or chromophores,
present in the tissue, and scattering due to the tissue structure and particle size. To characterise atten-
uation one must understand all of these effects individually before combining their effects.
Absorption
Absorption, in the simplest case of light travelling a short distance through an absorbing medium, was
characterised by Pierre Bouger in 1729. An absorbing medium has an absorption coefficient µa which
is defined as the probability over an infinitesimal path that a photon will be absorbed and is typically
expressed in cm−1. Bouguer observed that the proportion of light absorbed by the medium was always
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Figure 3.1: Attenuation of light through an absorbing medium.
the same, and in 1760 Johann Heinrich Lambert expressed it mathematically; for a medium of thickness
δd and absorption coefficient µa light with incident intensity I will be attenuated by δI, see Figure 3.1.
This is related via the following equation:
δI = −µa · δd · I (3.1)
which rearranges to
δI
I
= −µa · δd. (3.2)
If we assume that successive layers of material with thickness d absorb the same fraction of light, we
can integrate this expression:
ln I = −µa · d+ constant (3.3)
and also that when d = 0, I = I0 (the incident intensity) so the transmitted intensity I is given by:
I = I0e
−µa·d. (3.4)
This is the Lambert-Bouguer law. It can also be expressed in terms of log10 but this requires a change
in terminology. In base 10 logs, k is the extinction coefficient (also with units of cm−1):
I = I010
−k·d (3.5)
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and is related to µa by
µa = k ln 10. (3.6)
Attenuation A is defined as the ratio of the the incident to transmitted intensity. Attenuation
expresses the order of magnitude of the light loss and is dimensionless but has units of optical density
(OD). In the case where attenuation is solely due to absorption, we are able to derive an equation for
attenuation from 3.5:
A = log10 (
I0
I
) = k · d. (3.7)
In 1852 the Lambert-Bouguer law (3.4) was expanded by August Beer who found a link between the
absorber concentration c (molar) and the absorption coefficient:
µa = α · c (3.8)
where α is the specific absorption coefficient (usually quoted in molar−1cm−1) which represents the
probability of absorption for a unit concentration of a compound over the optical pathlength. Therefore
the combination of the Lambert-Bouguer law and the Beer law results in the Beer-Lambert law (in
natural logs):
I = I0e
−α·c·d (3.9)
which can be expressed in terms of the attenuation as:
A = α · c · d. (3.10)
The Beer-Lambert law can also be expressed in log base 10, but this requires another change in
terminology:
I = I010
−·c·d (3.11)
where  is the specific extinction coefficient, expressed in base 10 logarithm units, and is related to α
by:
α =  ln 10. (3.12)
In terms of attenuation, this is:
A = log10
I0
I
=  · c · d. (3.13)
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The Beer-Lambert law describes the attenuation of light travelling through a uniform medium con-
taining an absorbing substance. It predicts that light attenuation decreases exponentially with distance.
It is valid with many absorbing substances; each absorber contributes to the total absorption, this is
represented as:
A = 1 · c1 · d+ 2 · c2 · d+ ... =
∑
i
i · ci · d. (3.14)
Near-Infrared Window
Figure 3.2: The NIR window in tissue. Taken from [6].
The attenuation of light in tissue is complex as it is due to the absorption of many different chro-
mophores combined with multiple scattering events. In the absorption case, biological tissue can be
approximated as a homogeneous mixture of compounds with an overall absorption that is dependent on
the absorption coefficient and concentrations of those compounds.
In order to make measurements on tissue in-vivo and non-invasively, the light needs to penetrate the
tissue with an optical pathlength long enough to reach deep, interesting tissues (e.g. brain or muscle)
below the surface tissues and re-emerge to an external detector. Therefore we need to use a region of the
electromagnetic spectrum in which there is low absorption in tissue, and this exists in the near-infrared
(NIR) region. Water is a strong absorber in the ultraviolet (below 200nm) and far infrared regions (above
950nm) and light is strongly absorbed by haemoglobin below 650nm (see Figure 3.2); however within
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650-950nm there is what is known as a ’NIR window’.
Near-Infrared Chromophores in Tissue
As biological tissue is made up of approximately 80% water, it is important to be aware of its absorption
spectrum even within the ‘NIR window’. Figure 3.3 shows the specific extinction coefficient for water
across this window; between 650-900nm the extinction coefficient increases with wavelength but stays
very low relative to other chromophores (note that in Figure 3.3 the water spectrum is increased by 6
orders of magnitude). It is fortunate that the water absorption spectrum allows us a view into the tissue,
but we should be aware that the absorption of water in this region is neither negligible nor constant with
wavelength.
Figure 3.3: Extinction coefficient spectra for water, oxy-haemoglobin, deoxy-haemoglobin and oxidised
- reduced cytochrome-c-oxidase. Note that the water spectrum is multiplied by 106 to be visible. Taken
from [7].
The most interesting chromophores within this spectral range have absorption spectra that depend
upon their oxidation state: these are haemoglobin and cytochrome-c-oxidase. Haemoglobin exists in
the red blood cells and is the carrier of oxygen from the lungs to the rest of the body (i.e. tissues).
It is a complex protein with four iron-containing haem sites that can bind to oxygen and transport
it in the vascular system (this is discussed further in the next chapter). Its absorption spectra in
the visible and infrared is dependent on whether oxygen is bound to the haem group. This is why
oxygenated, arterial blood appears more red than the relatively more purple venous blood. Figure 3.4
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shows the haemoglobin absorption spectrum when oxygen is bound (HbO2) and without oxygen (HHb);
the spectrum of haemoglobin in the NIR changes as the saturation of oxygen increases. Note the point
at 800nm where the absorption does not change despite the saturation change; this is known as the
isosbestic point and can be used to monitor total haemoglobin levels.
Figure 3.4: Absorption coefficient spectra for haemoglobin at different values of oxygen saturation.
The curve for deoxy-haemoglobin corresponds to 0% whereas the curve for 100% corresponds to oxy-
haemoglobin. Taken from [8].
The other interesting chromophore in the NIR is cytochrome-c-oxidase within the mitochondria.
Mitochondria are described as the cell’s ‘powerhouse’ because they generate most of a cell’s energy
supply, ATP, from glucose and oxygen. CCO participates towards the end of a chain of reactions to
produce ATP; during the reaction its oxidation state is changed (i.e. it gains or loses an electron) as it
transports an electron to oxygen (as part of the electron transport chain, see Chapter 2.3). This change
in oxidation state is visible as a change in absorption spectrum (see Figure 3.3) but unlike haemoglobin
the total concentration of CCO does not change within the time of a measurement (in the order of hours)
so only the difference between the oxidised and reduced spectra is needed to monitor the oxidation state.
Figure 3.3 shows the difference (oxidised - reduced) spectra of CCO in the NIR. The oxidation state of
CCO (oxCCO) is a surrogate for tissue oxygen metabolism at the cellular level. A literature review of
clinical measurements of cerebral oxCCO is included in the next chapter (4), including a discussion of the
methods used to resolve the signal (section 4.3) and a summary of the work supporting the uniqueness
of the signal (section 4.4).
There are many other chromophores in the NIR in tissue, such as melanin, fat, collagen, etc. but
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these are assumed to remain stable during a monitoring period (in the order of hours of time). Their
absorption spectra are shown in Figure 3.2. A chromophore specific to babies is bilirubin, which is
the by-product of jaundice and is responsible for the yellow colour in jaundiced babies; bilirubin peaks
around 450nm and has low absorption beyond ∼525nm so does not interfere with the NIR window [111].
Scattering
Scattering effects are the largest cause of attenuation in biological tissue. Tissue heterogeneity causes
light to scatter, as scattering is caused by the mismatch of refractive indices at the boundaries between
tissue types and small particles within tissues. The size and shape of the structure will determine the type
of scattering event and the wavelength of light affected. Many factors such as the water concentration,
and temperature will affect the scattering of light. Refraction and reflection occur at the boundaries
between tissues, according to the ratio of the refractive indices of the tissues respectively.
Figure 3.5: Attenuation of light through a scattering medium.
The attenuation of light due to scattering can be described similarly to absorption. If we make the
same assumptions as with absorption (see Figure 3.5), then by analogy:
I = I0e
−µs·d (3.15)
where µs is the scattering coefficient which is the probability per infinitesimal path that a photon
will be scattered, and is typically expressed in mm−1. The measured I is position, area and direction
sensitive and only accounts for light that has not been scattered (i.e. when the scattering of the medium
is sufficiently low to prevent the detection of multiply-scattered light).
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A true description of light transport in tissue needs to take into account anisotropic scattering (i.e.
scattering that is not equal in all directions), which is a very complex problem. The anisotropy is
commonly characterised by the mean cosine of the scattering angle. This mean cosine of the scattering
angle is known as the anisotropy factor g and provides a measure of the mean direction of scatter. Most
tissues have a high g, which means that light scatters forward. When multiple scattering occurs (i.e. in
diffuse media), light rapidly loses directionality. It is then often useful to assume isotropic scatter where
the scattering coefficient has been reduced by a factor of 1 − g. This modified scattering coefficient is
called the transport scattering coefficient µ′s which gives directionality and is defined as:
µ′s = µs(1− g). (3.16)
3.1.2 Attenuation in Tissue
Tissue is a highly scattering medium [112]. By combining the effects of tissue absorption and multiple
scattering events it is possible to make a modification to the Beer-Lambert law (3.14):
A =
∑
i
1 · ci · d ·B +G. (3.17)
This equation is known as the Modified Beer-Lambert Law (MBLL). The scattering of light is taken
into account with an unknown scattering loss term G, and B is the dimensionless differential pathlength
factor (DPF) which is a multiplier to account for the increased optical pathlength within the tissue due
to scattering [113].
The effective mean optical pathlength β is the product of the geometric distance and the DPF, and
has units of length in cm:
β = B · d. (3.18)
The DPF is dependent on the wavelength of light as different wavelengths are scattered and absorbed
differently in tissue. The DPF has been measured experimentally for different tissue types [114] and
further the wavelength-dependency of the DPF has been quantified experimentally [115]. The DPF and
optical pathlength estimation is discussed further in section 4.3.
3.1.3 Differential Spectroscopy
The modified Beer-Lambert law cannot be used to measure absolute chromophore concentrations from
measured light attenuation because G is unknown. However, if it is assumed that G does not change
throughout the measurement period then it is possible to determine a temporal change in concentration
∆c from a measured change in attenuation ∆A.
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Figure 3.6: Schematic of a typical experimental set-up using differential spectroscopy. Taken from [9].
Figure 3.6 shows a typical measurement set-up to yield ∆A. For example for two chromophores,
HbO2 and HHb at one wavelength λj :
Aλj = log10
I0,λj
Iλj
= HHb,λj · cHHb · β + HbO2,λj · cHbO2 · β +Gλj .
(3.19)
Measuring at two times, t1 and t2 to get ∆Aλj (= ∆Aλj (t2)−∆Aλj (t1)) gives:
∆Aλj = log10
I0,λj (t2)
Iλj (t2)
− log10
I0,λj (t1)
Iλj (t1)
= HHb,λj ·∆cHHb · β + HbO2,λj ·∆cHbO2 · β +Gλj (t2)−Gλj (t1).
(3.20)
Assuming that there is no change in I0 over time and that there are no changes in losses due to
scattering effects (i.e. Gλj (t2)−Gλj (t1) = 0), the equation simplifies to:
∆Aλj = log10
Iλj (t1)
Iλj (t2)
= HHb,λj ·∆cHHb · β + HbO2,λj ·∆cHbO2 · β,
(3.21)
or in general terms [113]:
∆Aλj =
∑
i,λj
i,λj ·∆ci,λj · β. (3.22)
To solve for ∆c for two chromophores, two wavelengths are needed:
∆Aλ1
∆Aλ2
 =
HbO2,λ1 HHb,λ1
HbO2,λ2 HHb,λ2
∆cHHb
∆cHbO2
 · β. (3.23)
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and the solution is:
∆cHbO2
∆cHHb
 = 1
β
HbO2,λ1 HHb,λ1
HbO2,λ2 HHb,λ2
−1 ∆Aλ1
∆Aλ2
 . (3.24)
3.1.4 Broadband NIRS
To resolve changes in HbO2 and HHb from the differential spectroscopy equation (3.24) it is sufficient to
use just two wavelengths to solve for two unknowns. This is especially true if the wavelengths are chosen
to distinguish between the chromophores e.g. chosen either side of the isosbestic point (see Figure 3.4).
It is possible to use just two wavelengths because the differences between their absorption spectra are
distinct and they exist in large concentrations within tissue. In theory, it should be possible to resolve
for three chromophores (HbO2, HHb and oxCCO) with just three wavelengths. However, the oxidised
- reduced difference CCO spectrum has a relatively broad peak and further, CCO exists in tissue at
a much lower concentration than haemoglobin. Hence, it is difficult to accurately resolve changes in
oxCCO with only three wavelengths.
Broadband (or multi-wavelength) NIRS is therefore used to fully characterise the spectral attenuation
due to haemoglobin and oxCCO. Matcher et al. demonstrated in 1995 that using multiple wavelengths
improved the estimation of changes in oxCCO [48], and more recently this has been verified by many
more studies using broadband NIRS [52, 60, 61]. This can be described with a matrix solution to equation
3.22:

∆cHbO2
∆cHHb
∆coxCCO
 = 1β

HbO2,λ1 HHb,λ1 oxCCO,λ1
HbO2,λ2 HHb,λ2 oxCCO,λ2
...
...
...
HbO2,λn HHb,λn oxCCO,λn

−1 
∆Aλ1
∆Aλ2
...
∆Aλn
 (3.25)
See section 4.3 for more details regarding accurately resolving changes in oxCCO with broadband
spectroscopy, and section 4.4 for an evaluation of the broadband NIRS-measured oxCCO signal.
3.1.5 Spatially Resolved Spectroscopy
Spatially resolved spectroscopy (SRS) is a technique to resolve absolute concentrations of chromophores
using a solution to the diffusion equation which in itself is a special case of the radiative transfer equation.
The technique uses multiple detectors to resolve the change in attenuation at different distances. This
section begins with the derivation of, and solution to, the diffusion equation, and applies this to the SRS
technique.
Derivation of the Diffusion Equation
A more fundamental description of light transport through tissue is given by the Boltzmann transport
equation which describes the propagation of electromagnetic waves in scattering media. It is also known
CHAPTER 3. BROADBAND NIRS 68
as the radiative transfer equation (RTE) [9, 116]:
1
c
δL(r, sˆ, t)
δt
+∇L(r, sˆ, t)sˆ = −(µs + µa)L(r, sˆ, t) + µs
∫∫
4pi
L(r, sˆ′, t)f(sˆ · sˆ′)dΩ′ +Q(r, sˆ, t) (3.26)
where c is the speed of light, L(r, sˆ, t) is the radiance (units W/m2sr), sˆ is a unit vector pointing in
the direction of interest at the position vector r at time t, Q(r, sˆ, t) is the source term which represents
the power injected into a unit volume, dΩ is the solid angle, and f(sˆ, sˆ′) is the normalised differential
scattering cross section which satisfies:
∫∫
4pi
f(sˆ · sˆ′)dΩ′ = 1. (3.27)
The photons are treated as billiard balls undergoing elastic collisions travelling at speed c = (3.8 ×
108m/s)/n where n is the refractive index of the material. By integration over all solid angles and use
of the definitions of the source term S, fluence rate φ and the flux j the equation becomes [9, 116]:
1
c
δφ(r, t)
δt
+∇ · j(r, t) = −µaφ(r, t) + S(r, t), (3.28)
where
S(r, t) =
∫∫
4pi
Q(r, sˆ, t)dΩ
φ(r, t) =
∫∫
4pi
L(r, sˆ, t)dΩ
j(r, t) =
∫∫
4pi
L(r, sˆ, t)sˆdΩ.
(3.29)
When scattering is much stronger than absorption (µ′s  µa) i.e. a diffuse media, as it is in biological
tissue, the radiance is nearly isotropic and can be approximated as a combination of an isotropic fluence
rate plus a small directional flux [9, 116]:
L(r, sˆ, t) =
1
4pi
φ(r, t) +
3
4pi
j(r, t) · sˆ. (3.30)
Substituting this approximation into equation 3.26 and multiplying by sˆ and integrating over all solid
angles yields:
1
c
δj(r, t)
δt
= −1
3
∇φ(r, t)− 1
3D
j(r, t), (3.31)
where D is the diffusion coefficient and is given by:
D ≡ 1
3[(1− g)µs + µa] ≡
1
3[µ′s + µa]
. (3.32)
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In a steady state (i.e. δj(r,t)δt = 0) equation 3.31 becomes
j(r, t) = −D∇φ(r, t) (3.33)
which is analogous to Fick’s law of diffusion [9, 116].
The two relations between the fluence rate and flux (equations 3.28 and 3.31) can be combined to
give:
D∇2φ(r, t)− µaφ(r, t) = (1 + 3Dµa)1
c
δφ(r, t)
δt
− S(r, t) + 3D
c2
δ2φ(r, t)
δt2
− 3D
c
δS(r, t)
δt
. (3.34)
As stated previously, in most biological tissues the scattering coefficient is much greater than the
absorption coefficient hence both D and µa are small and therefore 3Dµa  1. If the source varies in
time with frequencies of less than ∼ 1GHz then the last two terms can also be neglected [9, 116]. This
leaves the diffusion equation:
D∇2φ(r, t)− µaφ(r, t) = 1
c
δφ(r, t)
δt
− S(r, t). (3.35)
Solution to the Diffusion Equation
Figure 3.7: Schematic of experimental set-up using spatially resolved spectroscopy. Taken from [9].
For a Dirac pulse from an isotropic point source (S(r, t) = δ(0, 0)) the solution to the diffusion
equation (equation 3.35) for an infinite and homogeneous medium is given by the Green’s function
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[9, 116]:
φ(r, t) = c(4piDct)3/2exp(− |r|
2
4Dct
− µact). (3.36)
It is then possible to apply this solution to the experimental set-up for SRS as seen in Figure 3.7.
From Fick’s law, the reflectance at the surface R is:
R(ρ, t) =
∣∣∣∣−D δδzφ(ρ, 0, t)
∣∣∣∣ (3.37)
which combined with equation 3.36 yields:
R(ρ, t) = (4piDct)3/2
1
µ′s
t(−5/2)exp(−
ρ2 + 1µ′s
2
4Dct
− µact). (3.38)
In the case of a continuous light source, such as in continuous wave NIRS,
R(ρ) =
∫ ∞
t=0
R(ρ, t)dt =
1
2µ′spiq2
(
1
q
+ µeff )exp(−µeffq) (3.39)
where
q =
√
(
1
µ′s
)2 + ρ2
µeff =
√
3µa(µa + µ′s).
(3.40)
If there is a large separation between the light source and detector then ρ is much greater than the
transport mean free path (z0 =
1
µ′s
), it is possible to simplify equation 3.39 [9, 116]:
R(ρ) =
µeff
2µ′spiρ2
exp(−µeffρ). (3.41)
Derivation of Equations for SRS
The attenuation in a semi-infinite slab geometry, as in Figure 3.7, is defined as:
A(ρ) = − log10R(ρ) = −
1
ln(10)
lnR(ρ). (3.42)
Substituting the expression derived for R(ρ) in equation 3.41 into equation 3.42, differentiating with
respect to ρ and letting µ′s ≈ µ′s + µa (from µ′s  µa) gives:
δA
δρ
=
1
ln(10)
(
√
3µaµ′s +
2
ρ
). (3.43)
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Using the set-up in Figure 3.7, it is possible to experimentally measure ( δAδρ ). To achieve the relative
magnitude of µa, an assumption regarding µ
′
s is made:
µ′s = k(1− hλ) (3.44)
which relates µ′s to wavelength via an unknown constant k and the slope of the wavelength dependency
of µ′s which is h and is set to 6.3× 10−4nm−1 [117]. Combining 3.43 with 3.44 leads to
kµa(λ) =
1
3(1− hλ) (ln(10)
δA(λ)
δρ
− 2
ρ
)2. (3.45)
Combining equations 3.8 and 3.12 gives µa = ln(10) ·  · c and therefore from equation 3.45 can be
used to solve for scaled concentrations of HHb and HbO2 using two wavelengths:
kcHHb
kcHbO2
 = 1
ln(10)
HHb,λ1 HbO2,λ1
HHb,λ2 HbO2,λ2
−1 kµa,λ1
kµa,λ2
 . (3.46)
To remove the unknown scaling factor k, we find the tissue oxygen saturation (also known as the
tissue oxygenation index (TOI)) which is the average percentage of oxygenated blood in the brain and
is related to oxygenation status, blood volume, flow changes and oxygen utilisation [9, 116, 117]:
TOI =
kHbO2
k(HbO2 +HHb)
× 100%. (3.47)
Figure 3.8: Schematic of SRS method. Taken from [10].
3.2 NIRS Instrumentation
There are many commercial and in-house built NIRS systems that are currently being used to monitor
changes in the concentrations of HbO2, HHb, and oxCCO, and/or TOI. These systems have many
similarities in terms of the instrumentation but also many distinguishing features that allow for different
applications. This section discusses those systems and also summarises the available commercial NIRS
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systems for neonatal monitoring. Continuous wave NIRS is focussed on here, although frequency domain
(FD) and time resolved (TR) NIRS are summarised briefly for completeness.
Essentially, a CW NIRS system consists of a continuous NIR light source coupled into tissue and
a detector to receive the diffuse reflected light emerging from the tissue at a short distance from that
source (see Figures 3.9 and 3.10 for illustrations). The three main components are therefore light sources,
detectors and a means to connect these between the device and the tissue.
Figure 3.9: A simplified NIRS schematic.
Figure 3.10: Schematic of continuous wave (CW) NIRS method. Taken from [10].
The key criteria when light sources are selected are illumination and stability. The radiated optical
illumination should be chosen to maximise signal-to-noise received at the detector, but the power should
not be so high so as to cause tissue heating which will distort the measurements but more importantly,
may cause discomfort or damage to the subject. Tissue safety limits must be adhered to (the patients
wear eye protection during monitoring so eye safety limits do not have to be adhered to). Stability of
the light source is important for the integrity of the measurement. A source with intensity fluctuation
will directly affect noise at the detector and temperature changes or emitter noise can lead to optical
drift (i.e. changes in the intensity of a specific wavelength over time).
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Most commercial NIRS systems use a small number of discrete wavelengths to evaluate changes in
HHb and HbO2 from the modified Beer-Lambert law 3.22 (see section 3.1). The different wavelengths
are switched on in sequence so only one detector is required to identify the resulting intensity from the
different wavelengths. The most widely used discrete light sources are laser diodes and light emitting
diodes (LEDs) [6], both based on semiconductor technology, as they provide narrow radiation spectra.
Laser diodes, based on stimulated emission, have a very narrow bandwidth (<1nm) so there is higher
confidence of the wavelength used in the algorithm, and are coherent which make focussing into fibres
simpler. However, laser diodes require large packing which is less suitable for miniaturisation. LEDs,
based on spontaneous emission, have larger bandwidths (typically 10-50nm) but are able to be produced
in smaller packaging and come in a wider range of wavelengths. In order to resolve oxCCO, a large
number of wavelengths is needed to accurately quantify changes in the NIR spectra. Broadband light
sources are therefore used in such systems, these are typically thermally-stable white light bulbs filtered
to the NIR region using appropriate bandpass filters.
On the detector side, when discrete sources are used it is satisfactory to use photodetectors without
spectrographs, however for broadband sources it is necessary to use spectrometers to record the entire
absorption spectrum. Photodetectors are normally based on the photoelectric effect (i.e. photon gen-
eration of free-charge carriers which are detected as an electronic signal). The most common detectors
in NIRS devices are photodiodes, photomultiplier tubes (PMTs), avalanche photodiodes (APDs) and
charge-coupled devices (CCDs). Photodiodes have a high dynamic range, are small and easy to use as
they do not require thermal or voltage stability, but have no internal signal amplification. APDs how-
ever, have moderate gains and dynamic range and also come in small packages. They require a stabilised
power supply and temperature control. CCDs are commonly used in combination with a spectrograph
for broadband NIRS as they provide spatial information (via an array of pixels) so can capture a spec-
trum of intensity across wavelengths. In a spectrometer, the light is passed through a system of lenses
or mirrors and diffracted at a grating or prism, all of which reduce the resulting intensity received at the
CCD; travelling through a spectrograph reduces the sensitivity, and therefore a high intensity source and
careful system design are needed to achieve good light throughput. All photodetectors encounter three
main types of noise [6]: shot noise, related to the quantum (discrete) nature of photons, is unavoidable
and is proportional to the square root of the signal intensity, so is more important at low light levels;
dark current, which is the current recorded when there are no photons from a statistical variation in the
number of electrons thermally generated, it can be controlled by lowering the device temperature; and
thermal noise, present in resistors internal and external to the detector due to the Brownian motion of
electrons.
The sources and detectors are either placed directly on the tissue (for small devices e.g. LEDs and
photodiodes) or the light is coupled to the tissue via fibre optics (for larger devices e.g. laser diodes
and PMTs) depending on their size and weight. In the cases where the light needs to be transported
to and/or from the tissue optical fibre bundles are used to guide the light. The fibres need to have a
high numerical aperture (NA) to collect the diffuse light from a wide range of angles and large bundle
diameter. Fibres have advantages in terms of safety as no electronic devices come into contact with the
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skin, and good fibre design will allow the device and subject to be far apart (metres away) which is
advantageous in clinical environments where bedsides can be crowded with monitors. However they can
be bulky and restrictive due to the fragile nature of fibres and the weight of fibre bundles, and are also
prone to coupling losses at junctions between the source/detector/tissue and the fibre. These losses are
avoided with direct placement of sources and detectors on the tissue.
Coupling the sources and detectors to the tissue is one of the most challenging aspects of NIRS
monitoring, especially in areas like the head where hair is a significant issue and in groups of patients,
such as babies, where movement is difficult to avoid [118]. Probe, or optode, design is therefore a huge
area of research [119] and it is important to design optodes and optode holders specifically for both the
subject and environment. Hair is a strong absorber of NIR light so it must be removed from under the
optode, one group has suggested fibre brushes to remove hair with the optode placement [120]. Changes
in pressure can cause artefacts during the measurement so another solution is the use of spring-loaded
optodes [121]. More typically, the optodes are attached with a supporting holder and double-sided tape,
bandages over the probes, or via head caps in the case of NIR imaging [6, 119].
Commercial NIRS systems and series include NIRO (Hamamatsu, Japan), OxyMon (Artinis, Nether-
lands), ETG (Hitachi, Japan), NIRScout (NIRx, USA), NIRSOptix (TechEn, USA), NTS Optical Imag-
ing System (Gowerlabs, UK), Imagent (ISS, USA), OEG (Spectratech, Japan), Brainsight (Rogue Re-
search, Canada) and LABNIRS (Shimadzu, Japan) [6].
Cerebral oximetry systems have had success in clinical environments [122]. These systems monitor
TOI and may not report changes in haemoglobin concentrations additionally. These systems use two or
more source-detector separations to resolve TOI via changes in attenuation with distance (see section
3.1.5 for theory). This either entails two or more sources with a single detector, or vice-versa. Commercial
oximeters include INVOS (Coridien, USA), CerOx (Ornim, USA), Equanox (Nonin, USA), and Fore-
Sight (CASMED, USA).
FD and TR NIRS systems are more complex machines that are able to calculate µ′s by measuring
the light intensity phase change through tissue, in the case of FD NIRS, and µ′s and µa from the time of
flight of photons with TR NIRS. Figure 3.11 shows schematically the methodology behind each technique.
Both domains require more advanced technology to measure phase and time of flight respectively so these
systems are more expensive and less commonly used than CW NIRS.
Figure 3.11: Different NIRS modalities. Taken from [6].
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Broadband NIRS Instrumentation: Spectrographs
In order to perform broadband NIRS a spectrometer is required. A spectrometer fundamentally consists
of an entrance slit for light input, collimating mirrors or lenses to reduce loss, a prism or diffraction
grating, and focussing mirrors or lenses to direct light onto the detector. A dispersive prism disperses
light into its wavelengths because the angle of refraction is dependent on the refractive index of a material
which in turn is dependent on the wavelength of light that is travelling through it. This means that
different wavelengths of light will travel at different speeds, and so the light will disperse into the colours
of visible spectrum, with longer wavelengths being refracted less than shorter wavelengths. A diffraction
grating diffracts light into its wavelengths through transmission or reflection of light through a series of
parallel ruled lines (see Figure 3.12).
Figure 3.12: Diagram of diffraction grating showing the diffraction of incident light at an angle θi
with reflected angle θr. Constructive interference occurs at the focus if the difference between the two
pathlengths of light (marked in red) is equal to an integer number of wavelengths (mλ).
The light of the same wavelength will constructively interfere at the focus (convergence at infinity)
when the difference between the pathlengths of light is equal to an integer number (m) of wavelengths
(λ). Figure 3.12 shows that for light incident at an angle θi and reflected at θr, the pathlengths differ
by the difference between the points CB and AD. These can be expressed in terms of the angles (note
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that the angle formed by CAB is equal to θi and the angle ABD is equal to θr):
CB = d sin θi
AD = d sin θr.
(3.48)
The difference between these must be equal to an integer number of wavelengths for constructive
interference:
CB −AD = mλ
d(sin θi − sin θr) = mλ.
(3.49)
A blazed grating is a special type of diffraction grating where the lines are separated by a sawtooth-
shaped cross section which is tilted at a blaze angle. The blaze angle can be chosen to maximise the
efficiency of a given diffraction order at a specific wavelength and therefore the grating achieves maximum
efficiency around this wavelength.
There are many different spectrometer types, the most common being mirror-based Czerny-Turner
designs which can be packaged into miniature spectrometers [123] (see Figure 3.13 for example system).
Larger lens-based systems, such as the one used in this PhD project (see section 5.2), are less compact
but have higher light throughput and a 2-dimensional optical plane which allows for multiple spectra
from multiple light sources to be resolved simultaneously.
Figure 3.13: Ocean Optics HR2000+ miniature spectrometer with Czerny-Turner design. Internal com-
ponents: 1) SMA connector 2) Slit 3) Filter 4) Collimating mirror 5) Grating and wavelength range 6)
Focussing mirror 7) Data collection lenses 8-10) CCD detector. Taken from HR2000+ manual (Ocean
Optics, USA).
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Broadband NIRS Instrumentation: CCDs
A CCD is made up of an array of metal oxide semiconductor (MOS) capacitors (pixels) which are read
out using the movement of electrical charge. Essentially, photons striking a silicon surface create free
electrons through the photoelectric effect and an associated positive charge or ‘hole’ is generated as a
consequence. If nothing else is done the hole and the electron will recombine and release energy in the
form of heat. Small thermal fluctuations are very difficult to measure and it is thus preferable to gather
electrons in the place they were generated and count them in some manner to create an image. This is
accomplished by positively biasing discrete areas to attract electrons generated while the photons come
onto the surface (this is shown in Figure 3.14). The substrate of a CCD is made of silicon, but photons
coming from above the gate strike the epitaxial layer (which is essentially silicon with different elements
doped into it) and generate photoelectrons. The gate is held at a positive charge in relation to the rest
of the device, which attracts the electrons to it. Because of the insulating layer (essentially a layer of
glass), the electrons cannot penetrate through to the gate, and are held in place by the positive charge
above them, this creates a ‘potential well’. The electrons build up in the potential well until the exposure
is complete up to the maximum depth of the well. To read the number of electrons at each well (or
pixel), the voltage (or potential) is shifted in one direction so that the electrons are moved along the
wells until they reach the end of the array. At the end of the array the electrons are pulled in the other
direction and read out by the camera electronics (‘digitisation’). In this way the computer can build
up a 2-dimensional intensity map (or image) of the incident light. Noise can be introduced by thermal
effects, shot noise, dark current, digitisation and erroneous signals from the camera electronics.
Figure 3.14: Simple diagram of a CCD pixel or MOS diode. In front-illuminated CCDs the light is
incident from the top of the diagram.
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3.2.1 NIRS Instrumentation for Neonates
Monitoring cerebral changes with NIRS on neonates is on one hand more challenging due to the the
fragile nature of infants; on the other hand it is simpler because neonates have thinner scalps and skulls,
so it is easier to transmit NIR light through to the cortex. Therefore the instrumentation at the optode
end needs to be specially adapted for neonatal studies.
The biggest challenge in NIRS monitoring is achieving adequate source and detector contact to the
tissue to ensure good light coupling. For adult devices contact can be improved by applying pressure
to the probes; however, for neonatal studies this is not possible because a baby’s head is very fragile,
and if the probes make the baby uncomfortable then he or she will move, so probes have to be carefully
designed to ensure effective light coupling without pressure. Furthermore, space on a baby’s head is
much more restricted as it is smaller.
Some commercial NIRS systems have optodes which have been developed specifically for use on
neonates: Fore-sight (Casmed, USA), INVOS 5100 C (Somanetics, USA), NIMO (NIROX, Italy), NIRO
100 and 200 (Hamamatsu, Japan), O2 C (LEA, Germany), OM-220 (Shimadzu, Japan), T.Ox (ViOptix,
USA) and TRS-20 (Hamamatsu, Japan) [124]. The neonatal probes are typically smaller, softer and
lighter than adult versions. Figure 3.15 shows an example of a neonatal NIRS sensor on a baby (INVOS
system).
Figure 3.15: INVOS probes on a neonate. Taken from INVOS Cerebral Oximetry Neonatal Sensor
website (Medtronic, USA).
3.3 NIRS Measurements
3.3.1 Typical NIRS Measurements
There is a lot of work using NIRS in human neonates and adults. The intention of this section is not to
review this work, but to briefly cover the use of NIRS in different environments and subjects to make the
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connection between the measurement and the application. It also covers some typical forms of analysis
of NIRS data. For more specific reviews of the literature, the use of NIRS in HIE neonates is covered in
the next section (3.3.2), and the measurement of CCO with NIRS in human neonatal and adult studies
is covered in sections 4.5 and 4.6, respectively.
NIRS measurements can be used in many different environments, subjects and areas of the body.
There is a large body of work on skeletal muscle measurements using NIRS to understand the physiology
of muscle oxygen consumption during exercise [125]. More relevant to this PhD are cerebral NIRS
measurements which have been performed in both clinical and psychological experiments. There has
been huge interest recently in functional NIRS (fNIRS) as an alternative to functional MRI (fMRI)
[126]. This section describes how NIRS measured signals can inform on physiology.
Interpretation of NIRS Signals
The most commonly used NIRS signals are changes in concentration of HbO2 and HHb. Changes in
these signals are from an arbitrary zero at the beginning of a measurement but can still inform on
responses to challenges or changes over time during pathophysiology. Furthermore, summing the two
haemoglobin signals gives a measure of changes in the total haemoglobin concentration (HbT = HbO2
+ HHb) which gives an approximation of the change in blood volume. Similarly, finding the difference
between the concentrations of the two oxygenation states of haemoglobin (HbD = HbO2 - HHb) provides
an estimation of the oxygen delivery to the tissue as it shows the mismatch between the oxygenated and
deoxygenated blood. Therefore the absorption spectrum of haemoglobin can be exploited to quantify
blood oxygen transport to tissues and further estimate the oxygen usage at the tissue.
These signals have been further exploited to quantify CBF and cerebral blood volume (CBV). It is
possible to use HbO2 as a tracer to calculate changes in flow from Fick’s law [127]; Fick’s law states that
the change in concentration of a tracer in a volume (i.e. HbO2 in the brain) is equal to the difference
between the rate of flow into, and out of, the volume. Therefore using fast changes in SpO2 by altering the
inspired fraction of oxygen (FiO2), it is possible to estimate CBF from the change in HbO2 concentration
in the brain. It is also possible to estimate changes in CBV using slower changes in SpO2 [128].
oxCCO is a chromophore of interest because of its potential to be a direct oxygen sensor due to
its position in the ETC and unique redox dependent absorption spectra [129]. It has the potential to
provide direct information on the state of cellular metabolism which adds information to the vascular
information from the haemoglobin species. The next chapter (Chapter 4) goes into detail about CCO
measurements and the physiology behind the signal.
The TOI signal is a combination of the oxygen saturation in the blood and the brain. A ‘normal’ TOI
in a healthy adult rests between 60-80% as it represents the average haemoglobin oxygenation across
the arteries, veins, and capillaries. A hypothetical argument can explain this range: assuming that the
total haemoglobin is made up of ∼25% arterial and ∼75% venous, and that at normal levels arterial
saturation (SaO2) is ∼98% and venous saturation (SvO2) is ∼70% yields an approximate TOI of 77%.
It can be shown by expanding equation 3.47 that the TOI is proportional to the arterial/venous volume
ratio and oxygen consumption, and inversely proportional to CBF [130]. The TOI measurement has
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the advantage that it is a percentage measure so it gives an assessment of tissue oxygenation that can
be directly compared between subjects, whereas the other NIRS measurements rely on challenges (e.g.
functional activation or changes in inspired gases) to provide context of the changes in concentration.
Functional NIRS
All of the cerebral measurements (HbO2, HHb, HbT, HbD, CBF and CBV) inform about oxygenation
and perfusion as well as oxygen consumption. This is particularly important in fNIRS which is looking
for changes in cerebral perfusion due to neuronal activation. As neurons do not have an internal reserve of
oxygen and glucose (required for metabolism) their firing causes a demand as neuronal excitation causes
changes in oxidative metabolism (neuro-metabolic coupling) which is related to neuro-vascular coupling
(NVC): blood vessel dilation causes an increase in CBF and CBV. The vascular response overcompensates
the metabolic demand and so there is an oversupply of oxygenated blood (functional hyperaemia) which
causes an increase in NIRS measured HbO2 and HbT, and HHb to decrease (as seen in Figure 3.16). This
is known as the haemodynamic response function (HRF). fMRI uses the blood-oxygen-level-dependent
(BOLD) contrast signal to observe the relative change in blood oxygenation (essentially via changes in
HHb) but cannot differentiate between the individual species as NIRS can.
Figure 3.16: Sketch of typical changes measured by fNIRS during a functional activation task. Taken
from [10].
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Neonatal NIRS
Despite the functional response being well understood in adults, the HRF in neonates has not been fully
characterised [126]. Both increases and decreases in HHb have been observed in fMRI and fNIRS studies
in neonates [11]. A longitudinal study of the HRF in rat pups until adulthood has shown that the HRF
evolves with age (see Figure 3.17). It was also observed that the neonatal HbT response correlated
with blood pressure but this was not observed in adults; this suggests immature cerebral autoregulation
in the neonatal brain impacts the cortical blood flow. The nature and cause of the inverted neonatal
functional response is still being debated. It has also been suggested that there may be superfluous
synaptic connections in younger infants which may play a role [131]. Nevertheless, it is important to be
aware of brain maturity when observing haemodynamic and metabolic responses in neonates.
Figure 3.17: Evolution of the HbT response to fore-paw stimulus in rats progressing from neonatal
response to adult response. Stimuli occur in the shaded region, p = postnatal day. Taken from [11].
Cerebral oximetry has become a popular technique in neonatal intensive care research [6, 124, 132].
Using the SRS method gives percentage assessment of cerebral tissue oxygenation so it has the potential
to be used in a way analogous to pulse oximetry, i.e. a defined limit in the tissue saturation, at which
clinical intervention is required (typically ∼85% in NICUs). A recent multi-centre randomised clinical
trial, SafeBoosC, in preterm infants has found that using NIRS-monitored cerebral oxygenation to guide
treatment, reduces the fraction of time that the infant is exposed to hypoxia [133], although it has not
been shown to improve the results from early biomarkers of brain injury [134].
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Optical tomography and topography techniques can provide information regarding the function and
health of the entire brain, and work on these techniques (particularly tomography) has focussed on
the neonatal brain due it its preferable optical properties and geometry. Optical topography produces
2-dimensional images of activated regions on the surface of the brain [135], while optical tomography
produces 3-dimensional images of the whole head, and therefore can identify changes occurring in deeper
tissues. Both techniques are performed using multiple sources and detectors to obtain data from multiple
light paths across the head. Whole-head optical tomography has been performed on neonates during
functional challenges [136], as well as in blood volume and oxygenation changes [137, 138]. Spontaneous
events, such as seizures, have been studied using optical tomography [139] and topography [140] in
neonatal populations.
NIRS Depth Sensitivity
Cerebral NIRS depends upon at least some of the NIR light both reaching the cerebral cortex and
returning to the surface from there, otherwise the measurements will only reflect scalp physiology. The
source-detector separation is key to ensure brain penetration. However it is not possible to measure
the signal depth experimentally. Therefore, light propagation models have been used to estimate the
sensitivity of NIRS measurements to the brain in the adult [141–143] and neonate [68, 144, 145] at different
source-detector separations. Due to the different geometries and tissue densities in adults and neonates,
there are differences in the propagation of light [68]. The cerebrospinal fluid has a large positive impact
on the sensitivity of absorption change in the brain [141] whereas the skull thickness has a negative impact
[142]. The thin skull and CSF layers in the neonate allow for more penetration of light into the cortex
[68, 145]. Monte-Carlo simulations of light transport through realistic adult head models (including
scalp, skull, CSF, grey and white matter) have found that 6% of the signal has travelled through grey
matter at a source-detector separation of 2cm [143]. In addition, computational modelling work from
Fukui et al. [68] suggests that while the white matter sensitivity in adults is almost negligible, even for
large (50mm) source-detector separations, the neonatal model shows high white matter sensitivity at as
low as 10mm separation. Another Monte Carlo-based simulation on anatomically accurate head models
has shown that source-detector distances greater than 8.4mm for adults, and 2.15mm for neonates, have
brain sensitivity greater than 5% [145]. Typical source-detector separations in adults and neonates are
3-4cm and 2-3cm respectively, so the simulation results suggest that these are sufficiently sensitive to
the brain, particularly the neonatal brain.
3.3.2 Clinical NIRS Monitoring of HIE
This section contains a literature review of NIRS monitoring of HIE. Table 3.1 presents a summary of
the literature covered in this section.
The first study to continuously monitor neonates with HIE using NIRS was performed in 1993 [21].
Babies with adverse outcome showed a decrease in CBV and oxCCO with age, whereas oxCCO remained
stable in healthy and good outcome HIE babies. A later study conversely saw that CBV and CBF
increased with age, especially in those with worse injury [71]. This is supported by the study by Grant
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et al. [146] who observed increased CBV and CMRO2 associated with brain injury. It is suggested that
the increased cerebral perfusion is due to increased brain activity [146] or impaired control of cerebral
haemodynamics [71]. However, lower CBF was seen in HIE neonates compared to controls [147] and in
more severe injury [148]. There is little consistency between results of studies of HIE with CBV and
CBF.
There is also no consistency across the cerebral oximetry studies of HIE. Five studies have found that
infants with an adverse outcome after HIE have higher TOI [149–152] or increasing TOI [153] (note that
infants were not treated with therapeutic hypothermia in this study) compared to those with normal
outcome; some studies saw lower TOI in those with adverse outcome [147, 148] or in infants with HIE
compared to age-matched healthy controls [154] (note that infants were not treated with therapeutic
hypothermia in this study); and two studies found no significant difference between infants with adverse
and normal outcomes [155] or in infants with HIE compared to age-matched healthy controls [146]. This
suggests that cerebral oxygenation is not related to injury severity in a consistent way and this may be
due to the heterogeneity of HIE injury, patients and treatment.
Therapeutic hypothermia (see section 2.5) is an important consideration in studies; cooling is known
to reduce optically measured CMRO2 and CBF [156] and so can confound conclusions reached about
HIE. As TH is standard treatment in the UK and many other western countries, analysis of NIRS
measurements during HIE must consider the effects of TH.
A study of HIE infants during inhaled oxygen challenges found the NIRS measured HbO2 and TOI
increased significantly less than in healthy controls (without TH) [154]. Further HHb declined to lower
levels in the HIE group. The authors suggest that due to hypoxia in the HIE group, more HHb was
oxidised during the challenge, but because flow is slower, more oxygen is released from the blood so the
increase in HbO2 is not as great.
There has only been one fNIRS study of HIE infants [157]; auditory stimuli were given to 22 HIE
infants in the first 3 days of life. The infants typically showed a decrease of HbO2 and HbT which is not
the expected response but has been observed in healthy neonates (see previous section 3.3). The authors
suggest this could be due to a ‘stealing of blood flow’ from the activated region if the probes are not
placed directly above the activation, or inhibitory synaptic activity.
A recent trend of neonatal NIRS monitoring is cerebral autoregulation assessment, and this is true in
HIE studies [158–162]. These studies typically measure cerebral autoregulatory vasoreactivity with the
haemoglobin volume index (HVx) which is the correlation between mean arterial blood pressure and HbT
and use this to identify optimum autoregulatory mean blood pressures (MABPOPT ). Children with long-
term neurological impairments tend to deviate from MABPOPT more than those without impairments
[158, 159].
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tu
d
e
in
te
gr
at
ed
E
E
G
in
an
as
p
h
y
x
ia
te
d
n
ew
b
or
n
d
u
ri
n
g
an
d
af
te
r
co
ol
ca
p
tr
ea
tm
en
t
H
IE
,
N
IR
S
,
aE
E
G
,
b
ra
in
co
ol
in
g
[1
63
]
C
a
se
re
p
o
rt
fo
r
o
n
e
H
IE
in
fa
n
t
b
ef
o
re
a
n
d
d
u
ri
n
g
h
y
p
o
th
er
m
ia
a
n
d
re
w
a
rm
in
g
m
o
n
it
o
re
d
w
it
h
N
IR
O
2
0
0
a
n
d
a
E
E
G
.
T
O
I
a
n
d
ti
ss
u
e
h
a
em
o
g
lo
b
in
in
d
ex
(T
H
I)
si
g
n
ifi
ca
n
tl
y
in
cr
ea
se
d
w
h
en
co
o
li
n
g
st
a
rt
ed
.
T
O
I
re
m
a
in
ed
st
a
b
le
d
u
ri
n
g
re
w
a
rm
in
g
.
T
H
I
d
ec
re
a
se
d
d
u
ri
n
g
co
o
li
n
g
a
n
d
th
en
in
cr
ea
se
d
a
g
a
in
a
ft
er
re
w
a
rm
in
g
.
T
h
is
su
g
g
es
ts
th
a
t
th
e
b
ra
in
m
et
a
b
o
li
sm
w
a
s
re
d
u
ce
d
w
h
ic
h
ex
-
p
la
in
s
th
e
st
a
b
le
ox
y
g
en
a
ti
o
n
d
es
p
it
e
ch
a
n
g
es
in
b
lo
o
d
vo
lu
m
e.
G
ra
n
t
(2
00
9)
In
-
cr
ea
se
d
C
B
V
an
d
ox
y
ge
n
co
n
su
m
p
-
ti
on
in
n
eo
n
at
al
b
ra
in
in
ju
ry
[1
46
]
N
IR
S
,
h
y
p
ox
ic
is
ch
ae
m
ic
in
ju
ry
(H
IE
),
st
ro
k
e,
n
eo
n
at
e,
C
B
V
,
C
M
R
O
2
D
o
F
D
N
IR
S
m
ea
su
re
m
en
ts
su
ch
a
s
S
O
2
,
C
B
V
a
n
d
C
M
R
O
2
h
av
e
th
e
p
o
-
te
n
ti
a
l
to
d
is
ti
n
g
u
is
h
b
ra
in
in
ju
ry
fr
o
m
th
o
se
w
it
h
n
o
n
-b
ra
in
is
su
es
a
n
d
h
ea
lt
h
y
co
n
tr
o
ls
?
M
ea
su
re
m
en
ts
w
er
e
a
cq
u
ir
ed
fr
o
m
u
p
to
4
d
iff
er
en
t
re
g
io
n
s
o
f
th
e
h
ea
d
fo
r
8
se
co
n
d
s
(r
ep
ea
te
d
3
ti
m
es
)
in
4
3
n
eo
n
a
te
s
(1
4
w
it
h
ev
id
en
ce
o
f
b
ra
in
in
ju
ry
).
S
O
2
n
o
t
a
se
n
si
ti
ve
m
a
rk
er
fo
r
b
ra
in
in
ju
ry
d
e-
ve
lo
p
m
en
t,
b
u
t
u
se
fu
l
d
u
ri
n
g
in
ju
ry
.
In
cr
ea
se
d
C
B
V
a
n
d
C
M
R
O
2
a
ss
o
ci
a
te
d
w
it
h
b
ra
in
in
-
ju
ry
.
In
cr
ea
se
d
ce
re
b
ra
l
p
er
fu
si
o
n
d
u
e
to
in
-
cr
ea
se
d
n
eu
ro
n
a
l
a
ct
iv
it
y
-
m
ay
n
o
t
b
e
se
en
o
n
E
E
G
if
u
n
sy
n
ch
ro
n
is
ed
.
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G
u
cu
ye
n
er
(2
01
2)
U
se
of
aE
E
G
an
d
N
IR
S
fi
n
d
in
g
in
n
eo
n
at
es
w
it
h
as
p
h
y
x
ia
d
u
ri
n
g
se
-
le
ct
iv
e
h
ea
d
co
ol
in
g
[1
64
]
P
er
in
at
al
as
p
h
y
x
ia
,
aE
E
G
,
h
y
p
ot
h
er
-
m
ia
tr
ea
tm
en
t,
N
IR
S
1
0
n
eo
n
a
te
s
w
it
h
m
o
d
er
a
te
o
r
se
ve
re
H
IE
w
er
e
st
u
d
ie
d
w
it
h
N
IR
O
2
0
0
.
M
ea
-
su
re
m
en
ts
w
er
e
ta
ke
n
b
ef
o
re
co
o
li
n
g
a
t
3
6
.5
◦ C
,
a
t
3
4
◦ C
d
u
ri
n
g
co
o
li
n
g
a
n
d
a
t
3
6
.5
◦ C
a
ft
er
re
w
a
rm
in
g
.
T
O
I
a
n
d
F
T
O
E
w
er
e
m
ea
su
re
d
.
S
u
b
je
ct
s
w
er
e
ev
a
lu
a
te
d
u
p
to
2
4
m
o
n
th
s
o
f
a
g
e.
L
ow
T
O
I
a
n
d
h
ig
h
F
T
O
E
b
ef
o
re
co
o
li
n
g
w
a
s
in
d
ic
a
ti
v
e
o
f
se
iz
u
re
s.
D
u
ri
n
g
co
o
li
n
g
th
es
e
p
a
ra
m
et
er
s
w
er
e
w
it
h
in
a
n
o
rm
a
l
ra
n
g
e
w
h
ic
h
co
u
ld
b
e
d
u
e
to
a
re
d
u
ct
io
n
in
b
ra
in
m
et
a
b
o
li
sm
a
n
d
C
B
F
b
ec
a
u
se
o
f
h
y
p
o
th
er
m
ia
.
T
h
er
e
w
a
s
n
o
re
la
ti
o
n
sh
ip
b
et
w
ee
n
T
O
I
a
n
d
F
T
O
E
le
v
el
s
d
u
ri
n
g
o
r
a
ft
er
co
o
li
n
g
.
A
n
co
ra
(2
01
3)
E
ar
ly
p
re
d
ic
to
rs
of
sh
or
t
te
rm
n
eu
ro
d
ev
el
op
-
m
en
ta
l
ou
tc
om
e
in
as
p
h
y
x
ia
te
d
co
ol
ed
in
fa
n
ts
.
A
co
m
b
in
ed
b
ra
in
am
p
li
tu
d
e
in
te
-
gr
at
ed
el
ec
tr
o
en
-
ce
p
h
al
og
ra
p
h
y
an
d
n
ea
r
in
fr
ar
ed
sp
ec
tr
os
co
p
y
st
u
d
y
[1
49
]
H
IE
,
aE
E
G
,
N
IR
S
,
h
y
p
ot
h
er
m
ia
,
T
O
I
1
2
n
eo
n
a
te
s
w
it
h
H
IE
w
er
e
st
u
d
ie
d
d
u
r-
in
g
co
o
li
n
g
w
it
h
N
IR
O
2
0
0
a
n
d
a
E
E
G
.
T
O
I
av
er
a
g
e
ca
lc
u
la
te
d
a
t
6
,
1
2
a
n
d
2
4
h
o
u
rs
.
T
O
I
a
t
1
2
h
o
u
rs
si
g
n
ifi
ca
n
tl
y
h
ig
h
er
in
in
fa
n
ts
w
it
h
a
d
ve
rs
e
o
u
tc
o
m
es
th
a
n
in
th
o
se
w
it
h
n
o
r-
m
a
l
o
u
tc
o
m
e.
T
O
I
w
a
s
a
ls
o
h
ig
h
er
a
t
6
a
n
d
2
4
h
o
u
rs
b
u
t
n
o
t
si
g
n
ifi
ca
n
tl
y.
P
ro
b
a
b
ly
d
u
e
to
lu
x
u
ry
p
er
fu
si
o
n
o
r
se
co
n
d
a
ry
en
er
g
y
fa
il
-
u
re
w
h
ic
h
ca
u
se
s
a
re
d
u
ct
io
n
in
co
n
su
m
p
ti
o
n
.
A
b
n
o
rm
a
l
a
E
E
G
w
a
s
p
ro
g
n
o
st
ic
a
t
a
ll
ti
m
es
.
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M
as
sa
ro
(2
01
3)
B
ra
in
p
er
fu
si
on
in
en
ce
p
h
al
o-
p
at
h
ic
n
ew
b
or
n
s
af
te
r
th
er
ap
eu
ti
c
h
y
p
ot
h
er
m
ia
[1
47
]
B
ra
in
,
H
IE
,
n
ew
-
b
or
n
s,
h
y
p
ot
h
er
-
m
ia
,
N
IR
S
A
S
L
-M
R
I
w
a
s
p
er
fo
rm
ed
in
th
e
se
co
n
d
w
ee
k
o
f
li
fe
o
n
te
rm
H
IE
n
eo
n
a
te
s
a
n
d
h
ea
lt
h
y
co
n
tr
o
ls
.
A
su
b
se
t
w
a
s
st
u
d
ie
d
w
it
h
N
IR
S
d
u
ri
n
g
a
n
d
a
ft
er
h
y
p
o
th
er
-
m
ia
.
M
R
I
sh
ow
ed
lo
w
er
C
B
F
in
th
a
la
m
u
s
in
H
IE
p
a
ti
en
ts
th
a
n
th
o
se
w
it
h
o
u
t
in
ju
ry
.
L
ow
er
ti
s-
su
e
ox
y
g
en
fr
a
ct
io
n
fr
o
m
N
IR
S
w
a
s
o
b
se
rv
ed
in
in
fa
n
ts
w
it
h
lo
n
g
-t
er
m
d
a
m
a
g
e
(i
n
ju
ry
o
b
-
se
rv
ed
o
n
M
R
I)
a
n
d
m
ay
b
e
d
u
e
to
p
se
u
d
o
n
o
r-
m
a
li
se
d
m
et
a
b
o
li
c
d
em
a
n
d
a
ft
er
ir
re
ve
rs
ib
le
b
ra
in
in
ju
ry
.
4
d
ay
s
o
f
co
o
li
n
g
d
ec
re
a
se
d
ti
ss
u
e
ox
y
g
en
fr
a
ct
io
n
.
W
in
te
rm
ar
k
(2
01
3)
N
IR
S
ve
rs
u
s
M
R
I
to
st
u
d
y
b
ra
in
p
er
-
fu
si
on
in
n
ew
b
or
n
s
w
it
h
H
IE
tr
ea
te
d
w
it
h
h
y
p
ot
h
er
m
ia
[1
48
]
B
ra
in
,
H
IE
,
M
R
I,
n
ew
b
or
n
,
N
IR
S
,
p
er
fu
si
on
T
h
is
st
u
d
y
a
im
s
to
d
et
er
m
in
e
th
e
co
r-
re
la
ti
o
n
b
et
w
ee
n
m
ea
su
re
m
en
ts
o
f
b
ra
in
p
er
fu
si
o
n
b
y
A
S
L
-M
R
I
a
n
d
N
IR
S
in
7
te
rm
n
eo
n
a
te
s
w
it
h
H
IE
.
2
N
IR
S
se
n
-
so
rs
w
er
e
p
la
ce
d
ov
er
ea
ch
si
d
e
o
f
th
e
fr
o
n
ta
l
lo
b
e
(o
n
th
e
n
ew
b
o
rn
s
fo
re
h
ea
d
)
a
n
d
re
co
rd
ed
co
n
ti
n
u
o
u
s
S
O
2
d
a
ta
d
u
r-
in
g
h
y
p
o
th
er
m
ia
a
n
d
re
-w
a
rm
in
g
.
N
ew
-
b
o
rn
s
u
n
d
er
w
en
t
M
R
I
1
-2
ti
m
es
w
it
h
in
th
e
fi
rs
t
7
2
h
o
u
rs
o
f
li
fe
.
C
M
R
O
2
es
ti
-
m
a
te
d
fr
o
m
N
IR
S
a
n
d
M
R
I.
S
tr
o
n
g
co
rr
el
a
ti
o
n
w
a
s
fo
u
n
d
b
et
w
ee
n
S
O
2
(N
IR
S
)
a
n
d
C
B
F
(A
S
L
-M
R
I)
.
N
o
d
iff
er
en
ce
b
et
w
ee
n
S
O
2
in
th
e
g
ro
u
p
s.
N
ew
b
o
rn
s
w
it
h
se
ve
re
H
IE
h
a
d
lo
w
er
C
B
F
a
n
d
ex
tr
a
ct
ed
le
ss
ox
y
g
en
(l
ow
er
ox
y
g
en
d
em
a
n
d
li
k
el
y
)
th
a
n
in
-
fa
n
ts
w
it
h
m
o
d
er
a
te
H
IE
.
N
IR
S
a
n
d
A
S
L
-M
R
I
u
se
d
in
co
n
ju
n
ct
io
n
h
av
e
th
e
p
o
te
n
ti
a
l
to
h
el
p
ta
il
o
r
n
eu
ro
p
ro
te
ct
iv
e
st
ra
te
g
ie
s.
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L
em
m
er
s
(2
01
3)
C
er
eb
ra
l
ox
y
ge
n
a-
ti
on
an
d
b
ra
in
ac
ti
v
it
y
af
te
r
p
er
i-
n
at
al
as
p
h
y
x
ia
:
d
o
es
h
y
p
ot
h
er
-
m
ia
ch
an
ge
th
ei
r
p
ro
gn
os
ti
c
va
lu
e?
[1
50
]
N
IR
S
,
H
IE
,
h
y
-
p
ot
h
er
m
ia
,
rS
cO
2
E
va
lu
a
te
s
p
re
d
ic
ti
ve
va
lu
e
o
f
N
IR
S
d
u
r-
in
g
h
y
p
o
th
er
m
ia
.
3
9
in
fa
n
ts
w
it
h
H
IE
st
u
d
ie
d
fr
o
m
b
ir
th
(b
ef
o
re
T
H
)
u
n
ti
l
re
w
a
rm
in
g
co
m
p
le
te
d
a
t
8
4
h
o
u
rs
o
f
li
fe
.
In
fa
n
ts
g
ro
u
p
ed
in
to
fa
vo
u
ra
b
le
a
n
d
a
d
ve
rs
e
o
u
tc
o
m
es
to
a
ss
es
s
p
re
d
ic
-
ti
ve
p
ow
er
o
f
N
IR
S
.
B
o
th
g
ro
u
p
s
h
ad
si
m
il
a
r
re
g
io
n
a
l
ce
re
b
ra
l
ox
y
-
g
en
sa
tu
ra
ti
o
n
(r
S
cO
2
)
b
ef
o
re
h
y
p
o
th
er
m
ia
a
n
d
rS
cO
2
in
cr
ea
se
d
w
it
h
p
o
st
n
a
ta
l
a
g
e
in
b
o
th
g
ro
u
p
s.
rS
cO
2
w
a
s
si
g
n
ifi
ca
n
tl
y
h
ig
h
er
in
g
ro
u
p
s
w
it
h
a
d
ve
rs
e
o
u
tc
o
m
e.
F
T
O
E
w
a
s
lo
w
er
in
a
d
ve
rs
e
g
ro
u
p
.
a
E
E
G
b
et
te
r
a
t
p
re
-
d
ic
ti
n
g
o
u
tc
o
m
e
th
a
n
rS
cO
2
b
u
t
co
m
b
in
ed
a
E
E
G
a
n
d
N
IR
S
g
iv
es
b
es
t
p
re
d
ic
ti
o
n
.
P
re
d
ic
-
ti
o
n
w
a
s
g
o
o
d
a
t
1
2
,
2
4
a
n
d
3
6
h
o
u
rs
o
f
li
fe
.
rS
cO
2
te
n
d
ed
to
in
cr
ea
se
to
le
ve
ls
o
f
n
o
rm
a
l
n
eo
n
a
te
s
b
et
w
ee
n
1
2
-2
4
h
o
u
rs
w
h
ic
h
m
ay
b
e
d
u
e
to
m
il
d
h
y
p
o
th
er
m
ia
ke
ep
in
g
m
et
a
b
o
li
sm
lo
w
.
H
ow
le
tt
(2
01
3)
C
er
b
ro
va
sc
u
la
r
au
to
re
gu
la
ti
on
an
d
n
eu
ro
lo
gi
c
in
ju
ry
in
n
eo
n
at
al
H
IE
[1
65
]
H
V
x
u
se
d
to
id
en
ti
fy
M
A
B
P
O
P
T
fr
o
m
rT
H
b
(I
N
V
O
S
)
a
n
d
M
A
B
P
in
2
4
H
IE
n
eo
n
a
te
s
fr
o
m
T
H
to
n
o
rm
o
th
er
m
ia
.
S
ig
n
ifi
ca
n
t
re
la
ti
o
n
sh
ip
b
et
w
ee
n
ti
m
e
sp
en
t
b
el
ow
M
A
B
P
O
P
T
a
n
d
b
ra
in
in
ju
ry
:
M
A
B
P
w
it
h
in
o
r
a
b
ov
e
M
A
B
P
O
P
T
w
a
s
a
ss
o
ci
a
te
d
w
it
h
d
ec
re
a
se
d
in
ju
ri
es
(a
s
m
ea
su
re
d
b
y
d
if
-
fu
si
o
n
te
n
so
r
M
R
I)
.
H
V
x
m
o
n
it
o
ri
n
g
sh
ow
s
p
o
te
n
ti
a
l
to
ta
rg
et
o
p
ti
m
a
l
h
a
em
o
d
y
n
a
m
ic
ra
n
g
es
to
su
p
p
o
rt
a
u
to
re
g
u
la
ti
o
n
a
n
d
p
re
ve
n
t
se
co
n
d
a
ry
in
ju
ry
.
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S
h
el
lh
aa
s
(2
01
3)
L
im
it
ed
sh
or
t-
te
rm
p
ro
gn
os
ti
c
u
ti
li
ty
of
ce
re
b
ra
l
N
IR
S
d
u
ri
n
g
n
eo
n
a-
ta
l
th
er
ap
eu
ti
c
h
y
p
ot
h
er
m
ia
[1
66
]
aE
E
G
,
H
IE
,
N
IR
S
,
T
O
I
1
8
n
eo
n
a
te
s
w
it
h
H
IE
w
er
e
m
o
n
it
o
re
d
w
it
h
N
IR
S
a
n
d
a
E
E
G
d
u
ri
n
g
h
y
p
o
th
er
-
m
ia
,
re
w
a
rm
in
g
a
n
d
n
o
rm
o
th
er
m
ia
.
S
u
b
je
ct
s
w
er
e
sc
o
re
d
fo
r
se
ve
ri
ty
o
f
in
-
ju
ry
b
a
se
d
o
n
M
R
I
sc
a
n
a
n
d
n
eu
ro
lo
g
i-
ca
l
ex
a
m
o
n
d
ay
4
.
C
er
eb
ra
l
rS
O
2
va
lu
es
a
t
a
n
y
st
a
g
e
d
id
n
o
t
p
re
d
ic
t
sh
o
rt
te
rm
in
ju
ry
se
ve
ri
ty
.
T
h
e
va
ri
-
a
b
il
it
y
(s
ta
n
d
ar
d
d
ev
ia
ti
o
n
)
o
f
sy
st
em
ic
rS
O
2
w
a
s
o
n
ly
p
re
d
ic
to
r
o
f
sh
o
rt
te
rm
o
u
tc
o
m
e
(l
ow
va
ri
a
b
il
it
y
p
re
d
ic
ts
w
o
rs
e
o
u
tc
o
m
e)
.
a
E
E
G
co
m
b
in
ed
w
it
h
sy
st
em
ic
rS
O
2
va
ri
a
b
il
it
y
w
a
s
th
e
b
es
t
p
re
d
ic
ti
v
e
m
o
d
el
.
S
h
el
lh
aa
s
(2
01
5)
A
n
E
va
lu
at
io
n
of
C
er
eb
ra
l
an
d
S
y
s-
te
m
ic
P
re
d
ic
to
rs
of
18
-M
on
th
O
u
t-
co
m
es
fo
r
N
eo
n
at
es
w
it
h
H
IE
[1
55
]
H
IE
,
aE
E
G
,
N
IR
S
,
ac
u
te
k
id
n
ey
in
ju
ry
,
d
ev
el
op
m
en
ta
l
ou
t-
co
m
e
E
va
lu
a
te
s
a
E
E
G
,
N
IR
S
a
n
d
a
cu
te
k
id
-
n
ey
in
ju
ry
a
s
p
re
d
ic
to
rs
o
f
H
IE
o
u
t-
co
m
e.
1
8
in
fa
n
ts
w
er
e
m
o
n
it
o
re
d
fo
r
fi
rs
t
7
2
h
o
u
rs
o
f
li
fe
.
N
IR
S
p
la
ce
d
b
i-
la
te
ra
ll
y
ov
er
p
a
ri
et
a
l
re
g
io
n
s.
P
re
se
n
ce
o
f
a
cu
te
k
id
n
ey
in
ju
ry
d
id
n
o
t
p
re
d
ic
t
o
u
tc
o
m
e.
a
E
E
G
w
a
s
p
re
d
ic
ti
ve
o
f
o
u
tc
o
m
e.
rS
O
2
n
o
t
d
iff
er
en
t
b
et
w
ee
n
th
e
g
ro
u
p
s.
D
eh
ae
s
(2
01
4)
C
er
eb
ra
l
ox
y
ge
n
m
et
ab
ol
is
m
in
n
eo
n
at
al
h
y
p
ox
ic
-
is
ch
ae
m
ic
en
-
ce
p
h
al
op
at
h
y
d
u
ri
n
g
an
d
af
-
te
r
th
er
ap
eu
ti
c
h
y
p
ot
h
er
m
ia
[1
56
]
C
er
eb
ra
l
b
lo
o
d
ci
rc
u
la
ti
on
,
S
O
2
,
C
M
R
O
2
,
N
IR
S
,
n
eo
n
at
al
H
IE
,
th
er
ap
eu
ti
c
h
y
-
p
ot
h
er
m
ia
1
0
n
eo
n
a
te
s
w
it
h
H
IE
a
n
d
1
7
h
ea
lt
h
y
co
n
tr
o
ls
w
er
e
st
u
d
ie
d
fo
r
th
e
fi
rs
t
d
ay
s
o
f
li
fe
.
T
h
e
H
IE
in
fa
n
ts
w
er
e
st
u
d
-
ie
d
d
u
ri
n
g
h
y
p
o
th
er
m
ia
,
re
w
a
rm
in
g
a
n
d
a
ft
er
n
o
rm
o
th
er
m
ia
.
C
M
R
O
2
,
C
B
F
,
C
B
V
a
n
d
S
O
2
w
er
e
m
ea
su
re
d
w
it
h
F
D
N
IR
S
a
n
d
D
C
S
.
C
M
R
O
2
a
n
d
C
B
F
w
er
e
lo
w
er
d
u
ri
n
g
h
y
-
p
o
th
er
m
ia
th
a
n
p
o
st
-h
y
p
o
th
er
m
ia
a
n
d
in
th
e
co
n
tr
o
ls
.
C
B
V
a
n
d
S
O
2
w
er
e
h
ig
h
er
d
u
ri
n
g
h
y
p
o
th
er
m
ia
.
CHAPTER 3. BROADBAND NIRS 92
P
en
g
(2
01
4)
D
o
es
N
IR
S
id
en
ti
fy
as
p
h
y
x
ia
te
d
n
ew
-
b
or
n
s
at
ri
sk
of
d
ev
el
op
in
g
b
ra
in
in
ju
ry
d
u
ri
n
g
h
y
p
ot
h
er
m
ia
tr
ea
t-
m
en
t?
[1
51
]
B
ir
th
as
p
h
y
x
ia
,
H
IE
,
M
R
I,
m
et
ab
ol
is
m
,
N
IR
S
,
n
ew
b
or
n
b
ra
in
,
p
er
fu
si
on
1
8
n
eo
n
a
te
s,
m
o
n
it
o
re
d
rS
O
2
d
u
ri
n
g
co
o
li
n
g
,
re
w
a
rm
in
g
a
n
d
a
ft
er
w
a
rd
s,
se
n
-
si
ti
v
it
y
/
sp
ec
ifi
ci
ty
a
n
a
ly
si
s
to
a
ss
es
s
p
re
d
ic
ti
ve
p
ow
er
.
H
ig
h
er
rS
O
2
d
u
ri
n
g
fi
rs
t
1
0
h
o
u
rs
in
se
ve
re
in
-
ju
ri
es
,
m
o
re
se
n
si
ti
v
e
a
n
d
sp
ec
ifi
c
th
a
n
a
E
E
G
a
t
p
re
d
ic
ti
n
g
a
d
ve
rs
e
o
u
tc
o
m
e.
N
o
ch
a
n
g
e
in
ox
y
g
en
a
ti
o
n
d
u
ri
n
g
re
w
a
rm
in
g
.
rS
O
2
in
-
cr
ea
se
d
d
u
ri
n
g
fi
rs
t
2
d
ay
s
o
f
li
fe
th
en
st
a
-
b
il
is
ed
in
b
o
th
g
ro
u
p
s
(a
d
ve
rs
e/
n
o
rm
a
l
o
u
t-
co
m
e)
.
H
ig
h
er
rS
O
2
in
a
d
ve
rs
e
o
u
tc
o
m
e
m
ay
b
e
d
u
e
to
d
ec
re
a
se
in
u
ti
li
sa
ti
o
n
o
f
d
ea
d
ti
ss
u
e
o
r
‘l
u
x
u
ry
p
er
fu
si
o
n
’.
T
ek
es
(2
01
4)
A
p
-
p
ar
en
t
d
iff
u
si
on
co
effi
ci
en
t
sc
al
ar
s
co
rr
el
at
e
w
it
h
N
IR
S
m
ar
ke
rs
of
ce
re
b
ro
va
sc
u
la
r
au
to
re
gu
la
ti
on
in
n
eo
n
at
es
co
ol
ed
fo
r
p
er
in
at
al
H
IE
[1
58
]
N
IR
S
,
H
IE
,
ce
re
-
b
ra
l
au
to
re
gu
la
-
ti
on
,
co
rr
el
at
io
n
an
al
y
si
s,
d
iff
u
si
on
te
n
so
r
im
ag
in
g
(D
T
I)
,
M
R
I
3
1
n
eo
n
a
te
s
m
o
n
it
o
re
d
w
it
h
IN
V
O
S
N
IR
S
a
ft
er
H
IE
.
C
o
n
ti
n
u
o
u
s
m
ov
in
g
co
rr
el
a
ti
o
n
o
f
H
b
T
v
s.
M
A
B
P
ca
lc
u
-
la
te
d
(H
V
x
)
to
m
o
n
it
o
r
a
u
to
re
g
u
la
ti
o
n
.
F
o
u
n
d
o
p
ti
m
u
m
M
A
B
P
fr
o
m
m
o
st
n
eg
-
a
ti
ve
H
V
x
.
T
im
e
w
it
h
b
el
ow
o
p
ti
-
m
u
m
M
A
B
P
w
a
s
n
o
te
d
a
s
a
p
er
ce
n
t-
a
g
e
o
f
m
o
n
it
o
ri
n
g
ti
m
e,
d
ev
ia
ti
o
n
b
el
ow
M
A
B
P
a
n
d
a
re
a
u
n
d
er
cu
rv
e
w
er
e
a
ls
o
re
co
rd
ed
.
T
h
is
w
a
s
co
m
p
a
re
d
w
it
h
re
-
su
lt
s
fr
o
m
D
T
I
(d
ec
re
a
se
d
d
iff
u
si
o
n
a
s-
so
ci
a
te
d
w
it
h
se
ve
re
H
IE
).
D
T
I
d
id
n
o
t
co
rr
el
a
te
w
it
h
ti
m
e
b
el
ow
M
A
B
P
O
P
T
,
d
ev
ia
ti
o
n
fr
o
m
M
A
B
P
O
P
T
o
r
a
re
a
u
n
d
er
cu
rv
e.
D
u
ri
n
g
co
o
li
n
g
in
b
a
b
ie
s
w
it
h
M
R
I
o
n
d
ay
<
1
0
a
ll
co
rr
el
a
te
d
w
it
h
D
T
I
sc
a
la
rs
in
p
o
st
er
io
r
ce
n
tr
u
m
se
m
io
va
le
.
R
e-
fl
ec
ts
co
m
p
le
x
n
a
tu
re
o
f
H
IE
a
n
d
p
er
il
s
o
f
o
n
ly
m
ea
su
ri
n
g
o
n
e
re
g
io
n
o
f
b
ra
in
(i
.e
.
M
R
S
).
CHAPTER 3. BROADBAND NIRS 93
N
ak
am
u
ra
(2
01
5)
S
im
u
lt
an
eo
u
s
m
ea
-
su
re
m
en
t
of
ce
re
-
b
ra
l
h
ae
m
og
lo
b
in
ox
y
ge
n
sa
tu
ra
ti
on
an
d
b
lo
o
d
v
ol
u
m
e
in
as
p
h
y
x
ia
te
d
n
eo
n
at
es
b
y
N
IR
T
R
S
[1
52
]
1
1
n
eo
n
a
te
s
w
it
h
H
IE
w
er
e
m
o
n
it
o
re
d
w
it
h
T
R
S
-1
0
(H
a
m
a
m
a
ts
u
,
J
a
p
a
n
).
5
w
er
e
tr
ea
te
d
w
it
h
T
H
,
6
w
er
e
n
o
t.
H
ig
h
S
cO
2
a
n
d
C
B
V
in
in
fa
n
ts
w
it
h
a
d
ve
rs
e
o
u
tc
o
m
e
a
t
2
4
a
n
d
4
8
h
o
u
rs
a
ft
er
b
ir
th
.
In
-
fa
n
ts
tr
ea
te
d
w
it
h
T
H
sh
ow
ed
lo
w
er
C
B
V
a
t
2
4
h
o
u
rs
a
n
d
h
ig
h
er
S
cO
2
a
t
2
4
h
o
u
rs
.
B
u
rt
on
(2
01
5)
A
p
il
ot
co
h
or
t
st
u
d
y
of
ce
re
b
ra
l
au
-
to
re
gu
la
ti
on
an
d
2-
ye
ar
n
eu
ro
d
ev
el
-
op
m
en
ta
l
ou
tc
om
es
in
n
eo
n
at
es
w
it
h
h
y
p
ox
ic
-i
sc
h
ae
m
ic
en
ce
p
h
al
op
at
h
y
w
h
o
re
ce
iv
ed
th
er
a-
p
eu
ti
c
h
y
p
ot
h
er
m
ia
[1
59
]
au
to
re
gu
la
ti
on
,
N
IR
S
,
H
IE
,
T
H
,
n
eu
ro
d
ev
el
op
m
en
-
ta
l
ou
tc
om
es
2
8
n
eo
n
a
te
s
w
it
h
H
IE
m
o
n
it
o
re
d
w
it
h
IN
V
O
S
-
m
ea
su
re
d
H
V
x
(M
A
B
P
v
s.
rT
H
b
)
to
fi
n
d
M
A
B
P
O
P
T
a
n
d
rS
O
2
d
u
ri
n
g
T
H
,
re
w
a
rm
in
g
a
n
d
n
o
rm
o
th
-
em
ia
.
C
o
g
n
it
iv
e
a
n
d
m
o
to
r
d
ev
el
o
p
-
m
en
t
w
a
s
a
ss
es
se
d
in
1
9
ch
il
d
re
n
a
t
2
1
-
3
2
m
o
n
th
s
o
f
a
g
e.
M
A
B
P
d
ev
ia
ti
o
n
b
el
ow
M
A
B
P
O
P
T
d
u
ri
n
g
re
-
w
a
rm
in
g
w
a
s
as
so
ci
a
te
d
w
it
h
g
re
a
te
r
im
p
a
ir
-
m
en
t.
rS
O
2
w
as
n
o
t
a
ss
o
ci
a
te
d
w
it
h
n
eu
ro
d
e-
v
lo
p
m
en
ta
l
o
u
tc
o
m
e.
CHAPTER 3. BROADBAND NIRS 94
M
as
sa
ro
(2
01
5)
Im
p
ai
re
d
ce
re
b
ra
l
au
to
re
gu
la
ti
on
an
d
b
ra
in
in
ju
ry
in
n
ew
b
or
n
s
w
it
h
H
IE
tr
ea
te
d
w
it
h
T
H
H
IE
,
C
B
F
,
M
R
I,
n
ew
b
or
n
[1
61
]
N
IR
O
2
0
0
m
o
n
it
o
ri
n
g
o
f
T
O
I
a
n
d
M
A
B
P
d
u
ri
n
g
T
H
to
n
o
rm
o
th
er
m
ia
in
3
8
in
fa
n
ts
w
it
h
H
IE
.
P
re
ss
u
re
p
a
ss
iv
it
y
in
d
ex
(P
P
I)
w
a
s
a
ss
es
se
d
v
ia
sp
ec
tr
a
l
co
h
er
en
ce
b
et
w
ee
n
M
A
B
P
a
n
d
H
b
D
.
H
ig
h
er
P
P
I
in
th
e
ri
g
h
t
h
em
is
p
h
er
e
w
a
s
a
ss
o
-
ci
a
te
d
w
it
h
a
d
v
er
se
o
u
tc
o
m
e
(d
ea
th
o
r
b
ra
in
in
ju
ry
d
et
ec
ta
b
le
b
y
M
R
I)
.
G
ov
in
d
an
(2
01
5)
A
n
ov
el
te
ch
n
iq
u
e
fo
r
q
u
an
ti
ta
ti
ve
b
ed
si
d
e
m
on
it
or
in
g
of
N
V
C
[1
67
]
E
E
G
,
N
IR
S
,
N
V
C
,
sp
ec
tr
al
co
h
er
en
ce
,
H
IE
S
p
ec
tr
a
l
co
h
er
en
ce
b
et
w
ee
n
E
E
G
a
n
d
N
IR
O
2
0
0
-m
ea
su
re
d
H
b
D
to
a
ss
es
s
N
V
C
in
4
in
fa
n
ts
w
it
h
H
IE
(2
w
it
h
g
o
o
d
o
u
tc
o
m
e,
2
d
ie
d
).
A
b
le
to
fo
ll
ow
N
V
C
ev
o
lu
ti
o
n
w
it
h
ti
m
e
b
u
t
n
o
si
g
n
ifi
ca
n
t
re
la
ti
o
n
sh
ip
w
it
h
in
ju
ry
se
ve
r-
it
y,
a
lt
h
o
u
g
h
tr
en
d
fo
r
lo
w
er
N
V
C
in
a
d
v
er
se
o
u
tc
o
m
e.
C
h
al
ak
(2
01
5)
C
er
eb
ra
l
h
ae
m
o
d
y
-
n
am
ic
s
in
as
p
h
y
x
-
ia
te
d
n
ew
b
or
n
s
u
n
d
er
go
in
g
T
H
:
p
i-
lo
t
fi
n
d
in
gs
u
si
n
g
a
m
u
lt
ip
le
-t
im
e-
sc
al
e
an
al
y
si
s
[1
68
]
N
eo
n
at
e,
H
IE
,
T
H
,
ce
re
b
ra
l
h
ae
m
o
d
y
-
n
am
ic
s,
N
IR
S
M
ov
in
g
w
in
d
ow
co
rr
el
a
ti
o
n
b
et
w
ee
n
M
A
B
P
a
n
d
S
cO
2
(I
N
V
O
S
)
in
1
0
H
IE
in
fa
n
ts
w
a
s
co
m
p
a
re
d
w
it
h
B
ay
le
y
d
e-
ve
lo
p
m
en
ta
l
te
st
sc
o
re
s
(5
a
b
n
o
rm
a
l)
.
S
tu
d
y
p
er
fo
rm
ed
in
th
e
fi
rs
t
7
2
h
o
u
rs
o
f
li
fe
.
In
fa
n
ts
w
it
h
ab
n
o
rm
a
l
o
u
tc
o
m
e
h
a
d
a
h
ig
h
co
rr
el
a
ti
o
n
b
et
w
ee
n
M
A
B
P
a
n
d
S
cO
2
.
CHAPTER 3. BROADBAND NIRS 95
3.3.3 Neonatal NIRS Study Design and Considerations
Review papers [124, 169, 170] highlight the advantages and challenges of using NIRS monitoring on
neonates. The advantages are central to the principles of NIRS; the measurement is non-ionising and
non-invasive, relatively simple compared with MR scanning, and is easy to apply to small infants at
the cotside. The articles raise concerns over the low precision of the measurements and the large inter-
and intra-patient variability. However, the authors agree that NIRS used as a trend-monitor for the
individual patient can yield important clinical information that could guide clinical treatment, especially
when combined with other parameters such as EEG and blood pressure. Wolf et al. [124] have noted
that the changes in chromophores from an arbitrary baseline are not useful clinically unless they are
combined with other physiological parameters or challenges.
The range of devices and parameters available can lead to confusion that prevents expansion of the
use of NIRS in clinical care; it is important that different NIRS devices produce similar results if NIRS is
to be adopted into routine use in neonatal intensive care. Dix et al.[171] performed comparison studies
on a population of over 500 neonatal subjects with different devices (and sensors) to investigate the
similarities or differences between rScO2 values. They concluded that although the rScO2 values were
similar in the majority of cases, there were occasional significant differences which would complicate
clinical application as it would compromise the possibility of using NIRS values as threshold markers
to direct neonatal care. Further work should be done to compare not only devices but the parameters
themselves to provide a uniform understanding of NIRS measurements across devices.
As well as variation in the parameters measured, the measurement time period varies from paper to
paper. Some studies have continuous monitoring lasting for several days whereas others use acquisitions
of less than a minute per measurement. Short measurement times reduce the possibility of movement
artefacts; NIRS systems have intrinsic problems with movement and ambient light artefacts due to their
high sensitivity [172]. Movement of the head or optodes cause changes in the light coupling to the
tissue, and high ambient light intensity levels can reach the photodetectors. Long studies lasting several
hours have the advantage of recording data over different stages of care and can look at specific events
occurring in that time; however the data quality may be restricted. The Centre for Biomedical Imaging
at Massachusetts General Hospital (MGH) uses multiple optical methods, such as frequency-domain
NIRS with diffuse correlation spectroscopy (DCS), to give a measure of the cerebral metabolic rate of
oxygen (CMRO2) [156, 173, 174]. Studies from MGH ([146, 156, 173–176]) monitor short periods of time
(10-16 seconds), whereas other studies ([147, 148]) record continuously over several hours. While the
short monitoring periods are not likely to be subject to optical drift or movement artefacts, the short
monitoring period may miss vital events which change the physiological status.
NIRS is used in conjunction with MR scanning in two papers: Massaro et al. correlate NIRS data
with CBF measured by ASL-MRI [147], Wintermark et al. found a correlation between the NIRS and
MRI measured markers of CBF [148]; and both studies found a lower CBF in patients with HIE. Massaro
et al. also saw a lower tissue oxygenation fraction in the infants with long term injuries as measured by
MRI.
Two studies have investigated the variation in NIRS measured signals with respect to the position of
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the infant. Lin et al. [173] found hemispheric asymmetry was not influenced by the side of presentation
(the side that infant was lying on, left or right). Bembich et al. [177] determined that the prone
position gave a higher CBF than the supine position. These results are vital for ensuring proper design
of experiments and comparison between studies.
3.4 Summary
NIRS is a non-invasive monitor of brain haemodynamics and oxygenation that can be performed at the
patient bedside. The use of NIRS in neonatal medicine research has increased in recent years, particularly
in the measurement of cerebral oxygenation, although the heterogeneity between different instrument
measurements has prevented the technique entering routine clinical practice [170]. Broadband NIRS has
the ability to monitor changes in the redox state of CCO which can give a complimentary measurement
of metabolic activity. This thesis describes the investigation of broadband NIRS-monitored CCO in
neonatal brain injury and its potential to give clinical insight.
Chapter 4
Review of Clinical NIRS
Measurements of Cerebral
Cytochrome-C-Oxidase
NIRS measurements of cytochrome-c-oxidase have the potential to yield crucial information about cere-
bral metabolism at the patient bedside. Developments in instrumentation and the analytical methods
used to resolve changes in CCO have led to many novel clinical applications of the measurement since
its first demonstration in 1977 by Jobsis [110]. There is a substantial literature of work on measures
of CCO in animal and in-vitro studies, however this chapter focusses on translational studies. Almost
forty years from the advent of the first measurement of CCO using NIRS, this signal continues to hold
significant interest in our understanding of the human brain in health and disease. This chapter discusses
methodologies for obtaining NIRS measurements of CCO in the clinic and reviews studies in neonates
and adults.
4.1 Introduction
A patient’s health is in great danger when there is a prolonged lack of oxygen delivery that is insuffi-
cient to meet the metabolic demand of the tissue; for example in traumatic brain injury (TBI) where
derangements of cerebral oxygen delivery and utilisation often occur, rendering the brain susceptible to
secondary, or additional, injury processes. Secondary injury can also occur in neonatal encephalopathy,
secondary to perinatal hypoxia-ischaemia. Clinicians currently cannot monitor the biochemical status
of the injured brain continuously and non-invasively at the patient bedside. There is an urgent need for
real time in-vivo measurements of brain tissue oxygenation and biochemistry in the clinic; as well as a
bedside sensor of brain tissue cellular oxygen utilisation that can improve diagnostic information.
Since 1977, when Franz Jobsis reported a new optical method in a seminal Science article [110],
near-infrared spectroscopy has been seen as the technique which could deliver a solution to this clinical
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need. NIRS was to become an established research and clinical tool for measuring changes in cerebral
oxygenation, in particular changes in oxygenated and deoxygenated haemoglobin (HbO2 and HHb)
concentration. However, Jobsis’s intention was to develop an optical technique to measure in-vivo changes
in CCO, an enzyme in the mitochondria, and hence monitor tissue metabolism. Jobsis discovered that
near-infrared light penetrates deep into living tissue and this optical window could be used to monitor
changes in the concentrations of absorbing compounds inside the tissue.
There has been a significant amount of work on measuring haemoglobin concentration changes with
NIRS since 1977 (see the recent reviews by Wolf et al. [135] and Scholkmann et al. [6]). A typi-
cal commercially available NIRS system is a non-invasive, inexpensive, portable, bedside monitor that
can measure, at multiple sites, the changes in HbO2 and HHb, and from those derive estimations of
changes in oxygen delivery (via haemoglobin difference, HbD) and changes in total blood volume (via
total haemoglobin, HbT). In addition, from technical developments in the late 1990s, we now have
clinical NIRS cerebral oximeters that measure absolute tissue saturation using techniques such as spa-
tially resolved spectroscopy [117, 133]. However, these measurements do not monitor metabolism at
a cellular level unlike a measurement of the redox state of CCO, which has the potential to yield an
in-vivo indication of cellular energy metabolism. Simultaneous measurement of the CCO signal and
haemoglobin signals can therefore provide complimentary information on haemodynamics, oxygenation
and metabolism. Monitoring of CCO with NIRS has been shown to be consistent with other measures
of metabolism; including those from more invasive techniques, such as microdialysis in humans [52], or
more expensive and less portable techniques, such as MRS in animal studies [12, 66, 178, 179]. Fur-
thermore, the concentration of CCO is much higher in the brain than in extracerebral tissues, so it is a
more brain-specific signal that is hence less prone to scalp and skull contamination than the haemoglobin
signals [60, 61].
Pre-clinical and in-vitro studies have contributed enormously to the understanding of the optical
issues surrounding the NIRS measurement of CCO, its role as marker of cellular metabolism, and its
potential as a clinically relevant measure. This was a focus for several research groups in the 1980s and
1990s [180–186]. More recently, from the Multimodal Spectroscopy Group and Institute for Women’s
Health collaboration here at UCL, a study in a piglet model of HI brain injury has demonstrated the
specificity of the broadband NIRS-measured oxCCO signal as a marker of tissue metabolism [12]. In this
study the percentage recovery of CCO after HI to baseline levels was highly correlated with percentage
recovery of phosphorus (31P) MRS measures of cellular metabolism (see Figure 4.1). Furthermore, this
study demonstrates the potential for CCO measures to identify outcome after injury. However, in this
chapter the focus is on the translational clinical and human cerebral studies that have been ongoing since
1985 [16].
Figure 4.2 shows how the number of publications on, and the populations studied by, NIRS-measured
CCO has varied over the years. Between 1977 and 1997, there was a gradual increase in the number of
papers published, varying in subject and research group (Duke University, University College London
(UCL), Hokkaido University, Sapporo and Keele University were home to the main groups involved).
After 1997, the interest in the CCO measurement gradually declined due to both some controversy over
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the optical instrumentation, methods and algorithms used to resolve it [49], and a shift of clinical interest
due to the emergence of the absolute tissue saturation measurement with NIRS [117]. In the 2000s, efforts
were made to optimise NIRS instrumentation and methods specifically for the measurement of CCO
[62, 187] and studies were performed in healthy volunteers and patients to characterised the behaviour of
the CCO signal as a marker of cerebral cellular oxygen metabolism [52, 60]. A resurgence in the number
of papers published over the last few years reflects the continued clinical desire for in-vivo measures of
metabolism and a renewed interest in the CCO signal following the demonstration of new technological
and analytical methods.
Figure 4.1: Measured changes in the oxidation state of CCO (oxCCO) following HI in a piglet model.
Each data point represents the recovery fraction of the broadband NIRS oxCCO signal and the 31P MRS
NTP/epp (a surrogate marker of ATP). The broadband oxCCO measurements show a strong association
(Pearson correlation, r = 0.82) with the MRS metabolic measurements and provide a good indication of
outcome (good outcome refers to piglets that survived for more than 24h following HI). The figure has
been produced from data presented by Bainbridge et al. [12].
The focus in this chapter is on measurements in patients and healthy volunteers, however in order
to fully understand the chronology and advances made in the methodology, some important pre-clinical
work is also discussed. While there is extensive work on the measurement of CCO changes in the visual
part of the light spectrum (see the review by LaManna for a historical perspective [188]); here I have
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Figure 4.2: Number of papers published per year on the subject of cerebral NIRS measurements of CCO.
The data were taken from the PubMed results for ’cytochrome oxidase infrared spectroscopy brain’ (with
the addition of the 1977 Jobsis paper). There are a total of 223 papers split into categories based on the
subject: adults 67 papers (green), neonates 36 papers (red), animals 98 papers (blue) and other 23
papers (purple, including reviews of the subject, in-vitro work and computational simulations).
focused on the measurements with near-infrared light (650-1000nm). This chapter provides a description
of the biochemistry of the enzyme to understand the origins of the optical signal; the methods, algorithms
and instrumentation used to study it; a discussion of the issues with the methodology; a summary of
the applications of cerebral NIRS measurements of CCO in neonatal and adult studies; and a forward
perspective on the future of the technique. Almost forty years from the advent of the first measurement
of CCO using NIRS, this signal continues to hold significant interest in the understanding of the human
brain in health and disease.
Note
This Chapter has been modified and presented as a review article which has recently been published in
the Journal of Biomedical Optics.
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4.2 Biochemistry and Spectral Features of Cytochrome-C-Oxidase
In order to fully understand the CCO NIRS signal, one must understand the biochemistry from which
the signal stems. CCO is a small but important part of the aerobic metabolism of glucose. Glycolysis
converts glucose into pyruvate and in the process generates ATP and NADH. After glycolysis, pyruvate
is transported into the mitochondria and converted to acetyl CoA, which then enters the tricarboxylic
acid (TCA) cycle. During the TCA cycle additional ATP and NADH are produced. NADH is an
electron donor; electrons from NADH can be used to, ultimately, convert oxygen to water, releasing
useful chemical free energy in the process. The mitochondrial electron transfer chain (ETC) mediates
this transfer, in the process converting ADP to ATP. The consequent change in ATP/ADP ratio provides
usable energy to drive a wide variety of cellular processes.
Figure 2.7 (in Chapter 2.3) shows the mitochondrial protein complexes involved in this oxidative
phosphorylation. Oxidative phosphorylation is the process where energy is harnessed through a series
of protein complexes (known as complexes I V) embedded in the inner-membrane of mitochondria to
create ATP. Oxidative phosphorylation can be broken down into two parts: oxidation of NADH (and
other electron donors) in the ETC via complexes I - IV, and phosphorylation, the production of ATP, at
complex V. Complex I accepts electrons from NADH and transfers them to the soluble membrane-bound
electron carrier ubiquinol (Q), producing ubiquinone (QH2). QH2 is oxidised by complex III, in the
process reducing the soluble electron transport protein, cytochrome c. Cytochrome c is then oxidised by
the terminal electron acceptor cytochrome-c-oxidase (also known as complex IV), the electrons ultimately
being used to reduce oxygen to water. The redox potential drop in the electron transfer processes
in complex I, III and IV is converted to a proton electrochemical potential, which ultimately drives
mitochondrial ATP synthesis via the mitochondrial ATP synthase (sometimes known as complex V).
The transfer of electrons within the mitochondrial ETC complexes occurs via a number of protein
bound redox factors. Of particular interest in this literature review, CCO contains 4 redox centres: 2
haems (known collectively as aa3) and 2 copper sites. The electrons pass between these centres in a series
of redox reactions. All of these redox changes have associated optical transitions. In the NIR region one
of the copper sites, the Cu-Cu dimer copper A (CuA), dominates the absorption spectrum, with a strong
peak in the oxidised form centred - in mammalian enzymes - around 830-840nm (see Figure 4.3). For a
recent detailed discussion of the relative contributions of CCO chromophores to the NIR spectrum see
[189] and references therein.
The difference between these absorption spectra (oxidised-reduced CCO) can be used to monitor
changes in the redox states of the mitochondrial proteins. Note that the total cytochrome-c-oxidase
concentration does not change over a short time period (hours), therefore for analytical purposes, it is
only necessary to use the difference spectrum between the oxidised and reduced species to obtain an
indicator of the changes in the CCO redox state.
The UCL group has shown that using the oxidised-reduced difference spectrum resolves changes
in oxidised CCO (and conversely, using the reduced-oxidised difference spectrum resolves changes in
reduced CCO). The proof uses the modified Beer-Lambert law and involves two scenarios. In Scenario
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Figure 4.3: The extinction spectra of the absorbing cytochromes in the electron transport chain in
the visible and NIR. a) Displayed between 400-1000nm, note that the cytochrome b spectra are plot-
ted on a secondary axis, and b) zoomed into the near-infrared region of 700-900nm. Oxidised and
reduced spectra of cytochrome c (oxCyt c and redCyt c respectively) measured by Chris Cooper at
the University of Essex in the porcine heart. Oxidised and reduced spectra of CCO (oxCCO and red-
CCO) measured by John Moody at the University of Plymouth in the bovine heart. Oxidised and
reduced spectra of cytochrome b (oxCyt b and redCyt b) measured by Mike Wilson at the University
of Essex. All data were taken from the UCL Biomedical Optics Research Laboratory (BORL) website:
http://www.ucl.ac.uk/medphys/research/borl/intro/spectra
1 (equations 4.1 - 4.5), CCO is fully oxidised (ox) at the initial time (t0) and so the Beer-Lambert law
states the attenuation (A) due to CCO is related only to the concentration (c) of oxidised CCO, its
extinction coefficient () and the optical pathlength of light (l):
A(t0) = l · oxCCO · coxCCO(t0). (4.1)
At a later time (t1) CCO is not fully oxidised so the attenuation is related to both oxidised and
reduced (red) forms of the enzyme:
A(t1) = l · [oxCCO · coxCCO(t1) + redCCO · credCCO(t1)]. (4.2)
Assuming that the total CCO concentration does not change, the initial concentration of fully oxidised
CCO is equal to the sum of the oxidised and reduced forms at the later time:
coxCCO(t0) = coxCCO(t1) + credCCO(t1). (4.3)
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Therefore it is possible to substitute the equations above into the difference measurement of the
attenuation:
∆A = A(t1)−A(t0)
= l · [oxCCO · (coxCCO(t1)− coxCCO(t0)) + redCCO · credCCO(t1)]
= l · [oxCCO · (coxCCO(t1)− coxCCO(t0)) + redCCO(coxCCO(t1)− coxCCO(t0))]
= l · (oxCCO − redCCO)∆coxCCO.
(4.4)
The oxidised-reduced difference (diff) extinction spectrum (diffCCO = oxCCO − redCCO) gives
rise to equation 4.5, which expresses the change in attenuation due to a change in the concentration of
oxidised CCO from the difference extinction spectra:
∆A = l · diff ·∆coxCCO. (4.5)
In a Scenario 2 (equations 4.6 - 4.10) where CCO is not fully oxidised initially (i.e. CCO exists in
both oxidised and reduced forms), the same expression can be achieved. The initial and later equations
are:
A(t0) = l · [oxCCO · coxCCO(t0) + redCCO · credCCO(t0)]. (4.6)
A(t1) = l · [oxCCO · coxCCO(t1) + redCCO · credCCO(t1)]. (4.7)
Assuming again that the total CCO concentration does not change:
coxCCO(t0) + credCCO(t0) = coxCCO(t1) + credCCO(t1). (4.8)
Therefore:
∆A = A(t1)−A(t0)
= l · [oxCCO · (coxCCO(t1)− coxCCO(t0)) + redCCO · (credCCO(t1)− credCCO(t0))]
= l · [oxCCO · (coxCCO(t1)− coxCCO(t0)) + redCCO(coxCCO(t1)− coxCCO(t0))]
= l · (oxCCO − redCCO)∆coxCCO
(4.9)
which gives rise to the same expression as equation4.5:
∆A = l · diff ·∆coxCCO. (4.10)
These proofs show that the oxidised-reduced difference spectrum can be used to resolve changes in the
concentration of oxidised CCO. An increase in the oxCCO signal therefore reports an increase in oxidised
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CCO and an equivalent decrease in reduced CCO. Note that if the sign of the measured signal is changed
it represents reduced CCO not oxidised CCO. The oxCCO term does not imply that we are only sensitive
to the oxidised species. Nevertheless oxCCO is the term used to describe the measured changes from the
difference spectra in this thesis.
To understand what a change in oxCCO means physiologically we need to know what the concen-
tration of oxidised and reduced CCO is dependent on and how it can be affected in-vivo. The redox
state is dependent on both the availability of oxygen in the cells and the supply of electrons entering
the ETC. The review by Cooper and colleagues [190] gives an overview of the influencing factors on the
CCO redox state. In the purified isolated enzyme these include changes in the 3 substrates (protons
(pH), reduced cytochrome c, and oxygen tension), as well as a range of terminal inhibitors (such as
nitric oxide and cyanide) and electrochemical potential. The complex interplay between these factors in
the mitochondrial ETC has been investigated mathematically by Banaji [191]. This informs on clinical
in-vivo measurements. Possible factors that might increase oxCCO in-vivo include: increase in oxygen
tension, increased ATP turnover, decrease in proton electrochemical gradient, decrease in pH, or decrease
in supply of reducing equivalents (substrates i.e. NADH) to the ETC, these factors have been discussed
by Heekeren and colleagues [56].
The oxCCO concentration can readily be decreased in animal models, either by large drops in oxygen
tension or the addition of inhibitors that act at the oxygen reduction site [181]. There have, though, been
questions regarding how easy it is to increase the oxCCO signal in-vivo, but animal models have shown
that there is the capacity to increase the oxidation state at normoxia [182, 192] as well as adult volunteer
studies in hyperoxia and hypercapnia [60, 193], and functional activation [56, 61]. I acknowledge that
there are some differences in the CCO response between the pre-clinical and clinical work, in particular
when compared to results from non-anaesthetised human adults; it is not the intention in this chapter
to discuss those physiological differences.
The CCO concentration in the brain is likely to change with maturity. Rodent studies have shown
that there is an increase in the number of mitochondria per cell, as well as an increase in mitochondrial
proteins and respiratory enzymes per mitochondrion in the first postnatal days [194]. Additionally
there is a difference in energy metabolism and functional activity in the rodent brain during postnatal
development compared with the adult, and so this must be taken into consideration when monitoring
CCO with NIRS.
4.3 Methods of Cytochrome-C-Oxidase Measurements
CCO is one of the most abundant enzymes in mammalian systems. However, its relatively low con-
centration compared to the haemoglobin chromophores presents some challenges for NIRS techniques.
The absolute concentration of CCO in the human brain is unknown, but optical methods have obtained
values of 5.5 and 4.5 µ M in the adult rat [195, 196]. This should be considered an upper limit for the
human CCO concentration as rats have a significantly higher cerebral metabolic rate of oxygen than
humans [190]. The contribution of CCO to overall absorption in tissue is considerably less than that
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of haemoglobin because of its lower concentration, despite a higher specific extinction spectrum in the
NIR region. Although the detectable absolute concentrations may vary with species, age and optical
set-up, it is clear that the overall maximal signal from CCO should be 5-10% of that from haemoglobin.
Therefore light attenuation changes due to CCO can easily be masked by the much larger attenuation
changes due to HbO2 and HHb; this can result in cross-talk. I define cross-talk as a genuine change in
one chromophore concentration inducing a spurious measured concentration change in another. Specific
instrumentation and algorithms are necessary to be able to resolve these concentration changes without
cross-talk; cross-talk is discussed later in this section and 4.4.
The principles of NIRS (only CW is considered here) are based on calculating changes in concentration
from the changes in the measured light attenuation in tissue. In order to do this, an algorithm and
instrumentation must be chosen, along with the selection of other variables such as the pathlength
that the light has travelled, the absorption spectrum of the chromophore, and a set of measurement
wavelengths. It is important that the algorithm and the other variables do not unknowingly induce
artefacts. The factors that make up the algorithm and its variables have been the subject of discussion
for many years. The choices to be made are:
• The algorithm
• The determination of the chromophore absorption spectra
• How the optical pathlength is estimated
• The number and choice of wavelengths
Calculating and validating changes in haemoglobin in both of its oxygenation states is simpler because
its concentration in tissue is high. It is also relatively simple to isolate the molecule to produce an
absorption spectra in-vitro. The absorption spectra have defined features in the near-infrared (see Figure
4.4) such as a peak at 750-760nm in HHb and the isosbestic point at 800nm. The CCO difference
absorption spectrum, once identified, has a broad peak which is significantly different to that of the
haemoglobin chromophores. However, the broad nature of the three chromophore peaks throughout the
NIR region confounds simple deconvolution via standard optical techniques such as dual wavelength or
derivative spectroscopy. Therefore to successfully separate the CCO signal from the larger haemoglobin
signals requires careful selection of the algorithm, wavelengths and extinction spectra used. One of
the biggest problems for the oxCCO signal is that there is no gold standard with which to compare
and validate the NIRS signal experimentally. Although, the same problem exists for NIRS detectable
haemoglobins, in this case there are at least invasive measurements that can be assumed to report on
similar parameters (such as tissue oxygen, blood volume and arterial/venous oxygen saturation). This
lack of external comparators is a problem in assessing which criteria produce the most physiologically
accurate oxCCO signal. Yet, there have been a range of in-vitro and in-vivo controlled studies that inform
on the success of the optical separation of the cellular oxCCO signal from changes in the haemoglobin
signals. Additionally, integrated mathematical models of the biochemistry and physiology can aid the
interpretation of results [197–199].
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4.3.1 Algorithm
Various algorithms have been developed by different groups, and these were assessed and described fully
in 1995 by Matcher et al. [48]. The algorithms can be reduced to those developed at Duke University
(Duke), University College London (UCL), Hokkaido University, Sapporo (Sapporo) and Keele University
(Keele).
The UCL algorithm is a generalised algorithm based on the modified Beer-Lambert law and the
concentrations are derived using multilinear regression [113]. The modified Beer-Lambert law forms the
mathematical basis of spectroscopic algorithms that relate wavelength-dependent optical attenuation sig-
nals to changes in chromophore concentrations. The generalised form of this algorithm for n wavelengths
(termed UCLn) is equation 3.25 [48].
The algorithm assumes that tissue scattering and pathlength remain constant throughout the mea-
surement period and is therefore suitable for all geometries and optical systems. It ignores, however, the
multiple scattering effects including the non-linear relationship between absorption and attenuation [7],
this is discussed later in section 4.3.3. A three wavelength version of this algorithm was also developed
by researchers at Keele using different extinction spectra [200].
The algorithm developed in Sapporo is a four wavelength algorithm which uses attenuation differences
between three measuring wavelengths and a fourth reference wavelength [201]. The reference wavelength
was selected in a region in which, the authors claim, has zero attenuation from CCO. The algorithm
was developed specifically for the intact rat head through a vertical plane from the roof of the mouth to
the top of the skull and the coefficients used (not shown here but presented in [48, 202]) contain optical
instrumentation factors so are only specific to one instrument. Their algorithm does not attempt to
quantify the concentration changes in haemoglobins and oxCCO and thus measurements are expressed
in relative terms [202]. The authors claim their algorithm to be robust to changes in scattering and
optical pathlength changes during the measurement period [202].
The Duke algorithm uses 4 wavelengths and specific extinction spectra determined in-vivo from the
intact cat brain to determine concentration changes [203]. The algorithm is not displayed here but can
be found in [48] where it is also discussed.
4.3.2 Chromophore Absorption Spectra
The difference between the oxidised and reduced form of CCO can be determined in many different
environments such as the isolated enzyme, in mitochondria and in-vivo. The first NIRS measurement
used difference spectra that were taken through animal heads during anoxic challenges [110]. These
spectra showed clear differences between oxidised and reduced CCO states. Later authors replaced blood
with optically clear oxygen carrying perflurocarbon solutions in an attempt to produce haemoglobin free
CCO spectra [183, 186, 204]. In addition, later studies were able to remove this contribution completely
in rats [205, 206], cats [207], and piglets [181].
The use of perflurocarbon perfused blood-free animals has been key to the development of algorithms
to detect oxCCO. In some cases these spectra were themselves used to generate the algorithms; in others
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they were used to validate the use of in-vitro spectra. The latter was the case for the UCL algorithms.
Figure 4.4: Specific extinction coefficients measured by Mark Cope (Cope 1991). The ox-redCCO spectra
are not the same as the difference between the CCO spectra presented in Figure 4.3. Data taken from
the UCL BORL website: http://www.ucl.ac.uk/medphys/research/borl/intro/spectra
Cope found that there is no appreciable difference between the spectra measured in-vivo and in-vitro
[7]. Matcher et al. found similar results when using the 4-wavelength UCL algorithm, which uses in-vitro
extinction spectra, and the 3-wavelength Keele algorithm, which uses in-vitro spectra but with whole
blood, not purified haemoglobin, to resolve concentration changes from the same attenuation data [48].
Chromophore absorption spectra used at UCL are displayed in Figure 4.4.
4.3.3 Optical Pathlength
The estimation of optical pathlength is the one of the most notable challenges for the calculation of
changes in oxCCO as it was thought that erroneous changes resolved in oxCCO (i.e. cross-talk) could be
due to pathlength changes causing insufficient chromophore separation [49, 181]. As mentioned earlier
in this section (4.3.1) the modified Beer-Lambert law does not account for tissue scattering and assumes
that the reduced scattering coefficient (µ′s) is constant throughout a measurement period. The optical
pathlength term is the only consideration of scattering in the equation so it must be estimated sufficiently
to produce physiologically accurate representations of chromophore changes in-vivo.
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The first attempts at optical pathlength estimation assumed a constant pathlength, equal to the
product of the distance between the source and detector optodes and the differential pathlength (DPF)
factor, an experimentally determined factor to account for the increased pathlength of light due to all
forms of scattering [113]. The DPF can be calculated using FD or TR NIRS which estimate the optical
pathlength [112–114]. In addition, to monitor the changes in pathlength in real-time with CW NIRS,
Matcher and colleagues at UCL developed a method to resolve the pathlength using the water absorption
spectrum and the measured broadband attenuation [208]; features in the second differential of the water
absorption spectra around 740nm and 820nm can be combined with an assumed concentration of water
in the tissue to estimate pathlength.
In 1993, the modified Beer-Lambert law algorithm was updated to account for the wavelength-
dependency of the DPF which allowed for the decreasing scattering effects at increasing wavelengths
in tissue [115]. DPF varies with wavelength through another attenuation mechanism; high absorption
of light at a specific wavelength decreases the likelihood that light at that wavelength will reach the
detector.
A few experiments have been set-up specifically to test whether changes in pathlength are respon-
sible for cross-talk in the oxCCO measurement; none of these studies found significant changes in the
pathlength during events where changes in oxCCO were observed, such as hypoxemia [52] or functional
activation [59, 61]. Skov and Greisen suggest that the wavelength-dependent DPF is a solution to the
cross-talk problems; they observed a linear relationship between HbT and oxCCO during hypoxemia
when using a constant DPF, but not when using wavelength-dependent DPF [23].
There are physiological factors that will affect tissue scattering. For example, glucose levels affect the
refractive index of extracellular fluid which contributes to the reduced scattering coefficient, therefore
changes in the glucose concentration may affect the overall scattering of the tissue [209]. Swelling of the
brain or oedema, which is common in HIE, is likely to change cerebral scattering properties. There is
therefore a need to understand the influence of changing tissue scattering properties on the calculation
of chromophore concentrations, or to measure scattering during the measurement period, particularly in
cases such as brain injury.
4.3.4 Wavelength Selection
In theory, to extract information for three chromophores requires measurements at three wavelengths.
Yet this approach is prone to noise and cross-talk artefacts that may lead to inaccurate quantification
of changes in concentrations and misinterpretation of data. When measurements at a larger number
of wavelengths are used in spectroscopic algorithms, any detrimental effects of cross-talk and noise are
expected to diminish.
Due to the broad spectral peak in the oxidised-reduced CCO spectra and its relatively low concen-
tration in-vivo, the choice of selection of the specific wavelengths and number of wavelengths used for
spectroscopy is a big factor. This is also relevant for the haemoglobin chromophores. Matcher et al.
[48] performed analysis to assess the separation of the oxCCO signal from the haemoglobin signals with
different number of wavelengths (4, 6, and ‘n’ or 112) in a range of data: rat head, piglet head, adult
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forearm, and a simulated data set. The results showed that the higher number of wavelengths used
produced more accurate simulations, and improved the in-vivo measurements. Despite this, pre-clinical
studies showed that limiting broadband measurements to 780-900nm improves the resolution of oxCCO
as exclusion of shorter wavelengths lessens the contribution of HHb which has a large peak at 760nm
[181]. Figure 4.5 shows graphically the selection of wavelengths used in the clinical papers mentioned in
this chapter.
Figure 4.5: Chart of wavelengths used in NIRS systems from all clinical publications mentioned in this
chapter. Systems are listed in chronological order from their first publication in this review and are
separated into 3 and 4 wavelength combinations and broadband spectra. The suggested wavelengths
determined by Arifler et al. are also shown [13]. Clinical papers using the wavelengths are: Duke 3λ
[14–16], UCL 4λ [17], Duke 4λ [18–20], Keele 4λ [21–24], NIR 1000 [25–28], Keele 3λ [29, 30], NIRO 500
[31–38], NIRO 300 [39–46], Critikon 2020 [47], UCLn [48–54], Humboldt A [55, 56], Humboldt B [57, 58],
UCL Hybrid [59, 59–62].
Broadband spectroscopy, offering a full range of measurement wavelengths, can be difficult to incor-
porate into wireless and multi-channel systems. A recent study has used a genetic algorithm method
to assess the minimum number of wavelengths needed to resolve oxCCO accurately (compared to the
current gold-standard of a broadband NIRS system across 780-900nm at 1nm wavelength resolution)
[13, 210]. The results show that the optimal combination of wavelengths is a set that almost evenly
spans the spectral range (see Figure 4.5). The error against the gold-standard reduces as number of
wavelengths increases; increasing to 4, 5 and 8 wavelengths from 3 wavelengths leads to a 2-, 3- and
7-fold improvement in the reduction of errors. The wavelengths selected need to be spread across this
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range in order to resolve the shape of the ox-redCCO spectra and disentangle it from the other chro-
mophores; Arifler et al. found that the optimum 8 wavelengths were 784, 800, 818, 835, 851, 868, 881
and 894nm (displayed in Figure 4.5).
4.3.5 Optical Instrumentation
Advances in optical systems have allowed further development of the instrumentation, as well as the
algorithm, which have contributed to the increased robustness of the measured oxCCO signal with
NIRS.
Initially, NIRS instrumentation for the measurement of oxCCO was performed using 3 or 4 narrow-
band lasers at specific wavelengths between 740nm and 905nm [16] (see Figure 4.5 for more examples)
using a PMT for detection. Commercial systems were developed to measure oxCCO using 4 discrete
wavelengths using lasers and either photodiode detectors or PMTs (NIRO 300 and NIRO 500 respectively,
Hamamatsu, Japan) [35, 39].
In UCL, systems have increasingly been developed in-house and focused on broadband spectroscopy
with the aim of obtaining a more robust oxCCO signal [48], (see section 4.3.1). These systems typically
use a broadband white light source (i.e. a tungsten halogen bulb) with a spectrograph and CCD using
optical fibres to transmit light both to and from the tissue [12, 54, 65]. The UCL broadband NIRS
systems include (i) a broadband instrument developed in the 1990s by Springett and colleagues [65]; (ii)
a multi-distance hybrid broadband and FD domain system developed by Tachtsidis and colleagues in
2010 (called Hybrid Optical Spectrometer or pHOS) [62]; and (iii) in 2014 two variations of that system
without the FD component developed by Bale and colleagues to be used in neonates (called Cytochrome
Research Instrument and appLication or CYRIL) [54] and Phan and colleagues with the capacity to do
imaging [63]. All UCL developed systems are broadband instruments with the capacity to apply the
UCLn algorithm in real-time and I explicitly mention them in the reported studies below.
Miniaturisation is a trend seen in all forms of technology and NIRS is no exception. The trend
towards making devices smaller, more portable and cheaper has pushed broadband spectroscopy towards
miniature spectrometers [211] and discrete wavelength systems towards wireless NIRS [212]. For wireless
devices, in which there is a need to eliminate heavy fibre optics, LEDs and laser diodes can be applied
directly to the head with wireless transmitters to send the data to a nearby computer. Versions of both
of these technologies are in development with the aim of incorporating a measurement of oxCCO [213].
In 2000, a combined CW and FD NIRS system was developed to use measurements of µ′s and µa to
inform the calculation of absolute chromophore concentrations [214]. This was further developed by UCL
to the pHOS system that attempted to measure oxCCO using the UCL hybrid algorithm [62]. These
hybrid devices use broadband CW systems and several lasers in the frequency domain (7 [214] and 4
[62] wavelengths) to achieve this. By resolving for both absorption and scattering it may be possible to
measure absolute concentrations of the chromophores.
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4.4 Analysis of Broadband Cytochrome-C-Oxidase Measurements
Here the clinical experiments that assess the oxCCO signal for robustness and independence from other
chromophores (i.e. cross-talk) are discussed. This chapter focusses mainly on clinical papers that use
many wavelengths (broadband NIRS) and use the wavelength-dependent DPF, methods which are re-
quired to minimised cross-talk. There is a strong weight of evidence against cross-talk if enough wave-
lengths are utilised.
The simplest way to assess cross-talk is to compare the oxCCO signals with the HbO2 and HHb, and
this has been done in many different experiments. In the assessment of the low frequency oscillations
during visual stimuli, there was a phase shift between the haemodynamics and the oxCCO signal [55].
Additionally, the authors noted that the oxCCO recordings were “remarkably stable...compared to the
changes in the haemoglobins, making a simple cross-talk rather improbable”. Another functional acti-
vation study also showed differences in the oxCCO directional changes despite normal haemodynamic
response functions [61]. Further, the same study confirmed that there was no relationship between ox-
CCO and the measured systemic changes. During blood pressure changes in orthostatic hypotension
patients, oxCCO dropped despite different HbT directional responses [46]. During spontaneous desatu-
ration events in infants with HIE, different directional changes were seen for oxCCO despite consistent
decreases in HbO2 and increase in HHb [54]. As discussed in the section 4.3.3, in no study where oxCCO
and pathlength have been measured simultaneously has a correlation been found between their changes.
Uludag and colleagues found from simulations that incorrect estimation of the wavelength-dependency
of partial pathlengths can contribute to cross-talk in chromophores with low concentration [57]. However,
when this was investigated experimentally by studies in healthy adult volunteers using the Humboldt B
broadband NIRS system they found that the majority of oxCCO changes could not be explained by this
effect [187].
Wolf et al. investigated the changes in oxCCO in 22 preterm infants during slow arterial oxygen
saturation changes caused by inspired O2 changes [47]. Changes in the concentrations of HbO2, HHb
and HbT, induced by small and slow O2 changes, were inversely correlated to the measured changes
in the oxidation state of oxCCO with a 4-wavelength Critikon 2020. This is a surprising result and
the authors suggest that, although there has been some evidence of oxCCO increases during hypoxia
in animal [66, 184], their oxCCO measurement is probably erroneous; the small number of wavelengths
used (4) to resolve oxCCO might be the explanation for this.
The most compelling evidence of a unique metabolic signal comes from human studies in which
simultaneously measured changes in metabolism have been made using other modalities. Increases in
oxCCO during hyperoxia correspond with decreases in microdialysis measures of lactate/pyruvate ratio
which is a marker of anaerobic metabolism [52]. Tisdall et al. saw a linear relationship between oxCCO
and estimated oxygen delivery (measured via pulse oximetry and TCD ultrasound) during hypoxemia in
healthy adult volunteers, this relationship was not seen between HbD and oxygen delivery [50].
Residual analysis enables an observation of the goodness of fit of the chromophore spectra to the
measured attenuation. To see if the CCO difference spectrum is necessary to explain the measured
CHAPTER 4. REVIEW OF NIRS MEASUREMENTS OF CCO 112
attenuation, 2- and 3-chromophore fits can be performed with and without CCO. Heekeren et al. found
that using the 3-chromophore fit explains in-vivo data better than the 2-component [56]. The residuals
for 2-component fit have the same shape as oxCCO which suggests that a chromophore with a similar
shape to oxCCO is needed to fully explain the spectra. Above 760nm, the 3-component fit residuals were
random. This result was also found in other broadband adult studies [53, 61] and a neonatal study [54].
4.5 Neonatal Studies
In this section NIRS measures of oxCCO in neonates are reviewed in different clinical environments:
during spontaneous changes in systemic physiology (e.g. periods of hypoxia, increases in blood pressure,
etc.), during surgery, with neonatal drug administration, and during functional activation.
4.5.1 Hypoxia and Other Spontaneous Systemic Changes
In 1985 Jobsis’s group published the first NIRS study on newborn infants [16]. They observed a decrease
in oxCCO during spontaneous oxygen desaturations in three preterm infants using the Duke 3-wavelength
system. Further, the timing and magnitude of the oxCCO decrease depended on the preceding oxygena-
tion state, the depth and length of desaturation event and presence of circulatory disorder. Another
study in which eight preterm infants were monitored with the NIRO 1000 (Hamamatsu, Japan) showed
that small SpO2 changes did not alter oxCCO [70]. To add to the heterogeneity of the oxCCO re-
sponse, Wickramasinghe et al. saw an inconsistent (increases and decreases) and insignificant change in
oxCCO in seven infants during the reduction of inspired oxygen fraction (FiO2) (SpO2 change ∼10%)
using a 3-wavelength Keele system [215]. A study of infants during repetitive apnoeas found a consis-
tent trend of reduced oxCCO during the breathing cycle [33]. More recently, a UCL broadband NIRS
study (with CYRIL) of over 200 oxygen desaturation events in six term infants with HIE saw changes
in the concentration of oxCCO in both directions, but with a decrease in oxCCO on average [54]. The
heterogeneous response to these hypoxias may be a reflection of the level of brain injury, prematurity,
previous oxygenation levels or influence of systemic pathophysiology. Animal work during anoxic swings
in piglets has shown that as the oxygen delivery rate is reduced, there is a linear decrease in HbO2, but a
biphasic elbow in oxCCO reduction [65]. A reduction in oxCCO may be a signal of impending damage,
and this has also been previously suggested by Cooper et al. [190]. The heterogeneity of the oxCCO
response to hypoxia has also been seen in a piglet study of increasingly severe episodes of hypoxia [66].
At lower severities of hypoxia (8 and 12% FiO2) there were small increases in oxCCO while at higher
degrees of hypoxia (6, 4 and 0% FiO2) oxCCO decreased with severity; consistent decreases in HbO2
and corresponding increase in HHb were observed in all hypoxic episodes. In 1985, Brazy called for an
investigation into the degree of CCO reduction that causes brain injury in order to protect those at risk
of injury [16], thirty years later there is still no answer but there is renewed effort to find it [54].
Following from the hypoxia work, the effect of respiratory changes, which cause a subsequent change
in PaCO2, on the cerebral metabolism was investigated in neonates. The 1985 infant study from Brazy et
al. saw oxCCO increase during hyperventilation; this was the first human study to suggest that oxCCO
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is not maximally oxidised in-vivo at normoxia and can be increased by hyperventilation [16]. The ability
to increase oxCCO from normoxia is supported by another investigation where an increase in oxCCO
was observed during an increase in PaCO2 [24]. Edwards et al. suggest that the strong relationship
between PaCO2 and oxCCO is either due to cerebral haemodynamic changes caused by vasodilation due
to CO2, or CO2 decreasing the pH in cells [70]. However, not all studies have seen this strong correlation;
a study of PaCO2 changes in 24 ventilated preterm infants observed changes in cerebral blood flow and
volume, but not in oxCCO (4-wavelength Keele NIRS system) [24]. Brazy et al. reported the effects of
crying on oxCCO and found different responses when lung disease was present and at different ages of
infant [15]. An insignificant small decrease was observed in oxCCO during endotracheal suctioning of 15
preterm infants in the presence of marked decrease in HbO2 and increase in HHb, monitored with the
NIRO 500 [35].
Another early NIRS experiment examined changes in oxCCO during alterations in mean arterial
blood pressure [14]. This study showed that increases in MABP were accompanied by increases in HbT
and HHb, and a decrease in oxCCO as measured by a 3-wavelength Duke system. Infants whose clinical
condition did not improve over the study duration showed larger changes in HbT and oxCCO. This area
has potential for further investigation, especially in terms of cerebral autoregulatory effects on tissue
metabolism.
The effects of changing intracranial pressure (ICP) was investigated during lumbar puncture [28] in
six infants with posthaemorrhagic ventricular dilation with the NIR 1000: three infants had an increase
in ICP which was accompanied by an increase in oxCCO, the other three had no change in either ICP nor
oxCCO: this is the only study to link oxCCO to ICP. In a 2004 study of 12 infants with intraventricular
haemorrhage (IVH), removal of CSF which is expected to cause a reduction of ICP, did not produce a
change in oxCCO measured with the NIRO 500 [36].
4.5.2 Surgery and Anaesthesia
Concern for cerebral health during major surgery such as cardiopulmonary bypass (CPB) brought the
introduction of NIRS to the operating room. The first use of oxCCO monitoring during neonatal surgery
was to monitor cerebral metabolism throughout cardiac surgery. In 1991, 15 children were monitored
during CPB at Duke with a 4-wavelength system [18] and a decrease of oxCCO was observed at onset of
bypass with hypothermia and reduced further when rewarming began. In 1995, 63 infants were monitored
during CPB and hypothermia, and interestingly oxCCO decreases were observed despite HbO2 increases
measured by the NIRO 500 [38]. Recovery of oxCCO was delayed despite HbO2 recovery to above baseline
levels. Larger and more rapid decreases were seen in oxCCO in older (>14 days) infants and those infants
had worse recovery. The divergence in intravascular and mitochondrial oxygenation suggest an abnormal
response, which the authors suggested could be due to: hypothermic temperature, effects of pH on the
ETC, a disturbance in oxygen delivery to the mitochondria, disturbed perfusion, or decreased HbO2
dissociation. The delay in recovery suggests mitochondrial dysfunction. Changes in haemodynamics and
oxCCO measured by a 4-wavelength Keele system were seen in 5 out of 14 children who were hypoxemic
during cardiopulmonary bypass for congenital heart disease [23]. Some recent studies with the NIRO 300
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during repair of coarctation of aorta (without CPB) [40] and cardiac surgery [216] showed no significant
change in oxCCO throughout either procedure.
Other stresses during surgery such as the use of therapeutic hypothermia and anaesthesia will have
effects on cerebral metabolism and such effects are interesting and important to understand if NIRS
monitoring of metabolism is to become clinically relevant. However, as du Plessis et al. note, it is
difficult to disentangle the effects of hypothermia on oxCCO from the pathology or the stress of surgery
[38]. The effects of the anaesthetic propofol during CPB in children (n=11) and CPB controls without
propofol administration (n=13) was studied in 2000 [34]. A decrease in oxCCO was observed during
CPB and a lower decrease was seen in those with propofol.
4.5.3 Effects of Drugs on the Neonatal Brain
The oxCCO response to other neonatal drugs, such as aminophylline have been monitored. A NIR 1000
was used to assess aminophylline delivery to 13 preterm infants in order to wean off ventilators [27].
A decrease in oxCCO was seen after administration, which the authors suggest could be mediated by
reduction in perfusion of CO2. A later similar study using a NIRO 300 on the effects of aminophylline
and caffeine for treatment of apnoeas in preterm infants [42] found that neither drug made a significant
change to oxCCO.
Measures of oxCCO have been used to identify cerebral metabolic changes caused by indomethacin for
the treatment of patent ductus arteriosus. Despite using different NIRS systems, three separate studies
recorded decreases in oxCCO, HbO2, CBV and CBF with increases in HHb when indomethacin was
administered [22, 26, 30]. This result, combined with other evidence from changes in CBF, have provided
evidence against the use of the drug due to its reduction in CBF and cerebral oxygen consumption, in
favour of other drugs, such as ibuprofen, which do not have such a cerebral metabolic effect [217].
4.5.4 Neonatal Brain Injury
In 1997, a review by Cooper and Springett [49] highlighted the potential for NIRS-measured oxCCO to
monitor the progression of neonatal hypoxic-ischaemic brain injury. The management strategy of HIE
could be improved with additional information regarding the cerebral metabolic state, as the development
of the injury progresses over time and can lead to a secondary energy failure (SEF). There have been a
handful of clinical studies of HIE with oxCCO which have promising results. A study of 11 infants with
HIE showed that increases of SpO2 and PaCO2 increased oxCCO (measured with the UCL4 algorithm)
which is a normal response and does not suggest pathophysiology [218]. van Bel et al. [21] saw a CBV
and oxCCO (using the Keele 4-wavelength algorithm) decrease in first 12 hours after birth in severe
HIE, but stable changes in mild HIE and controls; this could suggest the delayed neuronal cell death as
predicted by the animal models. They also saw a positive relationship between PaCO2 and oxCCO in
all HIE infants.
Recently, the relationship between the UCLn NIRS-measured oxCCO and oxygen delivery (HbD)
was investigated in 6 HIE infants and found that an increased affinity between cerebral metabolism and
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oxygenation indicated brain injury [54]. Analysis of the rewarming data after therapeutic hypothermia
from this cohort provides more evidence that the relationship between the multimodal signals is indicative
of brain injury [219]. Further analysis of these data with a multivariate statistical technique showed that
a strong relationship between oxCCO and the systemic physiology indicated more severe brain injury (as
measured by 31P MRS) [220]. This suggests that the importance of the oxCCO measurement may not
lie in the signal itself, but in its relationship with oxygenation or systemic physiology which can inform
about the delicate equilibrium in pathology. However, most of this study occurred during therapeutic
hypothermia, now a routine treatment for HIE, so it is difficult to compare with other earlier studies.
Further, therapeutic hypothermia may make it difficult to observe SEF and cause unusual metabolic
responses as mentioned before [38]. As previously discussed, there need to be more studies of the oxCCO
response during cooling.
Recent animal studies of HIE have shown promising results. The UCL group demonstrated a re-
lationship between broadband NIRS-measured oxCCO recovery fraction and HIE outcome in a piglet
model [12].
The oxCCO signal has recently been observed during neonatal stroke in a term infant for the first
time [219]. Repeated transient decreases in cerebral HbT, HbD and oxCCO were noted on both cerebral
hemispheres without significant changes in the monitored systemic physiology. A clear asymmetry was
noted in the degree of change between the two sides of the brain. Cerebral oxygenation (measured with
HbD) and oxCCO were only highly coupled on the injured side of the brain.
4.5.5 Functional Activation
There has been a huge wealth of work in fNIRS using HbO2 and HHb as indicators of the haemodynamic
response to neuronal activity since it was first presented in 1993 [221]. We have an opportunity with the
oxCCO signal to inform directly on cerebral metabolism during neurovascular coupling; there is no other
non-invasive in-vivo modality that can assess oxygen consumption during functional tasks. Concerns have
been raised regarding the likelihood of measuring ‘false positives or negatives’ in the haemodynamic
response using fNIRS from haemodynamic signals that do not originate from neurovascular coupling
[222]. Given that the oxCCO signal is more brain-specific than the haemodynamic signals, it could prove
to be a very valuable addition to the fNIRS toolbox [60, 61].
There has only been one functional activation study involving infants and oxCCO and this used the
NIRO 300. 19 newborns were given auditory stimulus and no significant oxCCO change was observed
despite a normal haemodynamic response [39]. The expected response of oxCCO during functional
activation is unknown, although an increase is often seen in adult studies of functional activation (see
section 4.6.2). Differences between the mature and neonatal brain are supported by the NIRS study
during cardiac surgery by du Plessis et al. where different oxCCO responses were seen at different ages,
which could either reflect greater mitochondrial hypoxic tolerance in younger infants or differences in the
concentration of CCO at different ages [38].
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4.6 Adult Studies
In order to characterised measured changes in the oxCCO signal, an increasing number of studies on
adults have been performed over the past 10 years. These studies fall into three categories: volunteer
studies with controlled inspired gas challenges to investigate the oxCCO response to systemic physiology,
functional activation studies on healthy volunteers, and clinical studies.
4.6.1 Volunteer Studies: Systemic Challenges
The first NIRS studies on adult volunteers were performed in the early 1990s at Duke University. Hypoxic
challenges were used to assess the changes in oxCCO in the adult brain at normocapnoea [19] and hyper-
and hypocapnoea [20] with 4-wavelength Duke NIRS systems. This work demonstrated a reduction of
oxCCO during hypoxia at all levels of PaCO2.
More recently, the UCL group has performed hypoxemia studies (SpO2 to 80%) during normocapnoea
in healthy volunteers using the UCLn algorithm to estimate oxCCO [50, 53]. The hypothesis was that
in non-anaesthetised humans a significant decrease in oxygen saturation should reduce oxCCO; this was
confirmed in the study. There was a linear correlation between oxygen delivery (estimated from the
measurement of the velocity of the middle cerebral artery (Vmca) an indicator of changes in CBF as
monitored with TCD ultrasound) and oxCCO. A temporal delay between the HbD drop and oxCCO of
∼5s was also observed. A later study using the pHOS and the UCLn algorithm confirmed the decrease
in oxCCO during hypoxia [60].
Conversely, in hyperoxia the oxCCO signal has been found to increase [60, 193]. Tachtsidis et al.
found that the oxCCO signal as measured with the UCLn algorithm was correlated with TOI (measured
with the NIRO 300), as well as Vmca [193]. Later, Kolyva et al. repeated this study using the pHOS and
also showed that the magnitude of the oxCCO decrease during hypoxia was dependent on the distance
between the source and the detector [60].
The oxCCO response to changes in PaCO2 was investigated first in 2009 [193]. During hypercapnoea,
Tachtsidis and colleagues increased inspired CO2 and saw a significant increase in oxCCO (estimated
with the UCLn algorithm) and Vmca from baseline. There was no correlation between oxCCO and
Vmca, but there were correlations with oxCCO and TOI (as measured with the NIRO 300). More
recently, Kolyva et al. confirmed the increase in oxCCO during hypercapnoea when monitored with the
UCL pHOS system [60]. They also performed hypocapnoea and saw a decrease in oxCCO. Increased
CO2 in the blood has a vasodilatory effect which can increase CBF, but it also decreases the pH which
can reduce oxCCO. The authors suggested that the increases in blood flow from hypercapnoea outweigh
the potential damage to the respiratory chain from acidosis. In these studies, the oxCCO signal had
a different trend to changes in HbT but oxCCO showed a similar trend to TOI. A hyperventilation
experiment from a different group also showed minor decreases in oxCCO with the NIRO 500 [31].
As well as answering physiological questions, the study by Kolyva and colleagues (Kolyva et al.
2014) was also designed to address scattering issues and brain-specificity questions using the UCL pHOS
system. The magnitude of the oxCCO response increased with detector distance, which was not true
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for the haemoglobin signals. This oxCCO depth dependence shows that the signal is more brain specific
which is due to the higher CCO concentration in the brain, so the signal is less prone to extracerebral
contamination than HbO2 and HHb. Neither this study [60] nor the previous one [50] saw any changes
in pathlength during any of these physiological challenges.
4.6.2 Volunteer Studies: Functional Activation
Functional activation in adults has been studied with fNIRS since 1993 (see section 4.5.5). Visual
stimulation of the occipital cortex provides a robust stimulation method and there have been a few
studies in this area to evaluate transient changes in the cellular energy metabolism that occur during
changes in neuronal activity. Heekeren et al. saw an oxCCO increase during functional activation with a
broadband NIRS (Humboldt A system), and they speculate that the cause of the increased oxCCO is not
due to increase in oxygen as it would imply that the tissue is in a low PaO2 state normally, but due to
decreases in proton electrochemical gradient increasing the rate of electron flow [56]. This phenomenon
was also seen by the same group in later papers with the Humboldt B broadband system [58, 187].
Fourier analysis of the frequencies showed that oxCCO and HHb signals have the same frequency as the
stimulation, whereas HbO2 has other peaks which can be due to other factors [58].
Significant heterogeneous oxCCO responses were seen in an anagram-solving working memory study
using the UCL pHOS system [59, 61]. No group significant change in oxCCO was seen during anagram-
solving task but there were significant increases and decreases seen in different subjects. In some subjects
a significant decrease in oxCCO was seen in the presence of a typical haemodynamic response (increase
in HbO2 and decrease in HHb) [59, 61]. It is hard to predict or model the effect of functional activation
on oxCCO; the authors suggested that the NADH oxidation and proton motive force can affect oxCCO
without affecting haemodynamics, which may provide an explanation as to the heterogeneity of the
oxCCO response despite a consistent homogeneous haemodynamic reaction. This would support the
theory of [56] regarding their visual stimuli data.
Different depths give different oxCCO responses, which could be explained by spatial distribution
of CCO which is more highly concentrated in the brain than in the extracerebral tissue [61]. A recent
UCL working-memory study with CYRIL at multiple source-detector distances showed that the increase
in oxCCO observed in the longer channels was not present in the short separation channels, despite a
typical haemodynamic response in all channels [223]. The addition of the measurement of a brain-specific
oxCCO signal in fNIRS functional studies could potentially reduce ‘false positives and negatives’.
4.6.3 Clinical Studies
Monitoring cerebral dysfunction in a clinical setting is important both in cases where the brain is at risk
of injury (e.g. cardiac surgery) or where brain injury has already occurred (e.g. TBI). There have been
an increasing number of clinical NIRS studies in adults for pathologies such as obstructive sleep apnoea
(OSA), cardiac surgery and hypotension, as well as brain injury itself.
The first investigation of cerebral oxCCO with NIRS during surgery occurred in 1995 due to con-
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cerns regarding cerebral stress of cardiac surgery causing post-operative neuropsychological damage. A
NIRO 500 study of 41 patients undergoing cardiac surgery with CPB found that patients who suffered
from neurological defects after surgery had lower minimum oxCCO values during surgery compared to
those without defects [224]. The oxCCO and venous saturation were inversely correlated during CPB
suggesting that increase in oxygen saturation may not be representative of an increase in tissue oxygena-
tion. Kakihana et al. [225] using the Sapporo algorithm and instrument saw that their measurement of
oxCCO was a good predictor of postoperative cerebral outcome in a group of 66 patients who underwent
thoracic aortic surgery; the recovery fraction of broadband NIRS-measured oxCCO following the surgery
was predictive of neurological outcome.
Further to cardiac surgery, investigators recorded changes in oxCCO with the NIRO 300 during
implantation of subpectoral implantable cardioverter defibrillators under general anaesthesia [44]. A
random change in both directions was seen in oxCCO (measured with the NIRO 300) during implantable
cardioverter defibrillator testing, despite consistent decrease in HbO2 and increase in HHb. This suggests
that the availability of oxygen at mitochondrial level was not affected by short term lack of oxygen delivery
and that mitochondrial function may be able to identify cerebral abnormalities in this group of patients
that haemodynamic changes do not reveal.
A case study of an adult woman with a long term neurological disorder examined the oxCCO response
to seizures with the NIRO 500 [32]. Prior to seizure activity, a gradual increase in HbO2 and HbT was
observed with a simultaneous reduction in oxCCO. Throughout the seizure there was an increase in
oxCCO, and HHb; seizures caused increased metabolic demand and the increase in oxCCO corroborates
this.
To investigate the response to hyperoxia in cases of brain injury, eight patients with TBI undertook a
hyperoxia challenge (60% and 100% FiO2) [52]. The concentration of oxCCO measured with the UCLn
algorithm increased during hyperoxia and correlated with brain tissue oxygen tension as measured by
microdialysis [52]; there was a negative correlation between oxCCO and lactate/pyruvate ratio which
shows that the oxCCO NIRS changes are related to cellular metabolism. Another investigation of 6
patients with TBI showed a mean increase in oxCCO during hypercapnoea, but not in all individuals
(4 increase, 2 decrease) despite increases in Vmca this could be due to heterogeneity of TBI [51]. This
study did not find an association between oxCCO and the lactate/pyruvate ratio, the authors suggest
that this may be due to more complex changes induced by CO2, such as pH, nitric oxide (NO) and
cerebral metabolic rate of oxygen (CMRO2) changes [51].
Bed tilts were performed in patients with primary autonomic failure to assess cerebral oxCCO during
hypotension measured with the NIRO 300 [46]. There was a range of NIRS-measured oxCCO responses
during large decrease in HbD and HbT. In patients where a significant decrease in oxCCO was observed,
there was a threshold in HbD and HbT reduction before that occurred. A similar threshold has been
seen in piglet studies of anoxia ([65] and it may indicate the point at which damage to the cells due to
hypoxia and/or ischaemia occurs.
Another population at risk of hypoxic injury is obstructive sleep apnoea (OSA) patients and these
have been studied with the NIRO 300. The first study looked at OSA patients during daytime naps with
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NIRS monitoring, polysomnography and laser Doppler, end tidal CO2 and SpO2 were also monitored
[43]. Correlations were seen during spontaneous hypoxias between changes in oxCCO and changes in:
TOI, CBF, SpO2 and MABP, there was a weak negative correlation between oxCCO and CO2. The
oxCCO signal was in phase with TOI but not HbO2 or HHb. These results suggest that OSA hypoxias
cause anaerobic metabolism or CO2 changes to reduce CCO. In another study of 62 sleep apnoea patients,
6 had deep apnoeas (TOI drop of >10%) and oxCCO dropped for all of these deep apnoeas [45].
4.7 Discussion
NIRS-measured oxCCO has been studied in many clinical environments. For neonates this has included
term and preterm infants, infants studied on neonatal intensive care units and during cardiac surgery.
The results from the neonatal cohort are not consistent but that is largely due to the heterogeneity of
the populations studied and differences between the protocols. A shining example of the application
of oxCCO in neonates is the indomethacin work which has shown that the oxCCO signal can provide
clinically important information [22, 26, 30]. The most recent work on neonatal HIE has shown that
the relationship between cerebral oxCCO and oxygenation is indicative of the level of brain injury as
measured by a 31P MRS biomarker of outcome [54], so oxCCO has potential clinical importance as a
cotside marker of cerebral well-being.
The adult literature also covers a wide range of clinical environments. The large study by Kakihana et
al. is an excellent example of the potential of oxCCO to be a clinical tool that is predictive of neurological
outcome after surgery [225]. Further, there is a great potential for the oxCCO measurement to be used
in fNIRS studies for a deeper understanding of oxygen metabolism during neurovascular coupling, and
for its brain-specificity [61].
Figure 4.6: hysiological stimuli and predicted NIRS-measured haemoglobin oxygenation and oxCCO
changes based on findings from this review chapter for the healthy adult brain.
The adult work also covers a portfolio of volunteer studies which have been used to deepen the
knowledge of the oxCCO signal in humans. The behaviour of the oxidation state of CCO is not fully
understood as there is no gold standard for the measurement in-vivo. However from the summary of
the results found in this review chapter, it is possible to summarise the changes in its behaviour from
challenges performed on healthy adult volunteers. The results are limited to the adult brain as it is
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not possible to obtain such controlled data on neonates. Quantification of a normal oxCCO response
in a healthy brain will allow the identification of abnormal, and perhaps pathophysiological, cerebral
responses. The generalised trends of the three NIRS chromophores are summarised in Figure 4.6.
Interpretation of a change in the oxidation state of CCO is complex because it represents a change
in equilibrium which may reflect fluctuations in any of several factors and the balance between them
including: O2 supply, glucose or other substrate supply, pH, temperature, and other ETC rates. Un-
derstanding the CCO signal is sometimes challenging as there are many different factors that can cause
increased oxidation or reduction of the enzyme. This complexity can be dealt with by using computer
modelling of the physiology [34].
The UCL group has developed a mathematical model of the physiology of brain metabolism and
circulation to aid the interpretation of the measurable cerebral signals [197–199, 226]. The first version
of the model was an elaborate representation of the adult brain [226] and was extended to simulate
changes in the NIRS variables, in particular changes in oxCCO [197]. The model has been used with
NIRS-based adult studies [197] and, after modification for the piglet brain [198], has been used in
controlled pre-clinical studies of HIE [199].
4.8 Future Directions
Measuring a real-time, bedside marker of brain tissue metabolism is an active area of NIRS research.
Many biomedical optics groups are measuring cerebral CMRO2 with combined NIRS and diffuse cor-
relation spectroscopy (DCS) [156, 174, 175, 227] and others are combining MRI and NIRS to measure
CMRO2 [148] confirming the need for a non-invasive measurement of tissue metabolism. NIRS-measured
oxCCO changes could be an alternative and/or complimentary measurement to these other monitors of
cerebral metabolism.
Near-infrared imaging (NIRI) or diffuse optical tomography (DOT) is under continuous development
[6]. Recent work by Phan et al. demonstrated the first oxCCO images, acquired using a multi-channel
broadband spectroscopy system (Figure 4.7) [63]. Topographical images with oxCCO in addition to HbO2
and HHb will allow investigation of regional changes in cerebral oxygenation and oxygen consumption
in the healthy and injured brain.
The most challenging but exciting foreseeable development for CCO would be an absolute measure-
ment. To resolve changes in the oxidised concentration with respect to the reduced concentration of CCO
would be revolutionary as it would allow more easy comparison between patients or volunteers and give
a better understanding of the state of tissue metabolism. The UCL group is working towards methods
to do this, both in new hardware and algorithms. The group has recently developed a multi-wavelength
TR spectrometer to quantify absolute changes in absorption and scattering with a view to measuring
absolute CCO redox changes [228].
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Figure 4.7: Images of block-averaged concentration changes over the occipital lobe from HbO2, HHb and
oxCCO for one subject shown during half-field chequerboard visual stimulation, demonstrating spatial
distribution of responses [63]. There is an increase in HbO2 and oxCCO on the contralateral hemisphere
during activation and a decrease in HHb. There are spatial differences between the haemoglobin and
oxCCO images as assessed by centre of gravity analysis.
4.9 Summary
This review chapter described the rationale, methods and analysis behind NIRS measures of oxCCO.
The range of human brain studies (in healthy volunteers and patients) was summarised from those first
performed by the Jobsis group, as early as 1985, to the present day. I found 103 papers published on
cerebral oxCCO NIRS measurements in humans, 65% of the studies are on adults and the remainder
on neonates. The need for a low-cost, bedside and non-invasive monitor of cerebral oxygen metabolism
remains an important and relevant clinical goal. This unmet clinical need has driven continued advances
to deliver NIRS instrumentation and methodologies which are optimised specifically for CCO measures.
With this comes renewed focus on defining the role of these measures in a range of clinical scenarios,
and fulfilling Jobsis’s vision for this optically derived metabolic marker.
Chapter 5
Development of a Novel Broadband
NIRS System: CYRIL
This chapter describes the design, development and preliminary testing of a novel broadband NIRS
system to monitor changes in cerebral cytochrome-c-oxidase in the neonatal intensive care unit.
5.1 Introduction
The biggest challenge in designing an optical system for use in a neonatal intensive care unit is the
environment. The system needs to be robust, adaptable, compact, easy to use and minimally invasive.
The key to undertaking studies within a high pressure clinical environment is ensuring that the device
does not interfere with clinical care and is simple enough for use by non-physicists. This chapter describes
the design considerations required to develop a monitor for the NICU and the development of such a
system.
Note
Some of the work described in this chapter and Chapter 6 has been published in Biomedical Optics
Express [54]. A copy of the paper is shown in Appendix B.
5.1.1 Design Considerations
The neonatal intensive care unit is a high pressure environment. The neonatal unit at UCLH has 25
intensive care/high-dependency cots, with four cots in each room. Each room has two specialist nurses
at all times, plus any number of doctors, support staff and family members. Acutely ill and premature
babies are treated in the NICU; conditions include respiratory problems, jaundice, anaemia, sepsis, as
well as all forms of brain injury. At UCLH there is a high turnover of infants (in February 2016: 85
infants were admitted, 87 infants were discharged and 27 infants were transferred). This is a challenging
environment to bring a new machine into, so the system was designed with this in mind (see Table 5.1).
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Table 5.1: CYRIL design specifications.
Specification Necessity Solution
Safety
Light intensity within
safety levels and does not
cause heating
Essential Low and high-pass filters block
light from either side of NIR
region (610-950nm) to minimise
heat deposition
Electrically safe on pa-
tient end
Essential Fibres applied so no electrical de-
vice at patient side
Electrically safe on device
end
Essential Isolation transformer to protect
from mains supply
Optics
Sensitive to low light lev-
els
Essential Lens-based spectrometer for high
throughput
Measures oxCCO Essential Broadband, UCLn algorithm
and high signal-to-noise from
spectrometer
Measures TOI Desirable Multiple source-detector dis-
tances
Measures both hemi-
spheres of brain
Desirable Dual light source and multiple fi-
bres
Insensitive to ambient
light
Essential Blackout fabric placed over
probe holder
Stable measurement over
long periods
Essential Cooling at CCD and thermally
stable light source
1Hz sample frequency Desirable Need high intensity from 1s ex-
posure: high NA and bundle fi-
bres, high light throughput in
spectrometer
Flexible detection Desirable Fibre configuration not fixed so
can change set-up via 3D print-
ing
Clinical Practicalities
Probes suitable for
neonate
Essential Light and small plastic fibres and
holders custom built
Probes stay on for long
studies
Essential Fibres attached by double-sided
tape
Compact and portable Essential All components fit on trolley
Device does not interfere
with patient care
Essential Long 3m fibres allow device to
be placed far from cotside and
optodes placed on forehead (not
used)
MRI safe Desirable Magnetically safe plastic fibres
(can be made up to 10m)
Stable and reproducible
data acquisition
Essential Device has no motorised parts -
all operation is done via software
Easy to use Essential LabVIEW GUI user friendly, be-
ing used by medical doctors
Data Storage
Stores data in event of sys-
tem crash
Essential Data saved on hard drive in real-
time
Continues running in
event of power cut
Essential Universal power supply
Simultaneous recording of
systemic monitor data
Essential ixTrend software installed on
laptop to record systemic data
with same time-stamp
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5.2 CYRIL Hardware
As discussed in section 3.2, a broadband NIRS system is made up of a broadband light source, fibres to
transmit the light to and detect from the tissue and a spectrometer. The system developed for this PhD
is no different. However, the system is specifically designed to be flexible and robust enough to perform
optical measurements within the NICU with minimal adjustments and the fibres are uniquely designed
to be comfortable for the neonatal head. In order to achieve the requirements set out in Table 5.1, the
components were carefully selected and designed; these components are described in this section.
The system is named CYRIL which stands for the CYtochrome-c-oxidase Research Instrument and
appLication (this name was chosen to reflect the key purpose of the system, to measure oxCCO) but
also to be a friendly name that would be accepted in the NICU. Figure 5.1 shows a schematic of the
core system components and a photograph of the CYRIL system in the NICU is shown in Figure 5.2.
Light is coupled into the dual source fibre bundle and carried to the tissue where the fibres are attached
with optode holders. Back-reflected light is collected by the eight detector fibres and transported to
the spectrometer where each channel is diffracted into its wavelengths and detected separately on a
2-dimensional CCD camera. The camera is controlled by, and records data in, a program created in
LabVIEW. These intensity spectra are converted into changes in chromophore concentrations via the
modified Beer-Lambert law 3.25 and displayed in real-time.
Figure 5.1: Schematic of CYRIL in the NICU. a) The portable instrument. b) The optodes and optode
holders on an infant.
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Figure 5.2: CYRIL in NICU.
5.2.1 Broadband Light Source
A broadband light source was chosen to be thermally stable with high output intensity over the NIR
region. The ORIEL Fibre Optic Illuminator 77501 produces a thermally stable broadband white light
source with a high intensity in the NIR region to illuminate the tissue. The bulb is a 100W quartz
tungsten halogen lamp with an axial filament. The lamp output is collimated with an aspheric lens and
focussed onto the fibre input to ensure good coupling into the fibre bundle (see Figure 5.3). A shutter
and iris can be used to block or limit the light entering the fibre. To minimise the heat deposition on
the subject’s head, a 610nm long-pass filter and 950nm short-pass filter were placed in the collimated
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Figure 5.3: Optical configuration of the ORIEL fibre optic illuminator 77501. Taken from 77501 manual
(ORIEL, USA).
region between the lamp and the fibre. The resulting spectrum is shown in Figure 5.4, measured with
the QE65 miniature spectrometer (Ocean Optics), and Figure 5.5, measured by CYRIL.
The effects of elevated skin temperature caused by the probe and the illuminating beam of the light
source were measured by Sonya Mahony in her MSc thesis [64] on a phantom (Figure 5.6) and human
arm (Figure 5.7). The biggest rise in temperature is due to placing probes on the arm with no change
in temperature caused by turning the light on. In the studies described in this thesis, no thermal effects
or damage to the tissue has been observed in any use of the system.
5.2.2 Spectrograph
The spectrograph was primarily selected for its ability to maximise the light throughput in the NIR
region. The Acton LS785 by Princeton Instruments (USA) is a lens-based spectrograph; lens-based
systems have a higher effectiveness than mirror-based spectrometers with respect to the throughput of
light (over 99% transmission throughout the entire working range of the spectrograph). The lenses have
anti-reflection coatings to provide high throughput in the NIR (specifically 740-1050nm). This system
uses fast lenses (f/2) to maximise the light gathering power. The lenses provide a flat 2D focal plane
that is 8 x 27mm. The LS785 is f-matched to a high NA input which is essential for minimising loss.
The light input is through a fibre adapted entrance and a variable slit which prevents overexposure. The
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Figure 5.4: Intensity spectrum of the ORIEL 77501 fibre optic illuminator with a 610nm long-pass filter
over 400-1100nm as measured with the QE65 spectrometer.
slit size was chosen to be 20µm for the CYRIL set-up as it allows good throughput but also maintains
a high spectral resolution (see section 5.5). The light is collimated to reduce loss by a series of lenses
and then is incident upon a gold-coated diffraction grating (see Figure 5.10). The grating is blazed at
1000nm and has 830 grooves/mm (each groove is 0.7nm) which gives a 136nm bandwidth. The grating
is mounted on a rotating platform so it is possible to select the range of wavelengths that are recorded
with a micrometer control gauge; as oxCCO is a strong absorber at 830nm, the 770nm-906nm range
was selected (see section 4.3 for further details, previous in-house systems built to measure oxCCO have
used the 780-900nm range successfully [61]). After diffraction at the grating, the light is focussed onto
the CCD detector (discussed in the next section) with an f/2 focussing lens; focussing the light in the
y-direction reduces cross-talk between the detector channels. Figures 5.8 and 5.9 show the spectrograph
components described here. There are no motorised parts in the LS785 which makes it stable and
reproducible which is ideal for the clinical environment.
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Figure 5.5: Output spectrum of the ORIEL fibre optic illuminator 77501 over 770-906nm as measured
with CYRIL.
Figure 5.6: Thermal changes on a phantom to test the heating effect of the ORIEL 77501 light source.
The source was turned on when placed on the phantom. Taken from [64].
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Figure 5.7: Thermal changes on a human arm to test the heating effect of the ORIEL 77501 light source.
Taken from [64].
Figure 5.8: Internal view from above of Acton LS785 Spectrograph. Taken from LS785 manual (Princeton
Instruments, USA).
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Figure 5.9: External view of Acton LS785 Spectrograph. Taken from LS785 manual (Princeton Instru-
ments, USA).
Figure 5.10: Princeton Instruments Acton LS785 Spectrograph grating. Taken from LS785 manual
(Princeton Instruments, USA).
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5.2.3 CCD Camera
The PIXIS 512f CCD camera (Princeton Instruments, see Figure 5.11) was chosen to detect light from
the spectrograph because of its large detector array and high dynamic range. It has a two-dimensional
array of 512 by 512 detector pixels (each 24µm by 24µm) on a 12.3mm by 12.3mm chip with 16-bit
dynamic range (i.e. 65536 levels). It is a front-illuminated CCD which is good for the moderate to low
light levels of NIRS, and the peak quantum efficiency lies within the NIR region (see Figure 5.12). The
CCD is cooled to -70◦C (thermally stable to ±0.05◦C) during operation to reduce thermal noise and
dark count; at this temperature the dark current is 0.002 electrons per pixel per second. The low dark
noise allows the detection of faint signals which is ideal for the low light intensities in NIRS. The CCD
read noise at 1000kHz is 5 electrons root mean square (RMS). The CCD has a USB 2.0 data interface
for control and acquisition with a laptop (see section 5.3 below).
The 2-dimensional CCD chip is able to record data from the eight detector fibres simultaneously
by binning different regions of interest as seen in Figure 5.13 (this is explained further in section 5.3).
Binning effectively increases the pixel size to increase the light collection while retaining the selectivity
for each detector fibre.
Figure 5.11: PIXIS 512f CCD camera. Taken from PIXIS 512f manual (Princeton Instruments, USA).
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Figure 5.12: Quantum efficiency of the CCD chip (solid black line). Taken from PIXIS 512f manual
(Princeton Instruments, USA).
Figure 5.13: Intensity map on the CCD camera and the bins selected when using 8 detector fibres as
displayed in the LabVIEW program. The lines (labelled ‘Strips’) are used to define the region of interest
for all of the input fibres, see Figure 5.23 for more details.
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5.2.4 Optical Fibres and Holders
Optical fibres (optodes) and corresponding optode holders were designed to connect between the light
source and the tissue and the tissue and the spectrograph. Two channels with four detectors each were
used. This was possible with a single spectrograph and camera by using the 2-dimensional camera chip
which allows the individual detection of multiple fibres simultaneously (see Figure 5.20). The fibres were
custom built by Loptek (Germany) to fit the source and spectrometer at the system end, and to be as
light and small as possible at the patient end to maximise comfort.
The light source fibre bundle branches into two fibre heads to give two source channels; a bundle of
high NA optical fibres takes light from the source lamp, after 2.5m the fibres split into two parts each
with diameter of 2.8mm for 0.5m. The optical heads are made of magnet-compatible plastic to ensure
that they are light but also MR scanner compatible (see Figures 5.16 and 5.17).
The detector fibres consist of eight individual fibres with high NA that have a 1mm diameter. Each
fibre has an individual head (see Figure 5.17) of diameter 5mm which detects light on the tissue surface.
The fibres bundled into one cable and are arranged vertically into a ferrule that inputs the light to the
spectrometer (see Figure 5.20) which enables the spectrum from each fibre to be detected individually
and simultaneously.
Optode holders were designed using AutoDesk Inventor, 3-dimensional computer aided design (CAD)
software, and 3D printed with the Objet500 Connex in a rubber-like black material (TangoBlack FLX973)
that is combined with a more rigid material (VeroWhitePlus) to increase stiffness. The design holds the
source optode next to the four detector optodes with a gap of 1.5cm between the source and the first
fibre, and 0.5cm between the centres of the other fibres (see Figures 5.15 and 5.18); this gives source-
detector distances of 1.5cm, 2.0cm, 2.5cm and 3.0cm (see Figure 5.14). The holders were designed to
be small and flexible to reduce the footprint on the head and to allow for curvature; several different
combinations of the rubber-like black material and rigid white material were trialled to find the balance
between flexibility and durability (the rubber-like black material has a tendency to tear). As there are
two sets of optodes, the two optode holders are mirror-images of each other so that the fibres can lead
from the same direction (typically up away from the head). For babies with smaller head circumferences,
another optode holder was designed that uses a single source but with four detectors each side (see Figure
5.18). This will allow the measurement of two hemispheres but with a smaller footprint on the head.
A double-sided tape that is safe for human use (Tape Range Distributors, UK) is used to apply the
optodes to the skin. The tape is placed on the underside of the optode holder (as in Figure 5.2) and then
placed on the head. This method holds the optical fibres to the skin securely which reduces the number
of movement artefacts and optical drift from a changing position. It also does not involve applying
pressure to the skull to maintain optode contact to the tissue which can result in pressure sores. There
is a possibility that some light may propagate directly from the source to the detector via the thin layer
of tape between the probe and the skin (known as light piping). If this is true, then the light piping
should remain constant throughout a measurement and thus is is unlikely to have a significant effect on
the measurement of changes in light attenuation, and therefore should have a negligible effect on the
changes in chromophore concentrations.
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Figure 5.14: Diagram of optode holder design.
Figure 5.15: CAD design of an optode holder with 1 source and 4 detectors (for left side of head) with
same dimensions as Figure 5.14.
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Figure 5.16: Patient end of optical fibre detectors shown in and out of optode holder (from CAD design
in Figure 5.15).
Figure 5.17: Optical fibre source and detectors in optode holder (left) and source fibre head (right).
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Figure 5.18: CAD design of an optode holder with 1 source and 8 detectors.
Figure 5.19: Optode holder with one source and 8 detectors from CAD design in Figure 5.18.
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Figure 5.20: Input ferrule of the detector fibres at the spectrometer end.
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5.3 CYRIL Software
A program was created in LabVIEW to control the CCD, collect the raw intensity data and calculate,
display and save the corresponding concentrations. Two versions of this program have been created and
are discussed in this section.
5.3.1 Version 1
Version 1 of the software was finalised in October 2013. Figure 5.21 is a flowchart which shows the main
functions of the first version of the program. The program is essentially structured in three sections
(as illustrated by different colours on Figure 5.21). The first section contains all of the settings for the
camera and GUI. Once the settings have been confirmed, the user presses ‘Start’ and the second section
initialises. The second and third sections are designed as ‘producer-consumer’ pair. The producer’s
job is to generate a piece of data, and place it into a fixed-sided buffer which is used as a queue. The
consumer then removes the data from the queue and processes it. This ensures that the producer can
generate data at regular intervals without having to wait for the consumer to process it. In this program,
the producer collects intensity data from the CCD and displays it, while the consumer calculates the
changes in chromophore concentrations and then displays and saves all of the data. The intensity and
concentration data are each saved in separate files for each detector channel along with a time log file.
This section describes the different parts of the graphical user interface (GUI) functions in more detail.
Settings
The ‘Settings’ tab on the left-hand side of the GUI is shown in Figure 5.22. The user can choose the
exposure time, the shutter settings and the temperature of the CCD. Variables for the calculation of the
concentration changes such as the optode distance, DPF and interpolation method are also available to
select in this tab. Further the user can specify the file name and folder to save the data.
Warning levels for low or high intensities in each channel can be set; these trigger a warning if any
part of the spectrum exceeds the saturation limit or drops below the noise level. The warning is placed in
the time log file so the user can identify periods of camera saturation or low light levels without looking
at the raw data. When a warning level is triggered this also appears on the GUI by illuminating an icon.
At saturation, the green icons labelled ‘S1-8’ for each detector will illuminate and at low intensities red
icons labelled ‘N1-8’ will illuminate. The user is also able to enter comments into the time log file (e.g.
about the subject’s status, a movement artefact or a medical event, etc.) using the ‘Comment’ box.
Figure 5.23 shows the CCD binning functionality of the GUI. The user can take and display an
intensity weighted image of the CCD pixel array and subsequently choose the region of interest (ROI)
for each horizontal strip to bin (see Figure 5.13 for a larger view). Each strip is related to one of the
detector fibres that are input into the spectrometer via the ferrule as in Figure 5.20. The strips can be
adjusted for each subject to maximise the intensity spectra at each channel without saturation.
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Figure 5.21: Block diagram of the main functions of the LabVIEW program - version 1. The colours
represent the three different sections within the program.
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Figure 5.22: CYRIL software version 1 - Settings tab. On the left side from top to bottom: the user
can set and view the CCD temperature, exposure time, and shutter state; adjust the file saving settings;
enter the optode distance and DPF; select the interpolation method to down-sample the spectra to every
wavelength; choose the number of concentration data points displayed, and send comments to the time
file. The warning icons also appear on the left side. On the right side the recorded spectra for all
ROIs are displayed with the start time and current time. The user can begin/end the data collection by
pressing the Start/Stop buttons above the tabs.
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Figure 5.23: CYRIL software version 1 - bin settings. The left side displays the CCD intensity map and
the user can take an image of the map using the Take Snapshot button and set the ROIs by moving the
strip boundaries. The right side is the same as in the previous figure.
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Intensity Data Acquisition
When the user selects ‘Start’ the CCD is programmed to acquire data per the settings using LabVIEW
drivers for the PIXIS 512f CCD (Scientific Imaging Tool Kit, R Cubed Software). The CCD collects
data separately from the ROIs and bins the data by wavelength. The intensity spectra for each ROI are
displayed on the upper right-hand side of the GUI and the user can move between the tabs to view each
detector ROI separately.
Chromophore Calculation
The intensity spectra are processed using the UCLn algorithm (equation 3.22) to give differential con-
centrations from an arbitrary baseline [48]. The changes in chromophore concentrations were calculated
from the measured changes in broadband NIR light attenuation using the modified Beer-Lambert law
as applied with the UCLn algorithm (illustrated in Figure 5.25). The UCLn algorithm in matrix form
(equation 3.25) is a least-squares fitting procedure based on multiple regression analysis, using the Beer-
Lambert law to determine the best fit of the chromophore extinction coefficients.
The change in attenuation is calculated (from equation 3.13) and interpolated to the nearest nanome-
tre across 770-906 nm using a spline interpolation (or the form of interpolation that the user selects in
the ‘Settings’ tab). The UCLn algorithm was applied to solve for changes in the concentrations of HbO2,
HHb and oxCCO across these 136 wavelengths. The specific extinction coefficient spectra used are dis-
played in Figure 4.4. The optical pathlength was derived from the product of the distance between the
optodes and the DPF, which was has been previously measured as 4.99±0.45 on the head of a newborn
infant [114], corrected for the wavelength-dependency of the DPF (also plotted in Figure 4.4). The
changes in concentration are displayed in real-time for each channel in the tabs on the right side of the
GUI.
Data Saving
The raw data (intensity spectra), processed data (differential concentrations) and time log for each
detector are saved as comma-separated value (.csv) files in real-time immediately after the data has been
processed for each measurement. Each new measurement is appended to the .csv file to ensure that the
data are saved in real-time which will prevent loss of data in the event of system failure. The time log
contains the time and date of each measurement, elapsed time from the beginning of the measurement
and warnings or comments which are encountered or entered at each time point.
Changes in concentrations of the chromophores are displayed in real-time on the lower right-hand
side of the GUI. The number of data points that are displayed can be adjusted in the ‘Settings’ tab.
However, in order to minimise the amount of data kept in random access memory (RAM) and therefore
reduce the processing time, it is advised to limit the number of measurements displayed.
CHAPTER 5. DEVELOPMENT OF A BROADBAND NIRS SYSTEM 143
Figure 5.24: CYRIL software version 1 - displaying concentrations of chromophores in real-time. Each
tab on the right side shows the intensity spectra (above) and changes in chromophore concentration
(below) from a different source-detector channel, set by the ROIs.
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Figure 5.25: Schematic showing modified Beer-Lambert law and the input variables. Intensity spectra, I,
are recorded simultaneously at all detectors (red = channel 1, blue = channel 2). The intensity spectra
are converted to change in attenuation ∆A and the change in concentration ∆c are calculated using the
UCLn algorithm with the specific extinction coefficient of the chromophores  and the pathlength β.
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5.3.2 Version 2
The software was updated in October 2014 after the first year of use to be more user friendly and also
to calculate the TOI in real-time (prior to this the TOI was calculated oﬄine in data pre-processing).
Figure 5.26 shows the major new additions to the software structure added to the version 1 flowchart
(Figure 5.21).
Settings
The new ‘Settings’ tab (Figure 5.27) has the same functionality as version 1 but it also includes a diagram
of the optode positions and the option to record a reference spectra (this was previously done manually).
To record a reference spectra the user selects ‘Reference spectra’ and then chooses the channels that
they are recording (either left side channels 1-4 (labelled ‘1234’) or right side channels 5-8 (‘5678’)). One
spectrum is captured for each of the four channels selected and this is saved as a single reference file
which can be loaded in the TOI tab (see the next section).
The new tab for the binning settings (Figure 5.28) has not changed apart from the intensity map
which has been made larger to allow more precise strip selection.
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Figure 5.26: Block diagram of the main functions of the LabVIEW program - version 2. The orange
coloured boxes represent the addition to the previous version.
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Figure 5.27: CYRIL software version 2 - settings. In this tab the user can set the exposure, optode
distances, DPF, and number of concentration data points displayed; send comments to the time file;
view the warning icons; and decide to record a reference spectra. The position of each channel in the
optode holder is illustrated in the bottom right corner for ease of use. Above the tab, the user must
enter the name of the file and can begin/end he data collection by pressing Start/Stop.
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Figure 5.28: CYRIL software version 2 - bin settings. The bin settings tab is the same as in Figure 5.23
but made larger for ease of use.
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Detector Displays
To see the full spectra of all channels in high resolution, a new tab was created (Figure 5.29). Further
each detector channel tab has been changed to a full screen width to allow the user a larger view of the
intensity spectra and chromophore concentrations (Figure 5.30). There is also a new tab that displays
the channels with the longest source-detector distances from both right and left sides of the head as well
as the TOI from each side (Figure 5.31); this allows the clinicians to see all of the most relevant clinical
information on one screen.
Figure 5.29: CYRIL software version 2 - displaying all intensity spectra.
TOI Calculation
The TOI is calculated in real-time within the consumer loop (discussed in section 5.3.1) - this process is
illustrated in Figure 5.32. The software calculates the gradient of the attenuation against the distance
(known as the ‘slope’) at every wavelength. This is fed into equation 3.45 and subsequently equation
3.46 to find the scaled concentrations of HHb and HbO2. From those the TOI is calculated with equation
3.47.
There is a new tab in the GUI that assists in this measurement (Figure 5.33). The user can load
the reference spectra (needed to calculate the absolute attenuation) and also decide to run the program
without TOI (for example if the reference spectrum has not yet been recorded). The GUI also displays
the plot of attenuation against distance at a single wavelength (780nm) so that the user can adjust the
optodes if there is not a linear relationship. The slope at every wavelength is also displayed to check for
normality. The TOI for both sides of the head is also displayed in real-time.
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Figure 5.30: CYRIL software version 2 - displaying concentrations of chromophores in real-time. Each
tab displays the data for a different channel as before but is larger for ease of use.
Figure 5.31: CYRIL software version 2 - summary of data collection tab. This tab gives the user a
summary of the most important clinical data collected. The changes in concentration for the left and
right side of the head (longest source-detector separation) are displayed at the top and the TOI for both
sides of the head are displayed below. This is the recommended tab for viewing the data in real-time.
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Figure 5.32: Flowchart of TOI calculation in LabVIEW software.
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Figure 5.33: CYRIL software version 2 - TOI tab. This tab allows the user to set the reference spectra
(required for TOI measurements) and view the TOI data. The plots at the top display the TOI for left
and right sides, while the plots below show the attenuation per distance for one wavelength (780nm) and
the slope across all wavelengths for both sides.
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5.4 Calibrations
5.4.1 Wavelength Calibration
Every pixel on the CCD chip of the CYRIL system corresponds to a certain wavelength in the x-direction.
The relationship between pixel and wavelength thus has to be determined through calibration. Each
pixel in the x-direction is calibrated to its corresponding wavelength using the LightField (Princeton
Instruments, USA) acquisition software with the IntelliCal calibration package. A neon-argon lamp with
multiple emission lines across the NIR spectrum (see Figure 5.34) was used to illuminate the CCD for the
IntelliCal calibration routine. The entrance slit width was set to 1µm. The spectrum was recorded (see
Figure 5.35) and then the pixels were matched to a wavelength by a non-linear least squares regression
refinement algorithm that minimises the intensity space residual with respect to a theoretical model
of the spectrometer. This was done for multiple wavelength ranges which were changed by rotating
the grating in the spectrograph. Therefore the system is calibrated for multiple wavelength ranges and
the user can select the range by turning the micrometer and selecting the corresponding wavelength
calibration file. The wavelength range of CYRIL is normally set to 770-906nm. The CCD resolution
error after calibration is 0.27nm.
Figure 5.34: Neon-Argon lamp used for wavelength calibration. Taken from Hg and Ne/Ar USB Dual
Light Source User Manual (Princeton Instruments, USA).
The wavelength resolution of the spectrometer alone was assessed during wavelength calibration. The
peaks in the calibration source spectra can be used to measure the resolution by testing the minimum
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Figure 5.35: Wavelength calibration spectra recorded with CYRIL.
peak-to-peak separation that one can resolve. Figure 5.36 shows two peaks in the spectrum 1.7nm apart,
therefore the resolution of the spectrometer is at least 1.7nm.
Figure 5.36: Wavelength calibration spectra recorded with CYRIL (shown in full in Figure 5.35) across
840-844nm to show resolution. The peaks at 840.7nm and 842.4nm are visible and distinct which confirms
that the resolution is at least 1.7nm.
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5.4.2 Intensity Calibration
The multiple detectors have different bin widths on the CCD and therefore require an intensity calibration
due to the different intensity proportions of the eight detector fibres. Usually a dark room is used to
record the intensity of the light source through free space with no absorbing medium. However, in a
clinical environment there are no dark rooms therefore a poster tube lined with blackout rubberised
fabric is used to collect the spectra. To ensure equal illumination of the four detector fibres the latter
are placed at the other end of the tube from the light source fibre as illustrated in 5.37. The spectra of
this set-up can then be acquired with the LabVIEW real-time program and saved as reference spectra in
an .csv file which is loaded when the program is started. Figure 5.38 shows an example of the reference
intensity spectrum recorded.
Figure 5.37: Reference intensity set-up in customised poster tube.
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Figure 5.38: Reference intensity captured in poster tube for right side channels.
5.5 CYRIL Specification
The CYRIL system has been characterised and Table 5.2 details the specification of the system. This
section described the processes to determine the specification.
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Table 5.2: CYRIL specifications.
Requirement Specification
Light throughput 99.4%
Bandwidth 136nm
Spectral range 770-905nm
Spectral resolution 4.48nm
CCD chip size 12.3mm x 12.3mm
CCD pixels 512 x 512
CCD Temperature -70◦C
Dark current 0.002 e−/p/s
Dark count ∼400 counts per second
Read noise 5e− RMS
Power output 1.62mW/mm−2
5.5.1 Optical Bandwidth
The wavelength range of an instrument is referred to as its optical bandwidth. In CYRIL it is limited by
the dimension of the CCD chip and the spectrograph grating groove density. The sensitivity of the CCD
chip would also limit the bandwidth but in this case the CCD was chosen specifically to have a high
quantum efficiency across the NIR (see Figure 5.12) so this does not limit it. The optical bandwidth is
thus defined by the groove density of the grating and the size of the CCD chip. The optical bandwidth
in this system has been measured to be 136nm. The range was selected to be 770-905nm
5.5.2 Optical Resolution
For broadband NIRS measurement of oxCCO an optical resolution of at least 5nm is required to char-
acterise the broad peak around 835nm in the CCO difference extinction spectrum [53]. The wavelength
resolution is dependent on the diffracting grating groove density, the entrance slit width of the spectro-
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graph and the size of the CCD pixels:
Dispersion =
Spectral Range
Number of detector elements
=
136nm
512pixels
= 0.27nm/pixel
Resolution = Slit Width×Grating groove density
= 20µm× 830lines/mm
= 16.6pixels
Optical Resolution = Dispersion× Resolution
= 0.27nm/pixel × 16.6pixels
= 4.48nm
(5.1)
Therefore the optical resolution of the spectrometer is 4.48nm which is sufficient for resolving changes
in oxCCO. This is larger than the resolution measured with the calibration source (section 5.4) because
the slit is wider.
5.5.3 Power Output
The power at the end of the source fibre was measured to ensure that it conforms with safety standards
and is not causing tissue heating that would be uncomfortable and potentially harmful to the patient. At
850nm the average power was measured with a power meter to be 10.03 ± 0.08mW. UK safety standards
for tissue states that the maximum power should not exceed 2mW per square millimetre. The diameter
of the source fibres is 2.80mm so the area is 6.15mm2 thus the power per square millimetre is 1.62mW,
which lies within safety limits.
5.5.4 Noise
The CYRIL system is not limited by noise under normal operation. The dark count was measured to be
∼400 counts per wavelength bin per second at -70◦C.
Binning Dependence
Potential disadvantages of using a lens-based spectrograph instead of a set of separate spectrometers is
the crosstalk among channels and/or reduction in the sensitivity. This issue of crosstalk between the
detectors is resolved by proper focussing of the light onto the detector with the focussing lens and careful
selection of pixels to be binned in the y-direction. The cross-talk was tested by blocking channels during
a measurement on a solid tissue-like phantom. The crosstalk effect was not observed between binning
regions. Figure 5.39 shows an image of the of the CCD chip where all detectors have been blocked except
the top (channel 8, at 1.5cm source-detector separation). This shows that although there is excess light
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outside of the binned ROI for that detector, the light does not affect the nearest binned ROI; there is
no significant cross-talk effect observed.
Sensitivity
The sensitivity of the system is controlled by the wavelength binning of the pixels on the CCD and
the dynamic range. The bin size ranges from 3 to 33 pixels. These ranges are comparable to micro-
spectrometers which range from 1 pixel (Avantes Ava Spec Mini) up to 64 pixels (Ocean Optics QE64000)
in the y-direction. The system has 16 bit digitisation for each ROI.
Figure 5.39: Intensity map of the CCD chip when all detectors have been blocked except the uppermost
(detector 8). There is no cross-talk between the detector binning regions (coloured lines). Amplitude is
measured in counts per pixel.
5.6 Preliminary Testing
CYRIL is able to successfully record data continuously at 1Hz for long periods (>90 hours) without
error. CYRIL is a compact and portable system that can be moved to the cotside without hindering
access to other equipment or the cot itself. The long (3m) fibres allow the system to be stored further
from the cot as space is limited. This also enables access to the baby for essential medical and nursing
care, which is especially vital in an emergency.
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5.6.1 Phantoms
In order to test the stability of the system over time, studies on solid phantoms with tissue-like optical
properties [229] were performed. Figure 5.40 shows the resolved changes in chromophore concentration
on a stable phantom showing negligible changes (on the order of nM) with time.
Figure 5.40: Changes in concentrations resolved from phantom study. Note that the scale is on the order
of nM.
5.6.2 Cuff Occlusions
To test that the system is able to measure chromophore concentration changes in-vivo, cuff occlusion
studies were performed on 5 healthy adult volunteers. Optodes were placed over the forearm muscle.
A baseline was recorded and then a blood pressure cuff on the upper arm was inflated to 60mmHg to
occlude the vein. After a period the cuff was deflated and the subject was given a rest. The cuff was
then inflated to 200mmHg to occlude both the artery and the vein, followed by a rest.
Figure 5.41 shows examples of the intensity spectra recorded during the three events (baseline, venous
occlusion and arterial occlusion).
The changes in the shape of the spectra reflect the different levels of chromophore concentrations
during each period. In the venous occlusion there is a normal supply of HbO2 but no way to remove
the HHb from the tissue, hence the concentration of both increases; the spectra is reduced in intensity
due to the increase in absorber concentration but does not change shape. However, during the arterial
occlusion a difference in the shape of the spectra is observed (shift of the peak from ∼770nm to ∼788nm
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Figure 5.41: Intensity spectra through arm during baseline (blue), venous occlusion (red) and arte-
rial occlusion (green) showing differences in spectra shapes in response to the change in chromophore
concentrations.
and increase in the ∼845nm ‘shoulder’) due to the decrease in HbO2 as it is converted to HHb. The
concentrations resolved from this study is shown in Figure 5.42. The oxCCO signal shows a small
decline throughout the occlusion which suggests that CCO becomes more reduced as the oxygenation
lowers which makes physiological sense. The gradient of the increase in HHb appears equal and opposite
to the slope of the decrease in HbO2 which corresponds with the physiological events. The stability of
the HbT signal confirms that the system is measuring the events of an arterial occlusion accurately. This
result was reproduced in all 5 subjects.
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Figure 5.42: Change in concentration during venous and arterial cuff occlusion on forearm.
Chapter 6
Monitoring Cerebral
Cytochrome-C-Oxidase in Infants
with HIE
The design and testing of the broadband NIRS system, CYRIL, was described in the previous chapter;
in this chapter the design of the studies of newborn infants with HIE is discussed. Infants with HIE
were monitored at the cotside throughout the first week of life with CYRIL. The CYRIL broadband
NIRS system was designed specifically for monitoring cerebral metabolism at the cotside in the NICU.
However, there are many challenges faced when performing studies in this environment. This chapter
describes those challenges and their solutions, and outlines the experimental protocol and data processing
performed.
6.1 Objectives and Challenges
This is the first time broadband NIRS has been used to observe cerebral changes in oxCCO after HI
injury in human newborns, and the second time oxCCO has been measured on this population [21]. The
objective for this study was to:
1. Demonstrate the measurement of cerebral changes in oxCCO with broadband NIRS at the NICU
cotside on HIE infants in the first days of life
2. Use the measurement of cerebral oxCCO in combination with multimodal data to assess brain
injury severity after HIE
As the studies are to be undertaken in the first days of life, they are performed in the NICU while
HIE is managed in an intensive environment (see section 2.5). This presents challenges and this chapter
describes how these were dealt with.
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6.2 Monitoring Set-Up
Ethical approval for the Baby Brain Study at University College London Hospital (UCLH), London was
obtained from the North West Research Ethics Centre (REC reference: 13/LO/0106) and research and
development (R&D) approval was obtained from the UCLH Trust. The NIRS study is part of the Baby
Brain Study which aims to assess the relationship between brain intracellular pH (pHi), brain perfusion
and oxCCO during neuroprotection therapies. The study is currently ongoing. Parents of term and
preterm infants born at or transferred to UCLH for treatment of acute brain injury were approached for
this project; only babies without congenital malformations are considered. Informed parental consent
was obtained before inclusion in the study. The focus of this work is on term infants with HIE but also
assesses the cerebral haemodynamic and metabolic changes in other term and preterm infants who have
developed or at risk of developing neonatal encephalopathy from other aetiologies (e.g. neonatal stroke
or seizures). The study details, parent information and consent forms are presented in Appendix A.
All infants were monitored continuously with 10 channel EEG using Nicolet monitors (Natus Medical
Incorporated, USA) which also presents aEEG data. Systemic data from the Intellivue Monitors (Philips
Healthcare, UK) were collected simultaneously using an application called ixTrend (ixellence GmbH,
Germany). Signals recorded include oxygen saturation (SpO2) measured by pulse oximetry on the foot
or hand, heart rate (HR) by electrocardiograph (ECG), respiratory rate (RR), mean arterial blood
pressure (MABP) from an intra-arterial catheter, and the partial pressures of O2 and CO2 measured
transcutaneously. The babies spent one hour in the MR scanner after rewarming. They are not known to
effect Lac/NAA.MR scans included a measurement of Lac/NAA with hydrogen (1H) MRS. The babies
were sedated with either morphine (intravenous) or chloral hydrate (oral); neither sedative is known to
affect the Lac/NAA. See Figure 6.1 for schematic of monitoring time line, Figure 6.2 for diagram of
monitors and Figures 6.3 to 6.6 for photographs of the study.
The CYRIL NIRS optodes are placed on each side of the forehead (as seen in Figures 6.5 and 6.6)
which is free from EEG electrodes and hair. The optodes and holders are affixed to the head with double-
sided tape which holds the optodes in place without applying pressure to the head. Each source-detector
pairing is positioned over one hemisphere of the brain (4 channels either side). The sources are applied
when the light shutter is closed for eye-safety reasons. The optodes are tucked underneath the EEG
cap and a piece of black-out fabric is held between the cap and the optodes to reduce interference from
ambient light. The infants were positioned in the supine position for the duration of the study.
All measurements were taken bilaterally on the forehead over the frontal lobe. NIRS measurements
began as soon as consent was granted from the parents, with a view to acquiring data as close to birth as
possible. Final NIRS measurements were performed immediately before and/or after the MR scan. The
CYRIL NIRS measurements were collected continuously over periods from 1 to 24 hours during the first
days of life at a sampling frequency of 1Hz. The aim was to record data for 4-6 hours each day during
therapeutic hypothermia and rewarming (days 1-4 of life), and 0.5-1 hour pre- and post-MR scan. The
protocol is fully described below.
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Figure 6.1: Typical time line of treatment and monitoring from birth to day 7 of life. Cooling starts
as soon as possible after birth for 72 hours. NIRS starts as early as possible once parental consent is
obtained. MR scan (MRI and 1H MRS) occurs for 1 hour between days 4 and 15 of life.
Figure 6.2: Monitors in the NICU on a HIE infant during the study.
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Figure 6.3: CYRIL in the NICU.
Figure 6.4: CYRIL in the NICU on a HIE infant.
6.2.1 Problems Encountered
The studies began in November 2013; over the first few months of the studies several problems and
challenges were encountered. Table 6.1 outlines these problems and describes the solutions implemented
to solve them.
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Table 6.1: Problems encountered during study set-up and solutions implemented.
Problem Solution
Patients
Having optode hold-
ers attached to fore-
head for long periods
of time (>24 hours)
caused minor derma-
tological abrasions on
a small number of in-
fants (these all re-
solved quickly)
Experiment protocol was
changed from long (up to 4
days) studies to studies of 4-6
hours per day
Some infants have very
small foreheads and
not enough space for 2
sets of optodes
A single source, double ended
optode holder was designed and
built to fit on a smaller forehead
without compromising the mea-
surement
Optics
Ambient light causing
artefacts in signals
Black-out fabric placed over op-
tode holders
Examination lamps
(halogen bulbs) caused
artefacts in signals
when moved
Medical staff were asked to re-
frain from using halogen lamps
and to use phototherapy lamps
(which have less interference
with our recordings as they emit
in the blue-end of the visible
spectrum, see Figure 6.8) for ex-
aminations
SRS measurements of
TOI were not produc-
ing ‘reasonable’ values
Software updated to display
the ‘slope’ at one wavelength
(780nm), the spectrum of the
‘slopes’ across wavelengths and
the TOI in real-time to allow ad-
justments (this problem has not
yet been solved, see section 7.3)
Clinical Practicalities
LabVIEW and ixTrend
software difficult to use
for medical staff
LabVIEW software was modified
to be more user friendly (see
section 5.3) and a detailed user
guide was drawn up
Infection control is an
important issue in the
NICU
The neonatal infection control
team advised us the appropriate
cleaning methods for the broad-
band NIRS instrument (see sec-
tion 6.2.3)
Data collection ixTrend software
would terminate
recording if there were
connection errors so
we were unable to
record for long periods
of time (> 4 hours)
Liaised with ixellence develop-
ers and arranged for new ver-
sion of the software that contin-
ues recording despite connection
errors
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Figure 6.5: Optodes and holders on a subject.
Figure 6.6: Optodes and holders on a subject after MRI.
6.2.2 Final Protocol
Once the problems encountered in the initial studies were solved the final protocol was finalised. The
study protocol is as follows:
1. Obtain informed consent from parent(s).
2. Clean and disinfect optodes and cables using anti-bacterial wipes (e.g. Clinell detergent wipes).
3. Switch on CYRIL system: plug in and turn on all devices (UPS, light source, spectrometer, laptop).
4. Use the shutter to shut off light in fibres (keep light on so it can stabilise but protect eyes from
fibres while unattached).
5. Check the focus and wavelength adjustment micrometres at the back of the spectrometer and
adjust if necessary.
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6. Open the LabVIEW software on the laptop. Press the ‘Run’ arrow and enter the CYRIL subject
number.
7. If the binning settings have changed, take a reference spectra:
(a) Place a source fibre at one end of the poster tube.
(b) Open the light source shutter and check that the light is visible at the other end of the poster
tube.
(c) For the first detector set (‘1234’ or ‘5678’) place the detector optodes at the other end of the
tube.
(d) Set the LabVIEW program up to record a reference spectrum (‘Settings’ tab → ‘Select Ref-
erence Spectra’ and ‘1234’ or ‘5678’).
(e) Record a reference spectrum (press ‘Start’) and ensure first measurement is not saturating in
any channel.
(f) Import the reference spectra into the LabVIEW software (‘TOI Slope’ tab → ‘Reference File’
and ‘1234’/‘5678’) and set this as default (right click → ‘Data Operations’ → ‘Set current
value as default’).
(g) Repeat for the other set of detectors.
(h) Close shutter light source and remove fibres from poster tube.
(i) set-up the LabVIEW program for normal data collection (remove ‘Select Reference Spectra’).
8. Start ixTrend software on the laptop and connect the laptop to the Philips Intellivue monitor.
9. Select patient (new or existing) and collect SpO2, ABP, HR, RR, tcpCO2, tcpO2, pulse, ECG data
using the ixTrend software.
10. Place the optodes through the cot and securely onto the infant’s forehead with the double-sided
tape and tuck under EEG cap.
11. Shield the optodes by tucking black-out fabric under the EEG cap and above the optodes.
12. Open the light source iris and shutter fully.
13. Take a short set of data to check the set-up (press ‘Start’).
14. Check the intensity spectra. Each channel should be >10000 counts and not saturating. Each
channel needs to have a smooth spectrum free of peaks from ambient light sources. If the spectra
are too low, increase the binning size for that channel (and ensure to take a reference spectra after
the measurement). If there are peaks from ambient light improve the detector shielding or reduce
ambient lighting if possible.
15. If recording TOI, check the TOI slope (‘TOI Slope’ tab). If not positive and linear then try
adjusting the optode contact to the skin.
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16. Press ‘Stop’.
17. Check the EEG timing and adjust CYRIL clock to match the EEG if necessary.
18. Begin data collection: press ‘Start’.
19. Aim to record data for 4-6 hours each day during therapeutic hypothermia and rewarming, and
0.5-1 hour pre- and post-MR scan.
20. When the study is finished, stop data collection (press ‘Stop’, data are saved automatically), turn
off all devices and carefully remove optodes from patient’s head using adhesive removal wipes.
21. Clean and disinfect optodes and cables using anti-bacterial wipes (e.g. Clinell detergent wipes).
6.2.3 Infection Control
Infection control is an important issue in NICU because neonates are immune compromised (especially
preterm babies). Further, antibiotics are widely used which can lead to resistant organisms that must
not be spread from one patient to another. The neonatal infection control team advised us on the
appropriate cleaning methods for the broadband NIRS instrument. They are as follows:
1. Hands must be thoroughly washed before entering the unit and before touching the patient.
2. Clean and disinfect probes and cabling thoroughly using detergent wipes (e.g. Clinell detergent
wipes). Thoroughly disinfect all areas of the optodes and the length of the cabling using 70%
isopropyl alcohol wipes (e.g. PDI Sani-cloth 70).
3. The other areas of the equipment and trolley should also be cleaned and disinfected in the same
manner before and after use.
4. Cover the equipment and store it in a clean and dry environment.
6.3 Subjects
At time of writing, 63 babies have been monitored with CYRIL under the Baby Brain Study between
November 2013 and December 2015. The experimental work for this PhD was completed in May 2015
when 38 babies had been studied (31 of whom were diagnosed with HIE). Table 6.2 shows the clinical
condition of each subject including the 1H MRS Lac/NAA results and Table 6.3 shows the timings of
the NIRS recordings across the days of life. All of the HIE babies were treated with TH. Some were
included in a randomised clinical trial assessing the therapeutic effects of inhaled xenon (TOBY Xe);
these babies were given xenon for 24 hours within the 72 hour cooling period [230]. data were recorded
continuously from 0.2 hours up to 77.5 hours (i.e. 3.6 days).
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6.4 Data Processing
To ensure that the NIRS data being analysed is free from system noise and artefacts, the data has to be
processed. This section describes the decisions made regarding processing and the protocol followed.
6.4.1 Synchronisation
Automatic synchronisation of the NIRS data with the systemic and EEG data was performed with a
program which was written in MATLAB (MathWorks, USA) to interpolate both the NIRS data and
the systemic data to the same time frame and frequency via spline interpolation. Therefore systemic
data were down-sampled to 1Hz. The data are put together into one Excel file (.xlsx) which allows easy
data sharing with the clinical team. This allows NIRS signals to be analysed in relation to the systemic
physiology.
6.4.2 Artefact Identification and Correction
Before the data can be analysed, light and movement artefacts have to be carefully identified and removed.
This is not a trivial task. Although we have strived to ensure good coupling of the optical fibres to the
scalp, movement of the head of the subject (normally by the clinical team as the infants are sedated)
will cause motion between each optical fibre and the scalp. This motion will cause a shift in the optical
coupling between the fibre and the scalp, which usually results in a period of high-frequency noise in the
recorded NIRS data. Even after the motion has subsided, the optical coupling is often altered, causing a
shift in the baseline measurements of the NIRS chromophores (see example in Figure 6.7). Because the
magnitude of this motion-induced noise is typically far greater than the changes associated with tissue
haemodynamics, any changes in haemoglobin concentrations in the cerebral cortex which coincide with
motion artefacts are usually so heavily contaminated that they are indiscernible.
Artefacts from changes in ambient lighting cause similar high-frequency shifts in the NIRS data. If
the lighting change is temporary and returns to its original state there will not be a shift in the baseline
of the measurement. However, a permanent change in the ambient light will cause an overall shift. To
characterise light artefacts in the NICU environment of this study they were deliberately induced to
help identification and prevention. Figure 6.8 shows the changes in concentration caused by changes in
the ambient lighting from the main fluorescent room light and moveable lights (phototherapy lamp and
halogen torch) that are attached to the cot itself for clinical purposes. Concentration changes induced
from turning the main room lights on were not significant. The lights on the cotside caused large artefacts
when held close to the neonate’s head, but the halogen lamp also caused noticeable changes when simply
turned on. Therefore, clinicians and nurses were asked to use the phototherapy lamp when examining
patients, rather than the halogen lamp as this will reduce the number of ambient light artefacts.
It was not possible for the clinical research team to provide cover to mark events when the baby’s
head was moved or when ambient light was changes so identification of artefacts was performed after the
measurement. In general, identification of artefacts can be performed manually through visual inspection
of the data, or automatically using an artefact removal algorithm [231]. There are many different
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Figure 6.7: Concentration change in oxCCO measured by CYRIL on an infant in the NICU during
movement artefact showing large spike and baseline shift.
approaches to automatic identification, some of which use another signal, such as an accelerometer [232]
or a reference NIRS channel [233], but there are also many approaches that can be applied to a standard
NIRS data set, like the one recorded with CYRIL. In NIRS studies where there are reproducible stimuli
(such as in fNIRS), one approach is to perform enough trials to minimised the average impact of the
artefacts or simply to remove any stimulus trials that coincide with identified artefacts. However, in
this study there are no reproducible stimuli therefore each data set is unique and cannot be averaged
out or rejected so simply. Correction of artefacts is, therefore, required to preserve these data. There
have been several approaches to artefact correction such as principle component analysis (PCA) [234],
spline interpolation [172], filtering based on wavelet transforms [235] and Kalman filtering [236]. Cooper
et al. [231] performed a comparison of these four different approaches using real NIRS data sets and
found that spline interpolation produces the largest average reduction in the mean-squared error while
wavelet analysis produces the highest average increase in contrast-to-noise ratio. On the basis of this
analysis, they recommended the routine application of motion correction techniques (particularly spline
interpolation or wavelet analysis) to minimise the impact of motion artefacts on NIRS data.
Heeding this advice, the spline interpolation method was trialled with the neonatal data recorded
with CYRIL. The movement artefact reduction algorithm (MARA) suggested by Scholkmann et al. [172]
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Figure 6.8: Concentration changes measured by CYRIL on an infant in the NICU during ambient light
changes. The NICU has several different light sources, main fluorescent lights for the whole room, a
phototherapy light attached to the cot and a halogen torch lamp also attached to the cot.
is based on moving standard deviation to identify the artefacts and spline interpolation for correction.
This method also corrects shifts in the baseline due to artefact. MARA was applied to our data, an
example is shown in Figure 6.9. However, due to the nature of our data, namely long (several hours)
data sets with random fluctuations caused by spontaneous changes in physiology, MARA struggled to
separate artefacts from real changes as they have similar changes in standard deviation (see Figure 6.10).
Using the systemic data to add additional information to the artefact identification allowed this insight.
Therefore, a new approach to use the extra information from the systemic physiology to inform a
manual artefact identification method was determined. A NIRS signal was displayed (for better visibility
the data are normalised) with the MABP and SpO2 and the artefacts are identified by visual inspection;
if there is a correlation between the suspected NIRS artefact and the systemic signal that indicates that
the NIRS signal is physiological. Removal of the artefacts is performed by destroying the signal within
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Figure 6.9: Changes in oxCCO measured by CYRIL during movement artefact. Upper graph shows
signal before and after MARA. Lower graph shows moving standard deviation with threshold used to
identify artefact.
the identified artefact period, shifting the baseline and interpolating across the period of artefact. Figure
6.11 shows the results from this procedure. The baseline shift is very simplistic as the baseline is moved
manually to the point at which the start of the artefact was identified. The method could be improved
by using a time-averaged signal either side of the artefact section and adding simulated noise to the
artefact period.
CHAPTER 6. MONITORING CCO IN INFANTS WITH HIE 177
Figure 6.10: Changes in concentration of oxCCO (both right ‘8’ and left ‘4’ channels) measured with
CYRIL showing two real rapid changes (around 4260s and 4530s) that MARA could not distinguish from
motion artefact. The MABP is also displayed to show that the changes identified were actually real and
caused by a physiological change.
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Figure 6.11: Concentration changes measured by CYRIL on an infant in the NICU before and after
artefact removal.
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6.4.3 Filtering
After artefact removal, NIRS data were processed with an automatic wavelet de-noising function which
reduces the high frequency noise but maintains the trend information [237]. The function wden from
MATLAB was used with a 4-level wavelet decomposition, using a Daubechies 4 as mother wavelet, hard
thresholding to remove noisy coefficients, and the noise level was found using a heuristic approach to the
Stein’s unbiased risk estimate. Figure 6.12 shows an example of this process.
Figure 6.12: Concentration changes measured by CYRIL on an infant in the NICU before and after
artefact removal and wavelet de-noising.
6.4.4 Data Post-Processing Protocol
All data post-processing as described above has been automated in Matlab code. The protocol is as
follows:
1. Save NIRS and systemic data onto internal server (FileZilla) and back-up hard drive. All data are
stored anonymously under CYRIL numbers.
2. Synchronise the NIRS and systemic data at 1Hz using ‘synchALL.m’ Matlab code and save Excel
files on the server.
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3. Artefact identification and removal using ‘cutInterpShift.m’ Matlab code.
4. Wavelet de-noising using ‘wdenPlot.m’ Matlab code.
6.5 Examples of Data
This section shows some examples of data recorded in the study. The CYRIL data are displayed with
the systemic physiology data. Large changes in the systemic physiology will impact upon cerebral
haemodynamics and metabolism. Figure 6.13 shows data from a HIE infant with a predicted poor
outcome: a decrease in arterial oxygenation with a corresponding increase in blood pressure, respiratory
rate and partial pressure of CO2, and the resulting cerebral signals; an increase in HHb, a decrease in
HbO2 and oxCCO.
Figure 6.13: Signals recorded on 26/11/13 20:06:04 on infant 2 during a multitude of changes in systemic
physiology.
Another example of data from a HIE infant with predicted poor outcome is shown in Figure 6.14.
There is a decrease in arterial saturation, blood pressure, and heart rate which corresponding with
decrease in cerebral oxygenation and metabolism.
A peak in blood pressure precedes a large arterial desaturation in Figure 6.15 in a HIE infant with
predicted good outcome. The blood pressure increases is visible in HbO2 and oxCCO signals and the
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Figure 6.14: Signals recorded on 03/01/14 08:38:47 on infant 6 during arterial desaturation with blood
pressure changes.
arterial desaturation correlates with a reduction in HbO2 and oxCCO, and an increase in HHb.
These examples give a glimpse into the data recorded in the study, observing changes in the cerebral
haemodynamics and metabolism due to spontaneous systemic changes. It is obvious that the data are
complex and there is no simple relationship between the multimodal signals. However, the hypothesis of
this thesis is that the relationship between the spontaneous systemic changes and the cerebral response
will give an indication of cerebral injury severity. The proceeding chapters will investigate this hypothesis.
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Figure 6.15: Signals recorded on 15/05/14 17:18:23 on infant 15 during desaturation (with blood pressure
changes).
Chapter 7
Evaluation of Clinical Broadband
NIRS Measurements
To my knowledge this is the first time that the in-vivo oxidation changes of brain tissue CCO have
been recorded with broadband NIRS in HIE infants in the NICU. The use of CYRIL in the NICU
for continuous periods over the first week of life has been demonstrated; recording from ∼1 hour up
to 24 hours per day, to simultaneously measure changes in cerebral oxygenation, haemodynamics and
metabolism in 38 newborn infants. In order to assess the data from the CYRIL system during its use,
optical analysis was performed on the data recorded in the NICU as described in the previous chapter.
This chapter describes the validation of the optical data recorded before the concentration data are used
for physiological analysis.
7.1 Measurements of oxCCO
The literature has shown that there is concern over the uniqueness of the oxCCO measurement (see
section 4.3). The oxCCO signal as measured by CYRIL was assessed to ensure that there is no cross-
talk from the haemoglobin signals. First, the direction of the signal was observed in relation to the
haemoglobin chromophores and then the residuals from the back-calculated attenuation changes were
investigated.
7.1.1 Examples of oxCCO Changes with Haemoglobin Changes
The most simple test to see if the oxCCO is independent of HHb and HbO2 is by observing changes
in the signals and visually assessing for similarities. Figures 7.1 and 7.2 show two different examples of
the oxCCO signal changing in the same direction as HbO2, HHb and neither respectively. Additionally,
Figures 6.13 to 6.15, and 11.4 show examples of oxCCO changing both with and against HbO2.
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Figure 7.1: Data recorded on infant 21 at 25/06/14 09:29:41 showing changes in oxCCO that are different
to the haemoglobin signals response during spontaneous hypoxia.
Figure 7.2: Signals recorded on infant 20 on 18/06/14 16:48:33 showing changes in oxCCO that are
different to the haemoglobin signals response during spontaneous hypoxia.
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7.1.2 Residual Analysis
The change in the shape of the intensity spectrum reflects the change in the levels of chromophore
concentration in the tissue; Figure 7.3 shows the intensity spectra before and during a SpO2 desaturation.
The peak of the spectra shifts from ∼780nm to ∼785nm due to the decrease in HbO2 and oxCCO, and
the increase in HHb. The resulting attenuation is shown in Figure 7.4, with the associated changes in
chromophore concentration in the legend.
Figure 7.3: Example of intensity spectra before desaturation (SpO2= 100%) and at the nadir of desatu-
ration (SpO2 = 77%) in subject 003, channel 1 from the longest source-detector distance. A shift in the
peak of the spectrum is observed.
To investigate the spectral changes due to the oxCCO chromophore, the UCLn algorithm was also
used to derive changes in chromophore concentrations when solving only for the other two chromophores
(HbO2 and HHb). Attenuation-change spectra were then back-calculated from these concentration
changes and the differences between the 2- and 3-chromophore fits were studied. If all of the chro-
mophores that explain the spectra are fitted then the residual error between the two sets should not
have a defined shape, it should be randomly fluctuating around zero. However, if there is a shape to the
spectra then this would suggest that there is a chromophore that is unaccounted for. Two examples of
this process are shown in Figures 7.5 and 7.6 for two different infants during spontaneous hypoxia. The
resulting residual fits have a similar shape to the oxCCO spectra which suggest that a change in all three
chromophores is necessary to explain the attenuation change.
The back-calculated attenuation-change spectra from the furthest detector in a selection of infants are
shown in Figure 7.7 as the difference between the 3- and the 2-chromophore fit for 6 subjects during their
largest desaturation. It is noted that the spectrum presented for each subject is an average spectrum,
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Figure 7.4: Change in attenuation between intensities shown in Figure 7.3 this relates to ∆[HbO2] =
∼-6µM, ∆[HHb] = ∼3µM and ∆[oxCCO] = ∼-1.5µM.
derived from all individual spectra corresponding to the largest desaturation event in that subject. The
spectra do not have an arbitrary distribution around y = 0, but appear to show a shape approximating
the oxidised minus reduced CCO spectrum (see Figure 7.7), featuring a broad peak at approximately
830 nm. This suggests that fitting the measured changes in near-infrared attenuation only for HHb and
HbO2 would leave a chromophore with the spectral features of oxCCO unaccounted for. Based on these
findings, only results from the 3-chromophore fit are discussed throughout this study.
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Figure 7.5: Example of residual analysis of NIRS data from the neonatal study. a) SpO2 spontaneous
decrease showing 2 time points, before and during hypoxia, from which the change in attenuation is
calculated. b) Concentration results from fitting change in attenuation spectra to 2-(HHb and HbO2)
and 3-(HHb, HbO2 and ox-redCCO) component models. c) Attenuation measured and attenuation fit
back-calculated from 2- and 3- chromophore fits. d) Residual differences between real attenuation and
back-calculated attenuations, and the difference between them; note the shape of the difference between
the residuals for the 2- and 3-chromophore fits is similar to the ox-redCCO spectra (also plotted for
comparison on a separate scale).
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Figure 7.6: Another example of residual analysis of NIRS data from the neonatal study. a) SpO2
spontaneous decrease showing 2 time points, before and during hypoxia, from which the change in
attenuation is calculated. b) Concentration results from fitting change in attenuation spectra to 2-(HHb
and HbO2) and 3-(HHb, HbO2 and ox-redCCO) component models. c) Attenuation measured and
attenuation fit back-calculated from 2- and 3- chromophore fits. d) Residual differences between real
attenuation and back-calculated attenuations, and the difference between them; note the shape of the
difference between the residuals for the 2- and 3-chromophore fits is similar to the ox-redCCO spectra
(also plotted for comparison on a separate scale).
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Figure 7.7: Difference between the 2- and 3-chromophore residual fits during a spontaneous hypoxia
event in 6 different infants: 2, 5, 7, 8, 9 and 10. Attenuation-change spectra back-calculated from the
calculated concentration changes during the largest SpO2 desaturation observed in each subject. The
presented spectra are the average of all spectra during the desaturation.
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7.2 Depth Sensitivity
Previous NIRS studies have suggested that a source-detector separation of between 1.0 and 2.5cm will
probe depths of ∼1cm which is sufficient to monitor cerebral activity [174]. In this section, the depth
sensitivity of CYRIL is not estimated, however, its ability to resolve changes from the cerebral cortex is
assessed.
7.2.1 Experimental Data
Using different source-detector distances it is possible to investigate the differences in the chromophore
concentration changes at different tissue depths. In theory, light travelling between the longer source-
detector separations will have travelled deeper into tissue (see Fig 3.8 for illustration) and so will be
more likely to interrogate the brain. Therefore, if there is a cortex specific change occurring in the NIRS
chromophores, the longer source-detector separation should resolve larger concentration changes. This
has been shown in adult functional activation studies [61] as discussed in section 4.6.
As the density of mitochondria, and therefore CCO, is much higher in brain tissue than in the
extracerebral tissue (ECT) it is expected that a change in oxCCO would be higher in this region.
Therefore, a longer-source detector separation would resolve larger changes in oxCCO. This would not
be as noticeable in the haemoglobin signals as the contrast between ECT and brain tissue vessel density is
less stark. An example of this is shown in Figure 7.8 taken from subject 17 during spontaneous hypoxia. It
can be seen that the haemoglobin signals have similar changes at all source-detectors distances, although
the change in oxCCO decreases much more in the longest separation (∼2µM) compared to the shortest
separation (∼0µM). This suggests that the light recorded at the longest source-detector separation is
travelling through more mitochondria dense tissue, most likely the cortex, than the shortest separation.
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Figure 7.8: Changes in concentration on subject 17 from different source-detector distances during an
arterial oxygenation decrease.
7.2.2 Simulations of Light Transport
A simulation based on work by Brigadoi and Cooper [145] was designed at UCL specifically for the
CYRIL hardware to investigate the propagation of light at the multi-distance channels and to estimate
the depth of light penetration. A neonatal head model of 40 weeks GA was used for the simulation.
This atlas model was based on 324 newborn scans [145]. The different layers of the head were segmented
into ECT, CSF, grey matter (GM) and white matter (WM). Due to the lack of MRI contrast in the
newborn head, the scalp and skull layers were modelled as one layer referred to as the ECT. Each layer
was modelled with different absorption and scattering coefficients; these optical properties are shown in
Table 7.1. The simulation was run at 800 nm as the optical properties for the entire wavelength range
770 nm - 906 nm as used in CYRIL are not known. This creates a challenge for simulation studies of
the broadband system.
In order to apply the model, an estimate of the probe positioning on the head was made (see Figure
7.9) and simulations were run for the source-detector separations of 1.5, 2.0, 2.5 and 3.0cm. The Monte
Carlo simulation was performed with 1x108 photons simulated as a source. The photon distribution at
the different source-detector separations in the neonatal head can be seen in Figures 7.10 and 7.11 for a
close-up of the longest source-detector distance. It can be seen that even the 1.5cm channel is sensitive
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Table 7.1: Optical properties used for simulation of light propagation in neonatal head (data from Fukui
et al. [68]).
Layer Transport
Scattering
Coefficient
(mm−1)
Absorption
Coefficient
(mm−1)
Scalp 1.9 0.018
Skull 1.6 0.016
CSF 0.25 0.004
Grey Matter 0.5 0.048
White Matter 1.0 0.037
to brain tissue with the furthest 3.0cm channel displaying the largest sensitivity to brain tissue. Table
7.2 shows the results from the simulation.
Figure 7.9: Position of CYRIL optodes on brain atlas used for simulations (right side only).
This analysis suggests that the CYRIL set-up is sensitive to brain (both GM and WM) at all source-
detector separations on a term infant. This agrees with analysis on a generic set-up on a range of infants
at different GA which found that channels with separations of 2.15mm or greater have brain sensitivity
greater than 5% [145]. It is not possible to check this experimentally without performing a challenge
which is specific to the brain (i.e. a functional task).
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Figure 7.10: CYRIL sensitivity to 40 weeks GA brain from all source-detector separations (channel 1:
1.5cm, 2: 2.0cm, 3: 2.5cm, 4: 3.0cm).
Table 7.2: Results from Monte Carlo simulation.
Optode distance (cm) 1.5 2 2.5 3
Number of photons detected 2691 2110 1500 993
Absolute attenuation 4.6 4.7 4.8 5.0
Pathlength (cm) 10.0 11.2 12.3 15.2
DPF 6.7 5.6 5.0 5.1
Percent of pathlength
through WM (%)
15 16 17 19
Percent of pathlength
through GM (%)
20 20 19 21
Percent of pathlength
through CSF (%)
36 36 37 35
Percent of pathlength
through ECT (%)
29 27 27 24
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Figure 7.11: Close up of CYRIL sensitivity to 40 weeks GA brain from 3.0cm source-detector separation
(channel 4).
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7.3 TOI Measurements
The CYRIL system has the capability to record multi-distance (MD) measurements of attenuation so, in
theory, it should be able to use the SRS method to resolve TOI. The TOI is an absolute measurement of
cerebral oxygenation and is commonly used in clinical neonatal research so is of great interest. It would be
particularly interesting to observe oxCCO activity with TOI; the knowledge of tissue saturation would
inform on the absolute oxygen levels within the tissue, which would help explain the changes in the
oxygen-dependent CCO redox state. However, there are many problems with the methodology and the
precision and variability of TOI [238].
The SRS algorithm, as described in section 3.1.5, has been applied to the CYRIL data (see section 5.3)
but there are many problems with the TOI results. In some instances the TOI calculated is negative or
greater than 100% which is not physiologically possible as the TOI represents the fraction of haemoglobin
which is oxygenated. An example of a data set from subject 27 where both of these cases occurs is shown,
as well as some periods of TOI within a ‘reasonable’ range (i.e. between 0 and 100%) in Figure 7.12. To
investigate the difference between these measurements the ‘slopes’ ( δAδρ ) at one wavelength for the three
different periods are plotted in Figure 7.13. All three slopes have very strong correlations (R2=0.97-0.99)
and it is observed that a very small change in the slope (from 0.055 to 0.059) changes whether the TOI
calculated is ‘reasonable’ or not. In this case the change in the slope is mostly likely due to poor optode
to skin contact as there appear to be large motion artefacts between the different periods.
The theory behind SRS assumes that the tissue is a homogeneous semi-infinite medium (see section
3.1.5) but in actuality the head is a complex layered structure with vastly different optical properties
between each layer (see Table 7.1). The SRS method was developed for the adult head and used a
source-detector distance of ∼5cm. Therefore, to ascertain whether the neonatal head anatomy could be
the source of the TOI problems, for example, if the change in attention with distance is not linear in
the CYRIL geometry on a neonatal head, the model described in the previous section 7.2 was used to
calculate the slope in an idealised situation (i.e. no optode contact losses). Figure 7.14 presents the
results from the Monte Carlo simulation which show that there is a strong linear relationship (R2=0.99).
The slope from the simulated data are an order of magnitude higher than that of the experimental data
which may allude to the problem. However, it is not possible to calculate a TOI from the simulated data
as more than one wavelength is required (see equation 3.46).
It is obvious that the calculation of TOI needs a significant amount of work but the measurement
of TOI is not the focus of this thesis, so this project has been moved to ‘Further Work’ (Chapter 11).
TOI measurements will not be used in the analysis, as the issues with the measurement mean that it is
unreliable even when it appears ‘reasonable’.
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Figure 7.12: TOI recorded from infant 27. Points highlighted at three different cases (red: negative TOI,
green: TOI between 0 and 100%, amber: TOI greater than 100%). The slope at each point is presented
in Figure 7.13.
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Figure 7.13: Slopes at 800nm from points highlighted in Figure 7.12.
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Figure 7.14: Slope at 800nm from simulated data in previous section.
CHAPTER 7. EVALUATION OF NIRS MEASUREMENTS 199
7.4 Summary
The CYRIL system has been demonstrated within the NICU and the oxCCO signals recorded have
been shown to be independent of the larger haemoglobin signals. Therefore this machine is capable
of monitoring changes in cellular metabolic activity, in addition to haemodynamics and oxyegnation.
CYRIL is sensitive to the neonatal cortex, both grey and white matter, in its current configuration.
Despite the capacity to record multi-distance data for SRS, the calculation of a reliable and reasonable
TOI was not possible and requires further work.
Chapter 8
Cerebral Oxygenation and
Cytochrome-C-Oxidase Changes in
Response to Spontaneous Hypoxia
in HIE Infants
Analysis of the data collected with respect to the underlying physiology begins in this Chapter and
continues in Chapters 9 and 10. The goal of broadband NIRS in intensive care is to provide a useful
measure of brain metabolism at the cotside. As CYRIL uses differential spectroscopy to determine
changes in concentration, it is not possible to use absolute measurements of chromophores to diagnose
brain tissue health. Therefore, in order to compare the signals across different infants, it is necessary to
assess the changes in response to external stimuli. Such stimuli include changes in the systemic variables
measured, the temperature, a change in clinical care (e.g. beginning of treatment) or with age. This
chapter uses spontaneous drops in arterial oxygenation as stimuli and examines the response in the
cerebral NIRS signals.
8.1 Introduction
A transient arterial saturation decrease could be caused by a wide range of events including, but not
limited to, apnoea, bradycardia (slowing of the heart rate), immaturity of the baby’s nervous system,
seizures, infection, acid reflux, high or low body temperature (note that HIE infants will be treated
with hypothermia over the first 3 days of life), obstructed ventilation, and decreased ventilatory drive
(caused by decreased mental status). Desaturation events are relatively common in HIE infants over
the first week of life, and most of this cohort have experienced several arterial desaturations during the
monitoring period. It is interesting to understand how they affect cerebral haemoglobins, oxygenation
and metabolism. In particular, it is most interesting to know if the level of brain injury affects the
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CHAPTER 8. CCO CHANGES IN RESPONSE TO HYPOXIA IN HIE 201
cerebral response to hypoxia and whether the response is related to the outcome as predicted by MRS.
Infant studies of oxCCO during hypoxia have found conflicting results, see section 4.5 for more
details. Brazy and Jobsis observed a decrease in oxCCO during spontaneous oxygen desaturations in
three preterm infants in the first NIRS study of neonates [16]. A preterm study showed that small SpO2
changes did not alter oxCCO [70]. Wickramasinghe et al. saw an inconsistent (increases and decreases)
and insignificant change in oxCCO during the reduction of FiO2 (SpO2 change ∼10%) in neonates [215].
A study of infants during repetitive apnoeas found a consistent trend of reduced oxCCO during the
breathing cycle [33]. The heterogeneity of the response to these hypoxias may be a reflection of the level
of brain injury, prematurity, previous oxygenation levels or influence of systemic pathophysiology.
Adult studies of hypoxia during normocapnoea in healthy volunteers have consistently found a de-
crease in oxCCO [50, 53]; there was a linear correlation between oxygen delivery (estimated from the
measurement of the Vmca) and oxCCO. A temporal delay between the HbD drop and oxCCO of ∼5s
was also observed. A later study confirmed the decrease in oxCCO during hypoxia [60].
Broadband NIRS studies of piglet models of HIE have found a strong link between the oxCCO signal
and MRS markers of cerebral metabolism during the HI insult [12]. Another piglet study found that
during anoxic swings a reduction in oxygen delivery caused a linear decrease in HbO2, but a biphasic
change in oxCCO [65] (shown in Figure 8.1). A reduction in oxCCO may be a signal of impending damage
and this has also been previously suggested by Cooper et al. [190]. The heterogeneity of the oxCCO
response to hypoxia has also been seen in a study of 4-week old piglets undergoing increasingly severe
episodes of hypoxia [66]. At lower severities of hypoxia (8 and 12% FiO2) there were small increases in
oxCCO, while at higher degrees of hypoxia (6, 4 and 0% FiO2) oxCCO decreased further with severity;
consistent decreases in HbO2 and corresponding increases in HHb were observed in all hypoxic episodes
(see Figure 8.2). It is possible that the influence of the anaesthetic may cause the unexpected increase in
oxCCO during hypoxia, although not many studies have investigated the influence of anaesthesia alone
on CCO. A study of infants undergoing surgery with and without propofol, an anaesthetic, observed a
larger decrease in oxCCO during surgery with propofol than without [34]. This suggests that anaesthesia
does affect metabolism, but it is difficult to untangle the effects of anaesthesia on CCO in studies without
a non-anaesthesia control group [38].
8.1.1 Aim
The hypothesis is that the relationship between oxygenation and cerebral metabolism during hypoxia
will depend on the level of brain injury. To test this hypothesis, the cerebral NIRS signals will be
analysed during spontaneous hypoxias, which are common in this cohort in the days proceeding birth.
The analysis will compare with the MRS-measured Lac/NAA biomarker of injury severity.
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Figure 8.1: Changes in oxCCO (represented here as the CuA redox state) plotted against HbO2 at both
normocapnia (N) and hypercapnia (H) during the onset of anoxia. The results are shown as mean±SD
(n=7 piglets). Taken from [65].
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Figure 8.2: Temporal association of NIRS and MRS variables during different levels of FiO2 in one
piglet (taken from [66]). The x-axes are time in minutes. Hypoxia starts at time 0 (HO) and extends
to time 10 (PO). NIRS changes are expressed in µM times DPF. Decreases in oxCCO (shown here as
CYTO2), temporally correspond to decreases in PCr as measured by MRS. More severe reduction of
oxCCO, is accompanied by decreases in both PCr (shown here as PC) and NTP. PCr and NTP loss are
not temporally associated with HbO2 (shown here as HbO), and HHb (shown here as Hb) changes.
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8.2 Method
data were collected and pre-processed as outlined in Chapter 6. Only infants diagnosed with HIE were
included in this analysis.
8.2.1 Data Analysis
data were analysed according to decreases in SpO2. For each SpO2 desaturation with a decrease of 5%
or greater, chosen as smaller changes may not be clinically significant, the magnitude of change in the
cerebral NIRS variables was recorded. The SpO2 signal was inspected and each desaturation start and
nadir was identified and selected manually; these time points were then used to calculate the changes in
HbD, HbT and oxCCO over the event. See Figure 8.3 for a schematic of this process. The surrogate
markers of cerebral oxygen delivery and blood volume changes were used (i.e. HbD and HbT) as they
are more intuitive representations of the physiology. Magnitude changes in HbD, HbT and oxCCO were
recorded for both NIRS channels above the frontal lobes of the right and left hemispheres, and then these
changes were averaged. The mean change in the NIRS signals were averaged per infant. The change of
MABP, HR and CO2 tension in the period between SpO2 desaturation start and nadir were also recorded
with their standard deviations.
8.2.2 Statistical Analysis
All statistical analysis was carried out in MATLAB (Mathworks, USA), in which scripts were written
to semi-automate the procedure. The coefficients of determination R2 (sometimes r2) were calculated
between the magnitudes of each SpO2 saturation changes and the corresponding changes in HbD, HbT
and oxCCO for each subject across all days of life. This tests how well the data fit to a linear model.
R2 was also calculated for oxCCO against HbD and HbT. Figure 8.7 shows 4 examples of this process.
These coefficients were then correlated with the Lac/NAA measurement for each subject to identify
trends between the relationships between SpO2 and/or the NIRS measured values and the severity of
injury. A p-value of less than 0.05 was considered statistically significant. If a subject had less than 5
desaturation events recorded, it was not eligible for this study as 4 data points were determined to be
too few to observe a significant correlation across.
8.3 Results
Examples of NIRS data recorded, alongside systemic measurements (MABP, arterial SpO2, heart rate,
respiratory rate, and arterial CO2 and O2 tension), are shown in section 6.5 and in Figure 8.3.
There were a total of 29 HIE subjects for which full data were recorded, of which 8 infants were
rejected from the analysis as there were less than 5 desaturation events recorded. Of the 21 eligible for
this analysis, 8 infants had severe injury and 12 were female. The mean birth weight was 3.2±0.5kg and
the mean GA was 39±1 weeks.
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538 desaturations from the 21 subjects were identified. There was no relationship found between
the number of desaturation events observed within an infant and the severity of injury. Desaturations
occurred over periods from a few seconds up to ∼40 minutes and the mean desaturation magnitude was
11.8±3.5%. On average the MABP increased by 1.9±6.2mmHg (recorded in 16 of the 21 subjects anal-
ysed), the HR increased by 0.4±3.6 beats per minute, and the CO2 decreased by 0.2±1.0kPa (recorded
in 16 of the 21 subjects studied). The mean change in each variable is displayed per infant in Table 8.1.
There were no significant correlations between the magnitude of change in any of the systemic variables
and injury, as defined by Lac/NAA.
Across all subjects there was a consistent negative change in the HbD and oxCCO measurements:
mean decreases were 3.8±4.3µM and 0.5±1.2µM; and a positive change in the HbT measurements: mean
increase was 1.3±2.5µM. The individual mean changes are displayed in Figures 8.4 to 8.6. There were no
significant correlations between changes in any of the NIRS variables and injury, as defined by Lac/NAA.
Table 8.2 presents the R2 between the magnitudes of each SpO2 change and the corresponding change
in HbD, HbT and oxCCO, and for oxCCO against HbD and HbT. These coefficients were correlated
with the corresponding Lac/NAA measurement across all subjects; these are displayed in Figures 8.8 to
8.12. Only the correlation coefficients between HbD and oxCCO has a statistically significant (p=0.018)
correlation with the MRS-measured Lac/NAA values.
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Figure 8.3: Example of SpO2 desaturation from channels 1 and 2 (right and left side respectively) on
subject 003 (mild injury) with start and nadir of desaturation marked for SpO2 and corresponding
position in the NIRS signals.
Figure 8.4: Mean change in HbD per infant during spontaneous desaturations.
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Figure 8.5: Mean change in HbT per infant during spontaneous desaturations.
Figure 8.6: Mean change in oxCCO per infant during spontaneous desaturations.
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Figure 8.7: Examples of the magnitude of changes in HbD and oxCCO during desaturation events for
four infants. Each point represents a single desaturation event. Notice that the severely injured infants (7
and 13) have strong correlations, whereas the infants with mild and moderate injury show no correlation.
Figure 8.8: R2 for Lac/NAA against SpO2 versus HbD. Each point represents an infant.
CHAPTER 8. CCO CHANGES IN RESPONSE TO HYPOXIA IN HIE 211
Figure 8.9: R2 for Lac/NAA against SpO2 versus HbT. Each point represents an infant.
Figure 8.10: R2 for Lac/NAA against SpO2 versus oxCCO. Each point represents an infant.
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Figure 8.11: R2 for Lac/NAA against HbD versus oxCCO. Each point represents an infant. The linear
correlation is statistically significant, p = 0.018.
Figure 8.12: R2 for Lac/NAA against HbT versus oxCCO. Each point represents an infant.
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8.4 Discussion
This analysis of multiple spontaneous hypoxias was successfully performed on 21 out of 28 HIE infants to
assess the clinical significance of the cerebral haemodynamic and metabolic information changes moni-
tored by CYRIL. A significant association has been found between known biomarkers of HIE outcome as
measured by 1H MRS. This confirms the hypothesis that the relationship between cerebral metabolism
and oxygenation are related to brain injury severity.
While there is, in general, a mean decrease in cerebral oxygenation per baby (HbD decrease in 19 out
of 21 infants) and increase in total haemoglobin (HbT increase in 18 out of 21 infants) during spontaneous
desaturation, the oxCCO response is less predictable with a decrease in 13, increase in 5 and no change
in 3 infants (see Figures 8.4, 8.5, and 8.6). The haemoglobin changes are as would be expected in a
healthy brain [60]; the reduction in cerebral oxygenation (via the surrogate, HbD) is a direct response
to the reduction in arterial saturation, while an increase in total blood volume (via the surrogate, HbT)
is an indirect response from cerebral autoregulation. In a healthy adult brain, a decrease in oxCCO has
been recorded [53, 60], and is expected because there is a reduction in available oxygen, the final electron
acceptor in the ETC, so CCO will be unable to pass electrons to it and thus will remain reduced (retaining
electrons). However, this assumes that the substrate flow is maintained throughout the hypoxia; this
will not be the case if the hypoxia is accompanied by ischaemia. Ischaemia will reduce glucose delivery
to the other end of the metabolic system and hence the supply of free electrons to the ETC will decrease,
leaving CCO oxidised (without electrons). Accordingly, it is sometimes difficult to interpret changes in
the concentration of oxCCO, but work in a piglet model of HI has shown strong evidence that reduction
in oxCCO represents the decline in ETC activity [12]. The unusual response of an increase in oxCCO has
been seen in anaesthetised rodent models at small FiO2 decreases [66] and may be caused by abnormal
physiology caused by anaesthesia, or perhaps in this case, injury to the brain. However, there was no
correlation between thalamic Lac/NAA and changes in oxCCO during hypoxia. This may be due to the
difference in the measurement location of the separate monitors (i.e. MRS voxel placed in the thalamus
and oxCCO measured over the frontal lobe) and the potential localisation of the HI injury. HI injury to
the immature foetal brain are usually localised to particular regions or groups of structures within the
brain as opposed to manifesting as a global injury to cerebral tissue [96].
One might expect that the correlation between the changes in oxCCO and cerebral oxygenation (via
HbD) would be similar to that of oxCCO and systemic oxygenation (SpO2); however this is not the
case as the strength of the relationship differs on a subject level (e.g. subject 13 had an insignificant r2
for SpO2 against oxCCO, but a strong r
2 for HbD against oxCCO). This perhaps emphasises the fact
that systemic arterial oxygenation at certain instances is not a good indicator of regional brain tissue
oxygenation. The HbD and oxCCO r2 values are significantly associated with the thalamic Lac/NAA
ratio (p=0.018) which suggests that a highly coupled cerebral oxygenation and metabolism is indicative
of a more severe brain injury. The data show that in more severely injured neonates the magnitude
of the drop in oxCCO correlates highly with the magnitude of the HbD drop during systemic oxygen
desaturations. This suggests a tight coupling between the oxygen delivery and oxygen utilisation in brain
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injury.
It is interesting that the relationship between cerebral oxygenation and metabolism is related to brain
injury severity while their individual changes are not. This might be because the change in the NIRS sig-
nals is from an arbitrary baseline (i.e. the initial oxygenation/oxidation state of the haemoglobin/CCO is
unknown). Furthermore, the lack of relationship between the haemoglobin signals suggests that cerebral
autoregulation impairment does not differ between the mild and severe injury levels as blood oxygen
delivery is not changing with injury. Therefore, the metabolic CCO signal gives a better indication of
the level of brain injury.
Edwards et al. studied oxCCO during spontaneous desaturations in newborn infants with no evidence
of brain injury and found no relationship between oxCCO and SpO2 over small (3-11%) changes in SpO2
[70]. They concluded that cerebral haemodynamic changes more readily affect oxCCO than systemic
oxygenation which agrees with our findings. The UCL group has recorded NIRS-measured oxCCO in
controlled preclinical animal models of NE [12]. The recovery of the oxCCO signal after HIE was shown
to correlate with the nucleotide triphosphate to exchangeable phosphate pool ratio (NTP/epp) which is
a phosphorus (31P) MRS-measured biomarker of HIE and is related to Lac/NAA. This feasibility study
suggests that this finding is translatable from the piglet model to the human neonate.
There have been a few recent studies of HIE with NIRS [148, 156] (see also section 3.3.2). Dehaes et
al. found that CMRO2 and CBF were significantly lower in neonates during TH compared with post-TH
and age-matched controls. This finding agrees with Wintermark et al. who reported that newborns
with severe HIE had lower CBF and seemed to extract less oxygen. The reduction in metabolic rate
in the most severely asphyxiated newborns may reflect mechanisms to minimise further injury. This
could either be a manifestation or the cause of the underlying severity of HIE. Both of these studies
noticed elevated tissue oxygen saturation in newborns with more severe HIE which suggest that they
were extracting less oxygen.
8.4.1 Study Limitations
It should be noted that the NIRS measurements were taken from above the frontal lobe, whereas the
MRS-measured Lac/NAA was from the thalamus. Thalamic Lac/NAA was used as our marker of HIE
severity however it does not give the complete picture of the brain injury as the pathology is not always
global, so a subject with injury localised in the cortical grey matter may not present a high Lac/NAA
ratio in the uninjured thalamus. The cohort of survivors will be given a quantitative developmental
assessment at regular intervals up to 2 years of age as part of the UCLH follow-up programme. The
results of this test will provide a more accurate assessment of the clinical outcome than the Lac/NAA
measurement, so the results of this analysis should be compared with the test results when they are
available.
The spontaneous desaturations will have occurred for a variety of reasons (as discussed in earlier in
section 8.1). The changes in cerebral oxygenation and oxygen utilisation recorded will vary depending on
the cause of the desaturation, and other physiological changes such as CO2, HR and MABP which were
not corrected for in this study, but were generally of low values during the desaturations. CO2, HR and
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MABP have a large effect on the cerebral oxygenation and metabolism [197]. In Chapter 10, a method
that considers multiple systemic variables, canonical correlation analysis [239], is used to assess the data.
Monitoring changes in the other systemic measurements aids our understanding of the desaturations, yet
there is still heterogeneity across and within subjects. As a controlled challenge could not be performed
on these patients for ethical reasons, we are limited to focussing on spontaneously occurring events, of
which spontaneous hypoxias are the most common.
One of the largest limitations of the data is the heterogeneity of the patients’ injury, clinical treatment
and response to treatment. Patients receive different sedatives and medication (dependent on their
clinical needs) which may affect cerebral metabolism and blood flow. The different days of life over
which this analysis is performed may be a confounding factor as the brain response to hypoxia will
change as the injury evolves, matures and is treated. These factors can confuse the results regarding the
relationship between brain injury and cerebral haemodynamic and metabolic changes. Future analyses
should try to limit the number of differing variables in order to eliminate some of these confounding
factors. The differences between the days of measurements and treatments (i.e. during or post-TH)
should also be investigated as the relationship may alter as injury and treatment progress.
The method of assessing the desaturation based on magnitude change may not be representative
of the data. A physiological lag might be expected between the arterial oxygenation changes and the
cerebral oxygenation and metabolic changes. This analysis does not account for this and could be
misleading, especially for oxCCO changes; a delay between an arterial reduction of oxygen and cerebral
oxCCO decrease would be predicted as cerebral tissue oxygenation must reduce before it will impact
upon metabolism. Perhaps those infants who show the largest changes in oxCCO are already at oxygen-
limited states, so small changes in oxygen cause quicker and larger reductions of the oxCCO. This may
also explain why the strongest relationship came from oxCCO and HbD as it could be expected that
there is less temporal difference between cerebral oxygenation and cerebral metabolism, as opposed to
arterial oxygenation and cerebral metabolism.
8.5 Summary
The relationship between cerebral oxygenation and metabolism was found to be stronger in infants with
more severe HIE injury. This suggests that more severe injury is more dependent on oxygen, or that it
has less capacity to buffer changes in oxygenation. The relationship between arterial oxygenation and
metabolism was not significant, which suggests that arterial oxygenation may not be an ideal monitor
of oxygen levels in the brain.
Chapter 9
Cerebral Oxygenation and
Cytochrome-C-Oxidase Dynamics in
Spontaneous Hypoxia in HIE Infants
This Chapter expands upon the work of the previous chapter to investigate the haemodynamic and
metabolic cerebral response to spontaneous hypoxia in more depth. In Chapter 8 a correlation was
found between severe brain injury and a tight coupling between cerebral oxygen and metabolism. In
order to investigate the cerebral NIRS signals in more detail, the dynamics of the changes during hypoxia
are examined in this chapter.
9.1 Introduction
The results in the previous chapter suggests that the way that the cerebral metabolism reacts to changes
in oxygenation can indicate injury severity. The analysis looked at the magnitude of the cerebral changes
but did not examine the relationship throughout hypoxia which is also interesting and could inform on
cerebral injury. Furthermore, there is concern from doctors in neonatal intensive care over the safety of
low oxygen saturation levels [240] but there is little evidence to give guidance over where the threshold
saturation level lies. Cerebral broadband NIRS-measured oxCCO can provide an indication of changes
in tissue oxygen availability. At the point where there is no oxygen available, CCO will be completely
reduced, therefore, there should be a threshold at which oxCCO will reduce no further, indicating com-
plete tissue hypoxia. The opportunity to study tissue hypoxia arises during spontaneous desaturations;
particularly the dynamics of the changes during desaturation are observed in order to understand the
nature of oxygenation within the brain. The relationship between vascular oxygen delivery and tissue
oxygen consumption may provide light on the limits of safe oxygen saturations i.e. answering the question
‘What is a safe systemic saturation level for babies with HIE?’.
Adult studies of hypoxemia have not seen a threshold in the oxCCO relationship with oxygen satura-
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tion (see Figure 9.1) [60]. One study reported a linear correlation between oxCCO and cerebral oxygen
delivery during the oxygen desaturations, but did not find a relationship between oxCCO and HbD [50].
It is possible that the lack of threshold observed is because the saturation cannot be safely and ethically
brought low enough to reach full CCO reduction in volunteers.
A biphasic relationship in oxCCO change with ATP production has been seen in a piglet model of
HI [12] (see Figure 9.2). The authors interpret the decreased oxCCO as impairment of the ETC, which
in turn results in failure of ATP production through ATP synthase (see section 4.2 for background).
The threshold point in the double-linear fit of the data has been interpreted as the point at which
ATP manufacture is almost completely suppressed. Furthermore, at this point over 60% of the eventual
reduction of oxCCO has occurred suggesting that the majority of the reduction in oxCCO occurs during
the period where ATP manufacture via ATP synthase declines.
Figure 9.1: Group data of the time courses of oxCCO measured by the detectors 2.0, 2.5, 3.0 and 3.5cm
away from the light source denoted, respectively, as det 2.0, det 2.5, det 3.0, and det 3.5. The averages
are based on the 15 volunteers that participated in a hypoxia challenge. Taken from [60].
Another porcine study of hypoxia has shown a threshold in the oxCCO response (see Figure 8.1)
in that as HbO2 decreases initially there is no change in oxCCO, but there is then a point at which
the redox state suddenly reduces. The authors postulate that this change is caused when metabolism
becomes oxygen limited.
Banaji et al. predicted how the oxCCO signal should respond during an oxygen desaturation using
a mathematical model of brain circulation and energy metabolism [197]. During hypoxia in a healthy,
‘normal’ brain there is an approximately linear relationship with HbO2. When the metabolic rate and
cerebral blood flow is lowered, however, the relationship becomes biphasic. This work shows that the
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Figure 9.2: (a) NTP/epp plotted against change in oxCCO during HI (different symbols for individual
piglets). The relationship between NTP/epp and oxCCO is similar for all piglets but for low NTP/epp
the oxCCO distribution clearly separates. (b) An example of a double-linear fit of an individual piglet.
A large proportion of NTP comes from ATP so it can be assumed the the changes in NTP/epp here
predominantly reflect ATP. Taken from [12].
relationship between oxCCO and HbD could depend on the neurological health of the brain; a biphasic
change in oxCCO during hypoxia has been hypothesised and observed in animal models.
9.1.1 Aim
The hypothesis is that the cerebral metabolism will have a different (i.e. non-linear) response to that
of the haemoglobin signals (i.e. linear) during hypoxia. Specifically, this study investigates whether this
is true in the injured neonatal brain. The aim of this section is to answer the questions: ‘What is the
oxCCO response to hypoxia?’ and ‘Is the oxCCO response dependent on the level of brain injury?’
9.2 Method
9.2.1 Data Analysis
Data were collected per Chapter 6. For this study, only data sections which had full systemic data
recorded (SpO2, MABP, PaCO2, PaO2, RR and HR) were considered to ensure that there was full
information of the systemic physiology during the event. All data processing was done in MATLAB
2013b (Mathworks, USA) with a custom built, semi-automated script. The data recorded for each
infant was scrutinised and any drop in arterial oxygen saturation from ‘normal’ levels (defined as 95%
or above) to below 85% was selected as an hypoxic ‘event’. This criteria is more well defined than that
in the previous chapter (Chapter 8) to improve consistency across the events (ensuring they begin at
normoxia) and to ensure that the events are causing cerebral hypoxia (dropping to below 85% which
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is the saturation at which clinical intervention is required). If there were no desaturations fitting this
description across the data recorded in an infant, then that infant was removed from this analysis.
For each hypoxic event the start time and nadir time were selected manually from the SpO2 data
(see example in Figure 9.3); the start time was defined as the time at which the SpO2 decreased from
baseline and the nadir time was first time during the desaturation that the SpO2 reached a minimum
stationary point. The NIRS variables were normalised to 0µM at the start time. As each event has
a different duration from the start of desaturation to the minimum point, the time between start time
and nadir time was split into ten epochs. The mean value of each of the systemic and cerebral NIRS
variables was found across each epoch until the nadir time. The mean baseline was calculated across the
10 seconds preceding the desaturation start time.
9.2.2 Statistical Analysis
The desaturation events were grouped into babies with mild and severe injury based on the Lac/NAA
ratio from the MRS scan; Lac/NAA of 0.3 or greater was considered a severe injury. The mean and
standard error across the groups were calculated for each variable at each epoch. The epochs are split as
such: epoch 1 = 10 seconds baseline, epoch 2 = start of desaturation, epochs 3-12 = desaturation period,
epoch 13 = nadir of desaturation. NIRS data are normalised to 0µM at the start of the desaturation
(epoch 2). The significance of the difference between the group NIRS variables and baseline was assessed
using a paired Student’s t-test for each epoch during the desaturation (epochs 3-13) for both mild and
severe groups. A t-test (unpaired) was also performed to test the difference between the mild and severe
groups at each epoch for all variables. A p-value of 0.05 or less was considered statistically significant.
The data were also grouped per day of life to assess the changing relationship with the progression of
injury and treatment.
The relationship between the SpO2 and each of the NIRS variables between baseline and nadir was
plotted for each group. The oxCCO signals were also plotted against the cerebral haemoglobin signals
to assess the relationship between the oxygenation and metabolism in the brain.
9.3 Results
Table 9.1 shows the infants included in this analysis (and the reason why an infant was not included, if
not), the number of events recorded per infant and the day of life on which those events were recorded.
An eligible desaturation event was identified in 17 out of 29 subjects with full data recorded, of these 7
infants had severe injury and 10 were female. The mean birth weight was 3.3±0.7kg and the mean GA
was 39±1 weeks.
A total of 48 events were identified (see examples of such events in section 6.5): 15 from the severe
injury group and 33 from the mild injury group. The average desaturation period occurred over 152±94
seconds, with a range from 22 to 455 seconds. The events were recorded from days 1, 2, 3, 4 and 5 of
life.
An example, from subject 15, is shown in Figure 9.3 (a) where a large fall in arterial oxygen induces
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Figure 9.3: Example of an SpO2 desaturation from subject 15 (a) and corresponding changes in NIRS
chromophores (b). The change in HbO2 and HHb with SpO2 is linear (c) whereas the change in oxCCO
shows a biphasic relationship (d).
a decrease in HbO2 and corresponding increase in HHb (Figure 9.3 (b)). When plotted against SpO2
in Figure 9.3 (c) it is clear that this is a linear response between SpO2 and the haemoglobin signals.
However, the oxCCO drops rapidly but then reaches a threshold; here CCO has a biphasic relationship
with SpO2 (Figure 9.3 (d)).
The group mean arterial saturation changes of the mild and severe groups split into epochs are shown
in Figure 9.4, the mean changes in each group appear similar and there were no statistical differences
between them. The mean nadir of SpO2 was 62.8±23.4%.
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Figure 9.4: Mean desaturation for mild and severe groups in epochs. Error bars show the standard error
of the mean. There were no statistical differences between the group means at each epoch.
9.3.1 Systemic Variation
The changes in each of the measured systemic variables during the SpO2 desaturation are shown in
Figures 9.5, 9.6, 9.7, 9.8 and 9.9. In order to ensure that the events are as close to pure hypoxia as
possible, only events in which the other measurements remained stable were chosen, hence, there were
almost no variation in these measurements; the only statistically significant change from the start of
desaturation occurred in the PaCO2 signal in the mild injury group.
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Figure 9.5: Mean change in MABP during desaturation for mild and severe groups in epochs. Error
bars show the standard error of the mean. There were no statistically significant changes from start of
desaturation. There were no statistical differences between the group means at each epoch.
Figure 9.6: Mean change in PaCO2 during desaturation for mild and severe groups split into tenths either
side of nadir. Error bars show the standard error of the mean. The statistically significant changes from
the start of desaturation are displayed as asterisks. There were no statistical differences between the
group means at each epoch.
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Figure 9.7: Mean change in PaO2 during desaturation for mild and severe groups in epochs. Error bars
show the standard error of the mean. There were no significant changes from start of desaturation.
There were no statistical differences between the group means at each epoch.
Figure 9.8: Mean change in RR during desaturation for mild and severe groups split in epochs. Error
bars show the standard error of the mean. There were no significant changes from start of desaturation
nor statistical difference between the group means at each epoch.
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Figure 9.9: Mean change in HR during desaturation for mild and severe groups split in epochs. Error
bars show the standard error of the mean. No significant change from start of desaturation nor statistical
difference between the group means at each epoch.
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9.3.2 Group NIRS Changes during Desaturation
The mean changes in the NIRS variables during the desaturation are shown in Figures 9.10, 9.11, 9.12
and 9.13. The increase in HHb and decrease in HbD were significantly different from the baseline
immediately (by the first epoch from the start) in both groups and both hemispheres. The HbO2 decrease
was significant immediately in the mild injury group (both hemispheres) but was slightly delayed in the
severe injury group. The HbT change was immediate in both groups on the right side of the brain, but
very delayed in the left. The oxCCO decrease from baseline has a different pattern to the haemoglobins;
in the mild injury group there were less epoch with statistically significant reduction from the baseline.
There was no difference between the injury groups per epoch in the haemoglobin signals, but there
was difference in the oxCCO signals between the two injury severity groups from the ninth epoch until
the nadir.
The mean changes in the NIRS variables at the nadir of SpO2 are: -4.2±4.8µM for HbO2, 5.8±5.1µM
for HHb, -10.1±9.5µM for HbD, 1.7±2.4µM for HbT and -0.4±1.2µM for oxCCO for the left side, and
-3.4±4.4µM for HbO2, 5.1±4.9µM for HHb, -8.6±8.8µM for HbD, 1.7±3.1µM for HbT and -0.5±1.5µM
for oxCCO for the right side.
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Figure 9.10: Mean cerebral response of left side to desaturation for mild and severe groups in epochs.
Note that oxCCO signal is scaled by a factor of 10 for visibility. Error bars show the standard error of
the mean. Asterisks represent statistical significance from the start of desaturation period (epoch 2) to
the nadir (covering epochs 3-13). There were no statistical differences between the group means for any
of the signals.
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Figure 9.11: Mean cerebral response of right hand side desaturation for mild and severe groups in epochs.
Note that oxCCO signal is scaled by a factor of 10 for visibility. Error bars show the standard error of
the mean. Asterisks represent statistical significance from the start of desaturation period (epoch 2) to
the nadir (covering epochs 3-13). Triangles represent statistical differences between the group means at
each epoch; there was no statistical difference between the group means for the haemoglobin signals.
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Figure 9.12: Mean cerebral response of left side to desaturation for mild and severe groups in epochs.
Note that oxCCO signal is scaled by a factor of 10 for visibility. Error bars show the standard error of
the mean. Asterisks represent statistical significance from the start of desaturation period (epoch 2) to
the nadir (covering epochs 3-13). There were no statistical differences between the group means for any
of the signals.
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Figure 9.13: Mean cerebral response of right hand side desaturation for mild and severe groups in epochs.
Note that oxCCO signal is scaled by a factor of 10 for visibility. Error bars show the standard error of
the mean. Asterisks represent statistical significance from the start of desaturation period (epoch 2) to
the nadir (covering epochs 3-13). Triangles represent statistical differences between the group means at
each epoch; there was no statistical difference between the group means for the haemoglobin signals.
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9.3.3 Relation of Cerebral Oxygenation and SpO2
The cerebral broadband NIRS haemodynamic measurements are plotted against SpO2 in Figures 9.14 to
9.21. The relationships between SpO2 and each of the haemoglobin signals are linear and the magnitudes
of change are similar on each side of the brain. There is no significant difference between the mild and
severe groups.
Figure 9.14: Changes in left mean HbO2 against SpO2 during desaturation for mild and severe groups
in epochs. Error bars show the standard error of the mean.
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Figure 9.15: Changes in right mean HbO2 against SpO2 during desaturation for mild and severe groups
in epochs. Error bars show the standard error of the mean.
Figure 9.16: Changes in left mean HHb against SpO2 during desaturation for mild and severe groups in
epochs. Error bars show the standard error of the mean.
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Figure 9.17: Changes in right mean HHb against SpO2 during desaturation for mild and severe groups
in epochs. Error bars show the standard error of the mean.
Figure 9.18: Changes in left mean HbT against SpO2 during desaturation for mild and severe groups in
epochs. Error bars show the standard error of the mean.
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Figure 9.19: Changes in right mean HbT against SpO2 during desaturation for mild and severe groups
in epochs. Error bars show the standard error of the mean.
Figure 9.20: Changes in left mean HbD against SpO2 during desaturation for mild and severe groups in
epochs. Error bars show the standard error of the mean.
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Figure 9.21: Changes in right mean HbD against SpO2 during desaturation for mild and severe groups
in epochs. Error bars show the standard error of the mean.
9.3.4 Relation of Cerebral Metabolism and SpO2
The cerebral broadband NIRS metabolic measurements are plotted against SpO2 in Figures 9.22 and
9.23. Unlike the relationships between SpO2 and the haemoglobin signals, the oxCCO relationships are
not linear and there is laterality between the hemispheres; there is a bigger decrease in the signal from
the right hemisphere. The oxCCO signals dropped linearly with oxygenation initially and then reaches
a plateau. The plateaus in oxCCO for the left side are ∼-0.3µM and ∼-0.6µM for the mild and severe
groups, respectively; and for the right side are ∼-0.2µM and ∼-1µM for the mild and severe groups,
respectively.
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Figure 9.22: Changes in left mean oxCCO against SpO2 during desaturation for mild and severe groups
in epochs. Error bars show the standard error of the mean.
Figure 9.23: Changes in right mean oxCCO against SpO2 during desaturation for mild and severe groups
in epochs. Error bars show the standard error of the mean.
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9.3.5 Relation of Cerebral Oxygenation and Metabolism
The relationships between the cerebral haemoglobins and oxCCO are presented in Figures 9.24 to 9.27
for the left side (the right side displays similar trends so the graphs are not presented here). The severe
and mild groups both show approximately linear relationships between the oxCCO and the haemoglobins
signals, but the gradients are steeper in the severe group for oxCCO against HbO2, HHb, and HbD.
Figure 9.24: Mean left oxCCO against HbO2 during desaturation for mild and severe groups in epochs.
Error bars show the standard error of the mean.
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Figure 9.25: Mean left oxCCO against HHb during desaturation for mild and severe groups in epochs.
Error bars show the standard error of the mean.
Figure 9.26: Mean left oxCCO against HbD during desaturation for mild and severe groups in epochs.
Error bars show the standard error of the mean.
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Figure 9.27: Mean left oxCCO against HbT during desaturation for mild and severe groups in epochs.
Error bars show the standard error of the mean.
9.4 Discussion
The response of the haemoglobin signals to hypoxia in general was similar across both hemispheres and
in both injury severities. This suggests that brain injury severity does not impact on the performance of
the cerebral vasculature. Increases in HHb and HbT are expected during hypoxia, as are the decreases
seen in HbO2 and HbD [60]. The slopes of the haemodynamic changes were similar between the two
injury groups so the oxygen delivery changes during the desaturation were not affected by injury. The
linear changes with arterial saturation decrease shows that the arterial and cerebral oxygenation are
directly linked, which is expected.
It was seen that there were more epochs with significant oxCCO reduction from baseline in the more
severe injury babies and there was a statistically significant difference between the group oxCCO levels
in the epochs at the lower end of desaturation. These results suggest that cellular metabolism in the
more severe brain injury is more vulnerable to hypoxic events.
Measurements of oxCCO from the right hemisphere showed a larger drop in oxCCO than the left.
No asymmetry was observed in the haemoglobin signals. Interestingly, a study of hemispheric laterality
in term and preterm infants, with NIRS and DCS monitoring of rSO2 and CMRO2, found that there
was no difference in cerebral oxygenation but the CMRO2 was much higher on the right side [173]. This
might suggest that the larger drop in the oxCCO signal represents a drop from a higher metabolic state.
Non-linear changes in the oxCCO signal were observed with desaturation, and there were differences
in the responses between the injury severity groups, as suggested by the hypothesis. This was not seen
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in the changes in haemoglobin concentrations, so this suggests that the injury severity causes differences
at the metabolic level but not in the vascular response. On average, the oxCCO concentration decreased
with SpO2 initially before reaching a stable value. As there was a linear relationship between SpO2 and
the haemoglobin variables, the oxCCO relationship with haemoglobin is also non-linear.
However, this result does not match with those in the literature. An animal model of hypoxia saw the
oxCCO stable at the start of desaturation and then drop at a threshold [65], which is opposite behaviour
to these results. The difference may be due to differing physiology in the piglet, the influence of sedatives
or general anaesthesia used in the animal model, and/or the severity of the hypoxia which was much
more extreme in the animal model. Furthermore, the animal model was performed on an initially normal,
healthy brain which was also more mature than these patients. A human adult study of hypoxemia to
80% SpO2 did not see a plateau in the oxCCO signal [60]. The difference between these results could be
from a different concentration of CCO in the adult brain [194], the lack of injury in the adults, altered
physiology due sedation in the babies, or, most likely, that the adult studies did not reduce to a level of
hypoxia needed to reach the threshold.
One theory is that the more injured brain may be at a lower energetic state so the CCO has less
capacity to buffer changes in oxygen delivery. Therefore, the drop in oxCCO is larger. After more severe
injury the infant undergoes secondary energy failure so the metabolic rate will be reduced. Dehaes et al.
[156] and Wintermark et al. [148] both found, using different CMRO2 measurement techniques, lower
rates of metabolism in infants with HIE compared to healthy controls [156] and in severe HIE injury
compared to infants with moderate injury as determined by aEEG. Lemmers et al. [150] observed a
lower cerebral fractional tissue oxygen extraction in infants with adverse outcome. van Bel et al. [21]
saw a decrease in oxCCO with time from birth in more severe injury; this suggests that the rate of
metabolism is decreasing as the injury progresses. However, the patients in this study were not treated
with hypothermia which will alter the metabolism, therefore it is not wise to simply compare their study
result with the results in this chapter. These studies all give weight to the theory that there is a reduction
in cerebral metabolism after severe HIE.
The SpO2 level at which the oxCCO stabilises is significantly lower in the severe HIE group. Higher
cerebral saturation has been observed in more severe HIE injury previously [150–152], so it is possible
that in severe injury the reduction in arterial oxygenation does not lower cerebral oxygenation to a critical
level as quickly as the mild cases. Alternatively, it may be that the metabolism takes longer to buffer
the reduction in oxygen so, therefore, the threshold is noted at lower SpO2 values. This argument is
supported by the similar rates of oxCCO decrease on the left side in the first few percent SpO2 decrease
(see Figure 9.28), and the steeper gradient in the severe group oxCCO on the right side (see Figure 9.29).
9.5 Study Limitations and Further Work
There is more detail to be drawn from these data but a larger sample size is required before any conclu-
sions can be made.
As in Chapter 8, the heterogeneity of the neonates’ conditions, treatment and the cause of spontaneous
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hypoxia are confounding factors in this analysis. However, the selection of the events was more controlled
in this analysis to reduce the impact of the heterogeneity. Yet there are large differences in the NIRS
responses, this is particularly evident in oxCCO with some increases in concentration across hypoxia,
which are problematic for the grouping of data across infants.
The difference across days means that the group analysis using all days could be problematic. It
might be wise to remove day 4 data from the grouped analysis, and only group data recorded during TH
as hypothermia will have a large impact on cerebral metabolism. Furthermore, some infants included in
this study were given xenon on day 1 so this may affect the cerebral oxygenation and metabolism. See
below for preliminary analysis of the variations with postnatal age.
Also, the timing of the desaturation events is removed in this methodology; the events occurred over
periods ranging from 22 to 455 seconds and the physiology will react differently depending on the speed
of the desaturation. The wide variation in the timings is a confounding factor in this analysis.
Although every effort was taken to select events in which there was little or no change in other
systemic variables, there were significant changes in the average PaCO2 during the event period in the
mild injury group. Changes in PaCO2 will affect blood flow as it is a vasodilator. The data included
could be re-assessed to remove events which have systemic changes greater than a threshold value to
reduce their impact on the results.
The use of epochs to normalise the data has enabled analysis on heterogeneous hypoxia events, with
different timings and oxygenation decreases. However, as suggested above, this approach is flawed. It
might be more useful to bin the data in terms of the SpO2 level, as in the method suggested by Tachtsidis
et al. [46].
The differences in the recovery of the cerebral NIRS signals after desaturation is interesting but has
not yet been investigated; more work is needed in this area.
9.5.1 Biphasic Fitting
A preliminary attempt at analysing the biphasic oxCCO response has been undertaken. A double-linear
fit was applied to model any threshold change and the r2 was found for each linear fit. The fits were of
the following form:
y = ax+ b : x < A
y = cx+ d : x > A
(9.1)
where y is the NIRS variable, x is the SpO2 and A is the point of gradient change. In order to find the
point of change, A was increased for each step in x from x(4) to x(8) (so that there were a minimum of
4 data points on each side of the threshold), and the A with the maximum mean of the r2 was selected.
The fits are presented in Figures 9.28 and 9.29. The fits for the severe and mild group were best at
different SpO2 levels: the severe group SpO2 turning point (A) was at 81.8%, whereas the mild group
turning point was at 86.5%. More analysis is required to confirm the validity of this model.
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Figure 9.28: Changes in left mean oxCCO against SpO2 during desaturation for mild and severe groups
in epochs. Lines show two linear fits. Point of inflection is at 81.8% SpO2 for the severe group and 86.5%
for the mild group.
Figure 9.29: Changes in right mean oxCCO against SpO2 during desaturation for mild and severe groups
in epochs. Lines show two linear fits. Point of inflection is at 81.8% SpO2 for the severe group and 86.5%
for the mild group.
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9.5.2 Variation of Cerebral Metabolism and Oxygenation with Postnatal Age
Another preliminary analysis into the changes in the relationship with age has been performed. The SpO2
changes during the desaturation event per day from birth are shown in Figure 9.30. The relationship
between the cerebral signals and SpO2 per day are shown in Figures 9.31 to 9.33, as well as the relationship
between cerebral oxygenation and oxCCO in Figure 9.34.
There are differences in the haemoglobin and oxCCO responses to hypoxia on different days. The
HbO2 and HHb signals have the same shape but different magnitude changes across days. This is
explained by the difference in the SpO2 decreases (Figure 9.30). The oxCCO response is lowest on day
1 which might suggest that the brain is less able to buffer from a reduction in oxygenation in the early
hours of injury. Day 2 appears to have no oxCCO change during the event; however, the average SpO2
change is smallest on that day.
One important factor to consider is the use of hypothermia; TH occurs over days 1, 2 and 3 and the
rewarming period begins on day 4. The SpO2 change is lowest on day 4 but not significantly so. Due
to the low number of subjects it is not possible to draw conclusions from the differences in the day-wise
response, a larger sample is needed.
Figure 9.30: Mean SpO2 during desaturation for each day of life in epochs. Error bars show the standard
error of the mean.
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Figure 9.31: Mean HbO2 against mean SpO2 during desaturation for each day of life in epochs for left
and right sides. Error bars show the standard error of the mean.
Figure 9.32: Mean HHb against mean SpO2 during desaturation for each day of life in epochs for left
and right sides. Error bars show the standard error of the mean.
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Figure 9.33: Mean oxCCO against mean SpO2 during desaturation for each day of life in epochs for left
and right sides. Error bars show the standard error of the mean.
Figure 9.34: Mean oxCCO against mean HbD during desaturation for each day of life in epochs for left
and right sides. Error bars show the standard error of the mean.
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9.6 Summary
This analysis shows that the dependence of cerebral metabolism on SpO2 is related to the level of brain
injury, unlike the cerebral oxygenation; as in Chapter 8, the oxCCO appears more sensitive to the brain
injury state. Larger decreases in oxCCO are related to more severe HIE injury. This is likely to be
caused by lower cerebral metabolic rate in the more injured brain which is less able to buffer decreases
in tissue oxygenation.
However, a larger sample size is needed to improve the current analysis. In the preliminary analysis,
clear differences have emerged in the changes of NIRS variables during desaturation with age which must
be taken into account for future analysis.
Chapter 10
Interrelationship Between Cerebral
and Systemic Changes in HIE
Infants
The previous two chapters have looked at the cerebral NIRS signals in response to spontaneous oxy-
gen desaturations. This approach has shown that the relationship between cerebral oxygenation and
metabolism is affected by the state of the brain injury. However, these spontaneous decreases in oxygen
saturation have different causes and are usually accompanied by, or caused by, changes in other systemic
physiology, such as arterial blood pressure or PaCO2. In order to account for the combined effect of all
of the systemic variables, this chapter presents the use of a multivariate statistical analysis technique.
10.1 Introduction
The relationship between systemic and cerebral changes after HI injury can give information regarding
the status of cerebral autoregulation/vasoreactivity (see section 2.2). Cerebral autoregulation is typi-
cally evaluated by assessing the relationship between MABP and CBF, but CBF is difficult to measure
continuously in the NICU. Surrogate NIRS measures of CBF have been used in practice. It has been
shown that, under stable arterial saturation (SpO2 changes of less than 5%), changes in TOI and HbD
represent CBF changes [72]. Wong et al. found that cerebral autoregulation impairment, as measured
by high coherence between cerebral TOI and blood pressure, was strongly associated with subsequent
mortality in premature babies [72].
CYRIL provides an indication of cerebral metabolism (via oxCCO) as well as oxygenation, so in this
chapter a multivariate statistical technique is used to assess the relationship between all of the cerebral
variables and the systemic physiology in order to assess both cerebral autoregulation and the impact of
systemic physiology on cerebral metabolism. The hypothesis is that more severe brain injury will be
accompanied by an impairment of cerebral autoregulatory effects, so there will be a stronger correlation
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between the cerebral and systemic signals.
10.1.1 Canonical Correlation Analysis
Canonical correlation analysis (CCA) is a multivariate statistical method that can draw relationships
between multiple independent and multiple dependent variables. It can be considered an extension to
multiple regression, which measures the ability of multiple independent variables to predict a single de-
pendent variable using a linear combination of the independent variables. Canonical correlation predicts
multiple dependent variables from multiple independent variables [241, 242].
The general form of canonical analysis is:
Y1 + Y2 + ...+ Yn = X1 +X2 + ...+Xn (10.1)
which relates one group of variables, Y , to another, X [241]. The key terms to understand the
concepts and terminology of CCA are described below.
Independent and Dependent Canonical Variates
CCA uses the linear combination of the independent and dependent variable sets (X and Y ) to create
the independent and dependent canonical variates (there is no mathematical difference between the
independent and dependent data sets). These form a single canonical variate pair. The number of
canonical variate pairs produced depends on the smallest number of variables in either set. For instance,
if there were four independent variables and six dependent variables, four canonical variate pairs would
be formed.
Canonical Weights
The canonical weights are a set of values that describe the contribution of each variable in a set to its
respective canonical variate. These weights will vary for different canonical variate pairs so that the first
set of weights maximises the correlation between the independent and dependent canonical variates in
the first pair. The next set of canonical weights would then maximise the correlation between canonical
variates in the second pair based on the residual variance not explained by the first variate pair and so
on for the remaining variate pairs.
Canonical Correlation Coefficients
The independent and dependent canonical variate in a pair can be inter-correlated to produce the canoni-
cal correlation coefficient. This quantity is maximised by the canonical weights so that the first canonical
variate pair will possess the most canonical correlation. Subsequent variate pairs will have lower canonical
correlations as more variate pairs form.
CCA looks for a linear transformation of the variables in the independent and dependent data sets
in such a way that the correlation between the generated canonical variates is maximised. This does not
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imply that the canonical weights represent a measure of the influence on the dependent dataset of the
corresponding variable in the independent dataset. In addition, the canonical correlation coefficients only
measure the explained variability between canonical variates. Therefore, conclusions cannot be drawn
based on these two parameters [243].
Independent and Dependent Loading Coefficients
Loading coefficients are expressed as a value between −1 and +1 as the linear correlation between a
variable and its respective canonical variate on the same side, and should not be confused with canonical
weight. For example, an independent loading coefficient is the linear correlation between an independent
variable and an independent canonical variate.
Independent and Dependent Cross-Loading Coefficients
The independent and dependent canonical variates can also be used to draw linear correlations with
individual variables of the opposite set, also expressed as values between −1 and +1. For example,
the first independent canonical variate can be correlated with any one of the dependent variables. The
resulting linear correlation is called the first independent cross-loading coefficient. Likewise, a linear
correlation between the first dependent canonical variate and with any one of the independent variables
is the first dependent cross-loading coefficient.
The loading and cross-loading coefficients can be used in order to draw conclusion about the rela-
tionship between variables in the dependent and independent data sets [243].
Redundancy Indices and Sum of Redundancy Index
The redundancy index of a dependent canonical variate is the product of the squared canonical correlation
and the mean squared dependent loading coefficients. This gives the proportion of variance in the
dependent variable set that can be explained by a single independent canonical variate. To derive the
proportion of variance in the dependent variable set that can be explained by the independent variable set,
redundancy indices for all variate pairs are summed, producing the sum of redundancy index [241, 242].
Simply, the sum of the redundancy index gives a measure of how strongly the variables in the independent
data set are related to the corresponding canonical variates in the dependent data set (analogous to r in
Pearson correlation).
10.1.2 Aim
The hypothesis is that the nature of the changes in cerebral oxygenation and metabolism, measured by
broadband NIRS, in response to systemic changes will indicate brain injury severity. Cerebral autoreg-
ulation has been shown to break down in cases of brain injury and become pressure-passive; therefore
changes in systemic physiology will cause changes in the brain. To test this, CCA is used to estimate the
strength of the relationship between the changes in the brain (cerebral NIRS signals) and the changes in
the body (systemic signals).
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Note
This Chapter contains work presented in a paper to be published in the Advances in Experimental
Medicine and Biology (currently in press), which can be found in in Appendix B.
10.2 Method
10.2.1 Data Analysis
Data were collected and processed as described in Chapter 6. Data analysis was carried out in MATLAB
(Mathworks, USA) and Excel (Microsoft, USA).
For consistency this analysis was applied to data sets recorded on postnatal day 3. Day 3 was chosen
because the most data were recorded on this day (at the time of analysis, April 2014). Also it is the
final day of hypothermia and so the therapeutic effects of cooling will have occurred, and the infants
are normally stable throughout the day (unlike day 4 when rewarming occurs, as the infant will be in a
different state at the beginning and end of the day). A period of 3 hours where the NIRS and systemic
data are stable was selected for CCA. This period should contain no large events (e.g. spontaneous
desaturations, BP decreases) or artefacts. The aim is to observe natural oscillations in the signals;
events in one variable rather than another are likely to increase the dependency of the other data set on
that variable. A time period of 3 hours was chosen as it is long enough to observe slow-wave oscillations,
but it is short enough to avoid artefacts which are more likely to occur in longer segments of data 1.
Furthermore, if dynamic changes were occurring then CCA would need to be performed on a shorter
time scale as the analysis over large changes will not be valid as large changes can disrupt the inherent
nature of the relationships.
For the CCA analysis, the signals were grouped into ‘cerebral’ (HbO2, HHb and oxCCO, for both
left and right sides) and ‘systemic’ sets (MABP, SpO2, HR, RR, PaCO2 and PaO2). Patients without
complete systemic data sets were excluded from this analysis. The CCA was performed using the
MATLAB function ‘canoncorr’. The first step of CCA is to form linear combinations of the variables in
each data set. Then the correlation between each group of variables is used to assess the dependency of
the cerebral signals on the systemic signals. All CCA terms as described in section 10.1 were calculated
and the results were compared with the severity of the injury which was assessed by MRS-measured
Lac/NAA.
10.2.2 Statistical Analysis
The CCA scores for the sum of redundancies, first dependent and independent cross-loading coefficients
of each variable per infant were plotted against Lac/NAA to assess the correlations with injury. This was
1This analysis decision was made in April 2014 when there were only 13 data sets recorded, at this point most studies
occurred for many hours per day so a period of 3 hours was common. The studies from November 2014 were shorter
because it was decided to collect data over 3-4 hours per day to reduce the time that the optodes are on the head (see
Table 6.1). Hence it is more difficult to find a stable 3 hour period in these data.
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done for each of the systemic variables as well as the NIRS variables, to find out whether their influence
over the brain is related to brain injury. For the NIRS chromophores the mean of the left and right
cross-loading coefficients was found. The Pearson’s coefficient r was used to assess the linear correlation
between cross-loading coefficients and Lac/NAA. The median of the dependent cross-loading coefficients
was found for mild (Lac/NAA<0.3) and severe (Lac/NAA>0.3) injury groups. As the data were found
not to be normally distributed, the median and Kruskal-Wallis tests were used to assess the significance
of differences between the groups. The level of statistical significance was set at p<0.05. The sensitivity
and specificity of the CCA scores to predict injury classification was also evaluated and plotted using
receiver operating characteristic (ROC) curves. ROC curves are created by plotting the true positive
rate against the false positive rate at various threshold settings.
10.3 Results
In 14 of the 29 patients with HIE, a period of 3 hours fitting the criteria was found and CCA was
successfully performed. Figure 10.1 shows an example of the data recorded for one infant. Table 10.1
shows the babies that were included in this study. However, most of these 14 infants were treated with
xenon in the first 72 hours (normally on day 1) so the other 3 were excluded from the analysis as the
effects of xenon on the cerebral regulation is unknown and having a mix of those treated with and without
xenon is likely to confound the results. Therefore, 11 infants remained in this analysis: severe injury n =
6, mild injury n = 5; female = 6, male = 5. All infants were born at term gestation (mean 39±1 weeks),
and were of normal birth weight (mean 3.1±0.6 kg).
10.3.1 Sum of the Redundancy Index
The average sum of the redundancy index was 0.65±0.14. The individual sum of redundancy indices
plotted against the Lac/NAA is shown in Figure 10.2. There is no relationship between the sum of the
redundancy indices and the level of injury as measured by Lac/NAA.
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Table 10.1: Table of infants eligible for CCA analysis and reasons for ineligibility. ‘Y’ means CCA
analysis was performed, ‘Y (xenon)’ means that CCA analysis was performed but was excluded due
to treatment with xenon, ‘not 3 hours data’ means that there was no data recorded that was clear of
significant systemic events or had low number of artefacts for a continuous three hour period.
CYRIL Injury CCA Analysis?
2 HIE Y
3 HIE Y
4 HIE Y (xenon)
5 Stroke not HIE
6 HIE Y
7 HIE Y
8 HIE Y
9 HIE Y
10 HIE missing systemic data
11 HIE Y
12 HIE Y
13 HIE Y
14 HIE Y (xenon)
15 HIE Y
16 HIE not 3 hours data
17 HIE Y
18 HIE not 3 hours data
19 HIE not 3 hours data
20 HIE Y (xenon)
21 HIE missing systemic data
22 HIE (no data) no systemic data
23 HIE (no data) no data
24 HIE (no data) no data
25 HIE not 3 hours data
26 HIE not 3 hours data
27 Preterm not HIE
28 HIE+PPHN not 3 hours data
29 HIE+head trauma+seizures no MRS
30 HIE not 3 hours data
31 HIE missing systemic data
32 Stroke not HIE
33 HIE not 3 hours data
34 Seizures not HIE
35 HIE not 3 hours data
36 Seizures not HIE
37 HIE not 3 hours data
38 IVH not HIE
TOTAL HIE = 28 11
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Figure 10.1: Example of cerebral and systemic signals measured on day 3 for infant 14.
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Figure 10.2: Sum of the redundancy indices against Lac/NAA as measured by MRS.
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10.3.2 NIRS Cross-Loading Coefficients
The CCA analysis showed that each of the cerebral signals could be in part explained by the systemic
physiological variations; the HbO2 signal had a mean cross-loading coefficient of 0.55±0.20 which means
that 55% of the HbO2 signal could be explained by systemic variations, the HHb and oxCCO mean CCA
scores were 0.59±0.23 and 0.58±0.18 respectively. The cross-loading coefficient scores for each cerebral
variable were grouped into mild and severe injury categories and are shown in Figure 10.3. There is no
statistical difference between the mild and severely injured groups in the dependency of either HbO2 or
HHb on the systemic signals (p = 0.62 and 0.32 respectively). However, the infants with severe injury
showed significantly (p = 0.04) higher oxCCO dependency (median = 0.74) than those with mild injury
(median = 0.49). Note that the outlier in the severe injury group dependency of oxCCO has a Lac/NAA
of 0.35 which is the lowest of the severe group. Neurodevelopmental tests at 18 months will determine
whether this infant did have a poor outcome as predicted by MRS.
The cerebral NIRS cross-loading coefficients are plotted against Lac/NAA in Figures 10.4 to 10.6.
The cross-loading coefficients for HbO2 and oxCCO have positive correlations with injury, but only the
HbO2 coefficients have a significant correlation (r=0.65, p=0.03). However, despite the linear correlation,
the HbO2 coefficients do not separate the mild and severe injuries (this is seen in Figure 10.3) whereas
the oxCCO coefficients, which do not have a significant linear relationship (r = 0.58, p = 0.06), do
discriminate for injury.
ROC curves for the ability of the NIRS cross-loading coefficients to predict injury category are
presented in Figures 10.7 to 10.9. The area under the curve (AUC) for the ROC curves are: 0.67 for
HbO2 , 0.43 for HHb and 0.83 for oxCCO. An AUC of 1 is perfect and less than 0.5 is useless (i.e. odds
of 50%). The best predictor of injury is oxCCO; the infants with severe injury were identified by an
oxCCO cross-loading coefficient greater than 0.6 (sensitivity = 100%, specificity = 83%).
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Figure 10.3: CCA scores (cross-loading coefficients) for mild (n = 5) and severe (n = 6) groups for each
chromophore. Median score for each group is displayed as a line. Kruskal Wallis test found statistical
significance between the groups for oxCCO only: HbO2 p = 0.62, HHb p = 0.32 and oxCCO p = 0.04.
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Figure 10.4: CCA scores for relationship between HbO2 and systemic physiology against Lac/NAA as
measured by MRS. There is a significant linear relationship (r = 0.65, p = 0.03).
Figure 10.5: CCA scores for relationship between HHb and systemic physiology against Lac/NAA as
measured by MRS. There is no significant linear relationship (r = -0.11, p = 0.97).
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Figure 10.6: CCA scores for relationship between oxCCO and systemic physiology against Lac/NAA as
measured by MRS. There is no significant linear relationship (r = 0.58, p = 0.06).
Figure 10.7: ROC curve for the HbO2 cross-loading coefficient to predict injury classification. The area
under the curve (AUC) is 0.67.
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Figure 10.8: ROC curve for the HHb cross-loading coefficient to predict injury classification. The area
under the curve (AUC) is 0.43.
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Figure 10.9: ROC curve for oxCCO cross-loading coefficient to predict injury classification. The area
under the curve (AUC) is 0.87. For threshold of 0.6 there is a sensitivity of 100% and specificity of 83%.
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10.3.3 Systemic Cross-Loading Coefficients
The systemic cross-loading coefficients are plotted against Lac/NAA in Figures 10.10 to 10.16. These
assess whether the strength of the influence of each systemic variable on the brain is related to injury.
There is a positive correlation between the heart rate cross-loading coefficient and injury as measured
by MRS (r=0.62, p=0.04). The ROC curve is presented in Figure 10.13 and shows an AUC of 0.83.
There were no significant correlations between injury and any other systemic cross-loading coefficients
(p>0.05).
Figure 10.10: Lac/NAA against CCA scores for relationship between MABP and systemic physiology
(given by the cross-loading coefficients).
Figure 10.11: Lac/NAA against CCA scores for relationship between SpO2 and systemic physiology
(given by the cross-loading coefficients).
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Figure 10.12: Lac/NAA against CCA scores for relationship between HR and systemic physiology (given
by the cross-loading coefficients).There is a significant correlation (r = 0.62, p = 0.04).
Figure 10.13: ROC curve for HR cross-loading coefficient to predict injury classification. The area under
the curve (AUC) is 0.83. For a threshold of 0.75, there is a sensitivity of 83% and specificity of 100%.
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Figure 10.14: Lac/NAA against CCA scores for relationship between PaO2 and systemic physiology
(given by the cross-loading coefficients).
Figure 10.15: Lac/NAA against CCA scores for relationship between PaCO2 and systemic physiology
(given by the cross-loading coefficients).
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Figure 10.16: Lac/NAA against CCA scores for relationship between RR and systemic physiology (given
by the cross-loading coefficients).
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10.4 Discussion
CCA showed that broadband NIRS measured cerebral signals could be explained, in part, by changes in
the systemic physiology. This is expected because the systemic physiology should influence the cerebral
haemodynamics and metabolism even when cerebral autoregulation is unimpaired. Although the rela-
tionship between changes in HHb and systemic signals varied between the infants, the relationship was
not indicative of injury as measured by Lac/NAA. The relationship between HbO2 and systemic phys-
iology (represented by the HbO2 cross-loading coefficient) was linearly related to injury. This suggests
that an increased dependence of cerebral oxygen delivery on cerebral changes indicates more severe brain
injury. Cerebral autoregulation impairment could explain this result; a pressure-passive relationship will
cause a stronger correlation between the cerebral HbO2 and systemic physiology.
The oxCCO relationship with systemic physiology was able to predict injury, although there was not
a significant linear relationship; a high oxCCO dependency on the systemic signals indicated a negative
outcome. This difference from the HbO2 signal could be explained by the difference between the cerebral
vasculature and tissue oxygenation. A high vascular oxygenation dependency on systemic signals may
highlight which infants have impaired autoregulation, whereas the tissue oxygenation dependency on
systemic signals may indicate which infants are suffering at a cellular level from impaired autoregulation.
Another theory is that lower cellular energetics in the more injured brain would mean that CCO has less
capacity to buffer changes in oxygenation from systemic variations. It is possible that the differences in
the metabolic responses are due to changes in the brain leading to, or after, SEF in the severely injured
brain.
In Chapter 8, a strong linear correlation between changes in oxCCO and NIRS measured cerebral
oxygenation was found during systemic desaturation events in infants with severe HIE. This relationship
supports the findings in this study; in the more injured brain CCO is more readily affected by changes
in oxygen delivery and, therefore, would be more disturbed by systemic variations.
There was a strong relationship between the cross-loading coefficient of the heart rate and injury (see
Figure 10.12). There was a significant linear relationship but looking at the data there appears to be
a biphasic relationship between the HR influence on the cerebral NIRS signals and injury. The ROC
curve shows that the HR cross-loading coefficient is a good predictor of injury severity. In severe injury
the cerebral NIRS signals were strongly dependent on the heart rate. This could suggest that there is
an impairment of cerebral autoregulation (although not in the traditional sense of MABP relationship
with CBF) in more severe injury, as cerebral oxygenation and metabolism is being strongly affected
by changes in vascular output (from heart rate). It is interesting that there is no relationship between
MABP cross-loading coefficient and injury as this suggests that cerebral autoregulation is not injury
dependent. The systemic cross-loading coefficient results are clinically interesting; in situations where
cerebral monitoring is not available it is important to know which systemic signals are linked to the brain
to focus attention upon.
CCA has been performed in one other NIRS study [243], and shows promise as a useful tool that
can decode complex physiological interrelationships that cannot be explained with more simple models.
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However, the most significant relationships to be reported in this study have stemmed from the cross-
loading coefficients between a single variable and a group variate. This case can be investigated with
multiple linear regression which is less complex to understand and explain (which is important when
trying to communicate results to an audience). Therefore, multiple linear regression should be explored
as an alternative method to interpret the data.
10.4.1 Study Limitations
There are several limitations to this study to discuss. Firstly, this is a small sample size which is due to
the requirement for a long period of stable physiology (3 hours). The sample size needs to be increased
to draw any firm conclusions. Also, this analysis should be expanded to investigate the other days
monitored after birth to see if and how the cerebral/systemic relationship changes with time. This is
particularly important for postnatal day 1 when a prognosis is useful for deciding therapeutic options
for neuroprotection.
Secondly, the Lac/NAA is measured in the thalamus and at a later day than the NIRS measurements
which are from above the frontal lobe. The difference in location and timings mean that the Lac/NAA
measurement is not an ideal outcome marker; the 2 year developmental outcome will be a more robust
indicator to assess our results against.
Finally, the CCA technique assumes a linear relationship between all of the variables which may not be
true in this complex system and, moreover, CCA examines the relationship over a long window of time (3
hours) during which the complex interrelationship between the systemic and cerebral physiologies might
change. A moving CCA, which calculates the relationship between the cerebral and systemic signals
over short windows of time, could be employed to examine changes in the relationships with time. This
would be particularly important if there are any large spontaneous events analysed as these can change
the relationships.
10.5 Summary
Using a multimodal statistical tool has allowed the use of all of the multimodal data to untangle the
relationships between the systemic and cerebral physiology. This results show that the relationship
between cerebral metabolism and systemic physiology is able to predict the level of injury; a strong
systemic influence on the cerebral metabolic changes in the brain indicates severe injury. This result
is most probably related to failed autoregulatory capacity, but only the metabolic oxCCO signal can
discriminate brain injury. This is likely because an abnormal response caused by brain injury is located
at the cellular level rather than in the vasculature. The CCA technique is suitable to use on every data
set recorded and has the potential to be performed in real-time at the cotside.
Chapter 11
Further Work
This thesis has presented a lot of advances in bringing broadband NIRS into the clinical environment
and represents a big step in using CCO as a biomarker of brain injury. However, there are many issues
that need to be addressed and warrant further study. Additionally, from the broadband NIRS system
design, clinical application and data analysis methods presented in this thesis, further areas of research
have arisen. There are more general future prospects in the field of broadband NIRS. The further work
following on from this thesis, some of which is already in progress, is briefly discussed in this chapter.
11.1 NIRS System Design
There are many upgrades that can be made to the CYRIL system, some in terms of the user experience,
and others developing the data recorded.
11.1.1 CYRIL Software Updates
The CYRIL GUI, despite being used successfully by members of the clinical team, could be improved
to be more user-friendly. Commercial NIRS instruments do not normally display the raw optical data,
only the concentration changes calculated, which makes the instrument more simple to use. To come
in-line with this, and reduce complexity of the understanding, a clinical version of the software will be
designed. This could include warnings to alert the user when the optical spectrum is not optimal, for
example, if the spectral intensity is low, the alert could be “signal low - improve optode contact”, rather
than expecting the user to observe a change in the spectrum and act appropriately. Furthermore, the
spectral amplitude changes can give information regarding the optode contact with the tissue; large
changes in the overall amplitude could be detected and inform the user that the optodes attachment
might be weakening. These warnings regarding the optical data could be emailed in order to notify the
user and allow relevant action to be taken.
Finally, the LabVIEW program can be removed from the LabVIEW environment and run as a
standalone executable file. This has now been implemented and will make the software easier to use and
also easier to transfer to different devices.
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11.1.2 CYRIL Hardware Updates
CYRIL has recently (as of March 2016) had a hardware upgrade in order to record a larger portion of
the NIR spectrum. The diffraction grating (previously 830 grooves/mm) has been replaced with a 600
grooves/mm grating which gives a larger bandwidth (consequentially sacrificing wavelength resolution).
Furthermore, the CCD chip has been upgraded to one with 1340 pixels in the x-direction (previously 512
pixels) which also increases the bandwidth. The new CYRIL system, named CYRIL 2, has a bandwidth
of 465nm (503 to 968nm). The wider bandwidth will allow investigation of CCO features in the lower
wavelengths (see Figure 4.3 and this is discussed below in section 12.2), while still providing continued
measurements within the previously used wavelength range.
A new version of the system has recently begun development (as of April 2016) and will have more
channels (∼16 detectors) which will allow whole head coverage. Due to the clinical EEG electrodes
covering the head, it was only possible to record data from the frontal lobe in this study. This is a
limitation of CYRIL in its current form as HIE injury can be localised to specific areas of the brain.
Therefore, in order to obtain data from above the whole cortex, the CYRIL optodes and optode holders
need to be miniaturised and designed to integrate with the EEG. Having many sources and detectors over
the whole head will allow for diffuse optical topography (DOT) which has been successfully performed and
combined with EEG on neurologically compromised neonates before [140], but not with broadband NIRS.
A broadband NIRS DOT study has recently been performed on adults [63] and has identified spatial
differences in the occipital lobe on the oxCCO signal to the haemoglobins during optical stimulation.
The oxCCO and haemoglobin signals have different origins (cellular and vascular, respectively) so it
is possible that these early oxCCO DOT measurements are observing this phenomena. Images of the
oxCCO signal may be important in both functional activation and brain injury studies to locate origins
of neurological activity/damage.
CYRIL has been successful in the NICU but would benefit from having a smaller footprint. Space is
precious at the babies’ cotsides and a smaller system, one that could fit directly behind the cot, would
make NIRS studies much easier and more acceptable for the clinical team. A new miniature version
of CYRIL (named mini-CYRIL) has been developed in the Multimodal Spectroscopy Group using an
‘off-the-shelf’ micro spectrometer, the Ventana (Ocean Optics, USA). Figure 11.1 shows CYRIL and
mini-CYRIL next to a model baby for size comparison. This miniature system will be packed into a
small package and so will be truly portable and easily deployable in the clinical environment.
11.1.3 Additional Data Recovery
The raw attenuation data from broadband NIRS contains a lot more information about the chromophores
within the tissue. For example, the optical pathlength can be estimated using attenuation due to water
in the tissue [208]. The method exploits the fact that the differential pathlength exceeds the geometric
pathlength (i.e. the optode separation) by a factor (i.e. the DPF) and so the amplitudes of any spectral
features of absorbers present in the tissue will be enhanced by approximately the same amount. Since
water is present in tissue in concentrations that are often known (with accuracies of a few percent)
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Figure 11.1: (a) CYRIL on a babys frontal cortex. (b) mini-CYRIL performing one-channel reflectance
measurement on a babys frontal cortex; white light from HL2000 miniature light source(Ocean Optics,
USA) is filtered and transmitted to the frontal cortex via an optical fibre. The reflected light is collected
and focused into the Ventana through an identical detector fibre.
[244], and it has a weak absorption feature at 820nm, it is possible to calculate the water concentration
from the amplitude of this spectral feature. When this is divided by the known water concentration, an
estimate of the differential pathlength is obtained. This method can be, and has been, performed in post-
processing using the second differential of the attenuation spectrum at 820nm, with the data collected
by CYRIL and shows promise (see Figure 11.2), although it has not been verified fully. This method
could be implemented in real-time to improve the estimation of chromophore concentrations using a
changing pathlength. This will improve the accuracy of the changes in chromophore concentration which
is especially important in babies with changing pathophysiology which may change the nature of the
anatomy (e.g. through swelling or oedema) during the measurement period.
Additionally, the absolute concentration of HHb can also be calculated using a second differential
method [245]. This method utilises peaks in the HHb spectra between 710-780nm so a larger bandwidth
is necessary. This will be possible with CYRIL 2, described above, whose bandwidth is currently 503 to
968nm.
11.1.4 SRS Measurements of TOI
As discussed in section 7.3, the biggest problem that was not solved in this work was the recording of data
suitable for SRS calculation of TOI. The primary goal of this PhD was to record in-vivo measurements
of oxCCO so the calculation of TOI was beyond its scope. Work on TOI measurements with CYRIL is
now in progress.
The challenges encountered and the first attempts to understand the problems are described in section
7.3. Many other trials and modifications to the algorithm have been performed to attempt to find a
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Figure 11.2: Chromophore concentration changes (above) and pathlength calculated from second dif-
ferential of the water spectrum method (below) during a spontaneous hypoxia event in infant 59. The
average DPF is 2.78 which is lower than the expected DPF (4.99).
solution to this problem including:
• Reducing the number and combination of wavelengths
• Reducing the number and combination of source-detector separations
• Altering the h scaling factor
• Using the water extinction coefficients to resolve for the concentration of water
• Adjusting the optodes to find a ‘reasonable’ TOI in real-time using the Version 2 of the LabVIEW
software (section 5.3)
• Improving light shielding
• Designing new optode holders (see Figure 5.19) to improve optode contact with tissue
• Calculating TOI in all data sets in attempt to find a pattern.
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Yet none of these have produced any enlightenment on the underlying problems or have produced a
reliable TOI. It is most likely that poor/uneven optode-tissue contact is the source of the problem, but
it is difficult to improve this as the neonates are very delicate. A solution to the problem is to modify
the probe design to improve tissue-to-optode contact across all detectors and prevent the differences in
attenuation caused by it. The fibres used to couple the broadband light in and out of the tissue have a
high profile protruding from the tissue (9mm) which might result in poor contact as the height makes
them unstable; new designs with a lower profile (5mm) are currently being developed with the fibre
manufacturer (Loptek, Germany). It is also possible that light piping through the tape used to attach
the optodes to the tissue could affect the absolute attenuation measurement; this should be investigated.
An absolute measurement of tissue saturation would be especially useful in aiding interpretation of
the oxCCO signal. As discussed in section 9.4, the differences between the changes in the oxCCO signal
with injury may be due to the initial CCO state being more highly oxidised in more severe injury. TOI
would give insight to this problem as it will reveal the level of available oxygen in the tissue.
This analysis of TOI is important more generally and it will be beneficial to the NIRS community
to understand the problems with broadband SRS, as they may be concealed in SRS methods with a few
discrete wavelengths. This is vital as there are clinical trials occurring with this technology [133, 246],
while there are still problems with inter- and intra-subject differences [247–249].
11.1.5 Absolute Measurement of CCO
The most ambitious but also most exciting future prospect is a measurement of the absolute redox state of
CCO which would give information on the fraction of CCO that is oxidised/reduced. An absolute redox
measurement would allow the assessment of metabolic function in real-time. To achieve this we need
instruments and methodologies that can decouple light absorption and scattering from light attenuation,
as well as measuring light absorption at multiple specific wavelengths.
The Multimodal Spectroscopy Group has recently developed a time resolved NIRS system which has
16 wavelengths [228, 250]. This instrument can measure the absolute optical properties (absorption and
scattering) of the tissue at multiple wavelengths within 600nm and 1100nm and will, hence, be able to
resolve absolute tissue concentrations of the brain tissue chromophores. Absolute measurements of CCO
redox state have been performed in the visible region previously [251] but it will be a challenge to achieve
this within the NIR window to interrogate deeper into tissue.
11.2 Clinical Broadband NIRS
11.2.1 Present Study
One of the biggest problems with the data discussed in the thesis is the low numbers of subjects so there
is not enough statistical power to draw strong conclusions from the results. This is being rectified as
the Baby Brain Study is continuing to study more infants with CYRIL, and now CYRIL 2. To date, 63
infants have been studied (of which 50 were diagnosed with HIE). The present methods of data analysis
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will be expanded to include all of these, and future, subjects. To improve the statistical power of any
results, the sample size must be increased by an order of magnitude [252]. The data recorded must be
monitored to ensure that each of the first few days of life are equally sampled, and that infants studied
have a spread of injury severities.
Another area of improvement would be to use the actual outcome of neurodevelopment (as opposed
to the predictive marker, Lac/NAA). Collection of these data has begun; the developmental tests have
begun for this cohort of infants so the results from those will be included into the data analysis. This will
also reduce problems with injury localisation (as the Lac/NAA measurement is taken from a thalamic
voxel whereas the NIRS measurement occurs over the frontal cortex).
The three analysis methods presented have a high infant rejection level: Chapter 8 includes 22/28
subjects, Chapter 9 includes 17/28 subjects and Chapter 10 includes 11/28 subjects. A method that
does not depend on observing spontaneous events (such as hypoxias) or long periods of stability needs
to be found. The CCA analysis method, as all analyses of slow-wave oscillations, has this potential as
the window of time studied can be reduced to minimise rejection of data.
11.2.2 Analysis in Progress
There are three data analysis methods currently being performed on the data. The first is multiple
linear regression a technique that is similar to the CCA analysis presented in Chapter 10. The results
of CCA found that the relationship between the systemic and cerebral data as a whole was not injury-
dependent. However, the individual cerebral signals’ correlation with the systemic data were specific to
injury. This case (one variable correlated to multiple variables) can be modelled with multiple linear
regression analysis so this is currently being investigated.
The second project is to investigate differences between the left and right NIRS channels. In Chapter
9 it was noticed that the change in oxCCO was larger when measured over the right hemisphere. This
hemispheric laterality is interesting and requires further investigation. Therefore, using a laterality index
method (a technique commonly used in fMRI experiments to determine hemispheric dominance [253])
this is being investigated. It will be interesting to see if hemispheric asymmetry occurs in HIE and if it
is dependent on injury, gender and/or age. Regional and hemispheric asymmetries have been observed
in preterm and term newborns previously [173]. Laterality index analysis may facilitate early detection
of abnormalities.
The aim of the third analysis is to use the spontaneous hypoxias observed to estimate CBF. The
method is based on Fick’s principle which states that the rate of accumulation of a tracer in an organ
is equal to the difference between its rate of arrival and departure. If a substance is introduced into
the arterial blood, and the time of measurement is less than the transit time through an organ, the
tracer will not appear in the venous blood. Therefore, the flow can be measured as the ratio of tracer
accumulated to the quantity of tracer introduced. It is possible to use a change in HbD as a tracer; when
a sudden change in SpO2 occurs, the change in HbD represents a change in tracer concentration and
thus calculates CBF. So far the CBF has been calculated in 30 HIE infants. For some neonates the CBF
was also measured with arterial spin labelling MRI and a strong positive correlation was found between
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the NIRS- and MRI-measured CBF values (r2 = 0.96, p = 0.04). For infants with severe injury there
was an increase in CBF with age. The relationship between CBF and injury will be investigated further.
Additionally, with the CBF and absolute haemoglobin measurement (discussed above) it is possible to
calculate CMRO2 [254]; it will be especially interesting to compare another marker of metabolism with
injury and oxCCO.
11.2.3 Interesting Examples of Data
A couple of interesting phenomena that have been recorded are shown here. Analysis into these is nec-
essary and ongoing. A strong systemic oscillation was seen in a HIE infant with predicted poor outcome
by MRS and is shown in Figure 11.3. The large fluctuations in blood pressure are translated to big
oscillations in the cerebral NIRS data. This suggest that the infant has impaired cerebral autoregulation
and so the changes in MABP are directly affecting the CPP. Analysis of the relationship between HbD
and MABP will allow an assessment of autoregulation impairment; this could be done through CCA,
coherence analysis [72], HVx [165], or wavelet cross-correlation [255] to name a few methods.
Figure 11.3: Signals recorded on 15/12/14 17:34:57 on infant 31 showing strong blood pressure oscillation.
A sequence of seizures was observed in an infant with severe HI injury during the rewarming phase.
Figure 11.4 shows the aEEG trace and the corresponding systemic and cerebral changes. Interestingly,
during the five periods of seizure activity there was an increase in the concentration of oxCCO suggesting
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an increase in metabolism during the seizure. This is accompanied by a decrease in HbO2, SpO2 and an
increase in HHb, MABP and HR. This observation is discussed fully in a paper written by Dr Subhabrata
Mitra which is currently under review [256].
Figure 11.4: Signals recorded on infant 18 during a series of 5 seizures. Lines show start and end point
of each seizure as identified from the aEEG by a clinician who was blind to the NIRS data.
11.2.4 Future Studies
In my opinion, the ideal study of HIE using broadband NIRS-measured oxCCO would have a repeatable
controlled event (for example, a controlled change in inspired oxygen, or a functional challenge), age-
matched healthy infants to get baseline data, and be performed over the entire head. A repeatable
event would remove the current problem of the heterogeneity of the data. Functional activation studies
have found differences in the haemodynamic response between different grades of HIE injury [157] and
adult studies have seen a response from the oxCCO signal during activation [61]. Therefore, studying
the oxCCO functional response in HIE could provide an assessment of brain health. Including healthy
infants as controls will allow for a better assessment of our results so far. Although it is possible to
assess the data based on grades of severity, there is a gap in the data as the oxCCO signal has not
been studied in healthy babies before. These data are vital in the translation of oxCCO into the clinic.
Whole head NIRS and DOT would add another dimension to the analysis; by examining the cerebral
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haemodynamic and metabolic response over all areas of the cortex, it may be possible to identify areas
of injury. This could provide data analogous to the EEG, ultrasound and MRI images which are the
technologies currently used to identify lesions. Furthermore, comparison with more cerebral monitors,
such as EEG, will help validate the measurement as well as advancing knowledge.
The work presented here has focussed on assessing the oxCCO signal in order to find a biomarker
of injury; further work into the nature of the signal and its physiology is required to gain confidence.
Historically, CCO has been studied in infants under clinical care (see section 4.5), adults, both clinical
and healthy (see section 4.6), and animal models (see section 4.2). NIRS measurements of CCO have
not been performed on a healthy human neonate, which means that CCO pathophysiology in HIE is
difficult to separate from normal neonatal physiology. However, it is difficult to obtain oxCCO data on
healthy neonates as evoked responses would be necessary.
Some of the questions regarding the underlying physiology behind oxCCO in HIE may not be able to
be answered using human infants. Pre-clinical models of HIE (particularly piglet models) have been used
successfully for clinical trials (notably for hypothermia therapy [257]) and in the assessment of changes
in metabolites, including oxCCO [12]. Animal models of HIE that assess oxCCO in a translational
manner, for example, by performing a challenge that is repeatable in humans, could bring answers to
the physiological questions but also shed light on the usefulness of the measurement in the clinic.
The analysis performed has shown that the multimodal data analysis provides more information
relating to injury than any single signal, this reflects the use of multiple monitors in the NICU. Doctors
make their case for a diagnosis based on a number of parameters and, therefore, we should not be striving
for a complete diagnosis from one biomarker; a marker that can give information on part of the clinical
pathology is sufficient. It may be the relationship between cerebral metabolism (via oxCCO) and other
variables provides the best assessment of cerebral health.
Chapter 12
Conclusion
This, the final, chapter summarises the work presented in this PhD thesis and discusses the various results
obtained as a whole. Appendix B contains copies of the publications resulting from these analyses.
12.1 Summary
This PhD thesis describes the development and characterisation of a novel broadband NIRS system, its
use in the NICU and methods to interpret the data recorded.
12.1.1 Instrumentation
This work provides new instrumentation and data analysis tools to investigate cerebral physiology, partic-
ularly oxygenation and metabolism, in neonatal brain injury. The use of the broadband NIRS instrument
developed has been shown to be feasible in the NICU, and has been successfully used by physicists and
clinicians alike.
The optical signals recorded on infants with HIE were analysed for cross-talk between the signals.
The oxCCO signal was found to behave independently to the haemoglobin signals. This is of particular
importance for the measurement of oxCCO as there is historical controversy over its independence.
Furthermore, the results suggest that using broadband spectra to solve for the haemoglobin signals
without the oxCCO component could be erroneous.
12.1.2 Biomarker Analysis
The system has been used successfully in the NICU on fragile infants suffering from HIE. This is, to
my knowledge, the first time that oxCCO has been monitored with broadband NIRS on a neonatal
population. The system was designed carefully to ensure that it can perform in the challenging NICU
environment and collect data from neonates safely and comfortably for any length of time. However,
the system has limitations and the biggest challenge faced was the recording of data suitable for SRS
calculation of TOI.
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Due to the nature of the experiment (i.e. observational without any stimulus) and the NIRS data
(i.e. changes in concentration from an arbitrary baseline) it is not trivial to analyse the data to re-
cover meaningful information. Therefore in this thesis, three different data analysis methods have been
suggested and trialled. Two methods use spontaneous hypoxic events as stimuli and the other method
applies multivariate statistical analysis over long periods of stable physiology to assess the link between
the systemic and cerebral changes over time. All three methods have found a link with the oxCCO signal
and injury. These tools have been written as code and so can be applied to further data and also for
other studies.
The analysis has found some interesting results, however, the number of patients studied is low so
conclusions are speculative. In general it was found that HHb and HbO2 respond predictably despite
different levels of brain injury. There is little difference between the haemoglobin response to arterial
desaturation in mild and severe injury, which suggests that the vascular response is not affected by injury
level. This has one exception from the CCA analysis where the strength of the HbO2 dependency on
systemic physiology had a positive linear relationship with injury. The oxCCO response is less understood
but appears to be injury dependent:
• A strong linear oxCCO relationship with cerebral oxygenation (from HbD) during hypoxia was
correlated with injury
• A larger decrease in oxCCO during hypoxia was observed in the severe brain injury
• A strong relationship between oxCCO and systemic physiology predicted severe injury
The results are not conclusive but, with the exception of HbO2 in the CCA analysis, only oxCCO has
significant relationships with injury. This is interesting but it is not surprising that relationships with
injury were not found in the haemoglobins in general; as discussed in section 3.3.2, HIE has been studied
with NIRS for the past 25 years and there has not been any strong evidence that changes in HbO2
or HHb are related to injury. Therefore, the result that the metabolic marker, oxCCO, does have an
injury-dependent response is promising. This suggests that, if the experimental paradigm and analysis
are optimised, then CCO could be an early marker of brain injury in HIE and, potentially, other forms
of brain injury.
Chapters 8 and 9 present slightly different conclusions. In the analysis of the magnitude of change
across all desaturation events per baby (Chapter 8), there was a significant relationship between injury
and a strong relationship between HbD and oxCCO; in the analysis of the dynamics of the hypoxia, the
decrease in the oxCCO signals was larger in infants with more severe injury. There was no relationship
found between the magnitude of the oxCCO change and injury found in Chapter 8. This is likely caused
by the different selection processes; in Chapter 9 the hypoxic events were chosen to begin at normoxia
and to decrease more than 10%. Starting from normoxia increases homogeneity amongst the events and
the larger (10%) decrease is more likely to provoke a change in oxCCO.
The system and data recorded have also been used by medical doctors to answer other questions
regarding the cerebral changes occurring during HIE. Although not described in this thesis, the CYRIL
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data has been used to answer medical questions regarding the cerebral changes during stroke [219],
rewarming after TH [258] and seizures [256].
12.2 The Future of CCO in the NICU
Thus far, NIRS, and in particular NIRS-measured oxCCO, has remained a research tool rather than a
clinical one. There are many hurdles to overcome before oxCCO becomes a routine measurement, some
of which are described in Chapter 11. In summary, the hardware needs to be easy to use (both in terms
of the software and the application of the optodes), compact, and robust; the oxCCO signal needs to be
better understood, particularly in the healthy newborn; and the experimental method needs to take into
account the limitations of a differential measurement.
NIRS is relatively inexpensive so the cost is not an obstacle and also the signals are quite simple to
understand, especially when compared to EEG, which have become routine measurements in the NICU.
Therefore, providing this future work is undertaken, the broadband NIRS measurement of oxCCO has
strong potential as a cerebral monitor in the NICU, with applications beyond HIE, such as in stroke or
seizure monitoring.
12.3 Impact
Brain monitoring is a very important tool in critical intensive care as it can help guide diagnosis and
direct treatment. In particular, in neonatal intensive care, the brain is one of the most important organs
to protect because it is also the most vulnerable. An incremental improvement in clinical care could make
a huge impact on the patient’s quality of life, or in extreme cases, their chance of survival. Monitoring
brain metabolism continuously at the cotside could provide a unique view into the cerebral well-being.
The broadband NIRS measurement of oxCCO has the potential to provide this insight. This thesis has
demonstrated that the use of a broadband NIRS device is feasible within the NICU, and further, that
the oxCCO signal is linked to brain injury severity. CCO has promise as a biomarker of brain health
after HI injury, and could improve the lives of many babies and their families. There is more research
to be done but this body of work has shown that changes in oxCCO from broadband NIRS is a clinical
measurement with a hopeful future.
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SYNOPSIS 
 
Title 
The UCH Baby Brain Study: Near infrared monitoring and 3T 
MRI/MRS in Babies with Acute Brain Injury 
 
Acronym Baby Brain Study 
Chief Investigator 
Nicola J Robertson, Professor of Perinatal Neuroscience and 
Honorary Consultant Neonatologist, University College London 
Objectives 
In term and preterm infants with acute brain injury 
 
1.What is the predictive value of intracellular brain pH (pHi) for 2-
year outcome? (primary outcome) 
2. How does the bedside near Infrared spectroscopy (NIRS) 
derived measurement of cytochrome oxidase relate to: 
 brain pHi,  
 brain lactate/N-acetyl aspartate ratio(Lac/NAA),  
 brain perfusion using arterial spin labelling, and  
 venous oxygenation using T2-relaxation-uder-spin-tagging 
(TRUST)? 
3. How does brain 31P-MRS pHi relate to pHi measured by 
Chemical saturation transfer (CEST) ? 
4. How does pHi relate to other measures obtained by MR 
spectroscopy? 
5. What are the predictive values of cytochrome oxidase and MRS 
measures for information processing and short term memory over 
the first postnatal year 
Study Configuration Prospective cohort study 
Setting Neonatal unit and outpatient clinics  
Sample size estimate 
Prospective cohort study of 70 newborn babies born preterm and 
term with acute brain injury  
Number of 
participants 
70 babies 
Eligibility criteria 
All term and preterm babies born at UCH or transferred to UCH for 
treatment of acute brain injury without life threatening congenital 
malformations and considered likely to survive 
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Description of 
interventions 
Alongside routine continuous EEG, babies will be monitored using 
NIRS, and receive 1 MRI scan at 5-14 days. This MRI scan is 
carried out routinely in babies with acute brain injury and lasts 45-
50 minutes. In those infants who remain stable, we will continue 
the acquisition of sequences for a total scanning time of 90 mins. 
A range of neurobehavioural tests will be undertaken over the first 
2 years after discharge home 
Duration of study 5 years from February 2013 
Outcome measures 
 NIRS cytochrome oxidase measurement  
 EEG background activity and seizures 
 Brain intracellular pHi and metabolite ratios on phosphorus-31 
(31P) and proton (1H) MR Spectroscopy  
 Structural MRI scan 
 Brain perfusion using arterial spin labelling 
 Brain venous oxygenation using T2-relaxation-uder-spin-
tagging (TRUST) 
 Brain pHi measured using Chemical saturation transfer (CEST) 
imaging 
 Neurodevelopmental assessment Bayley Scale of Infant and 
Toddler Development -3rd edition (BSID-III) 
 
Statistical methods 
Data will be compared between subgroups and over time using 
appropriate categorical or continuous statistical methods. Linear 
regression will be used to adjust associations for confounding 
variables. Two statistical software packages will be used, SPSS 
and Stata in their most up to date version at the completion of the 
study. 
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Neuro-monitoring and 3T MRI/MRS in Babies with Acute Brain Injury 
 
BACKGROUND 
Neonatal encephalopathy 
Neonatal encephalopathy (NE) occurs in 1-2 per 1000 live term births in the UK – with a 
term birth rate of 750,000 births in the UK, the number of affected infants is estimated to 
be 750-1125 infants annually in the UK. There is an unmet need for objective, 
quantitative cerebral magnetic resonance (MR) markers of perinatal brain injury for 
clinical trials of neuroprotection; such markers will improve our understanding of the 
tissue response to injury and may expedite clinical translation of novel neuroprotectants.  
As adjunct neuroprotective therapies evolve, we need more accurate MR biomarkers 
that can detect earlier and more subtle changes in brain structure and function than 
before. We believe that phosphorus MR spectroscopy (31P MRS) combined with the 
other state-of the art imaging techniques (e.g. Chemical Exchange Saturation Transfer 
(CEST) imaging and brain perfusion) developed by the co-applicants will provide the 
detail needed to enhance our care of infants undergoing neuroprotection.  
Magnetic resonance imaging and spectroscopy 
UCL has been a world leader in cerebral MRS for over 30 years. The first ever “in man” 
31P MR brain spectrum was obtained by Prof Reynolds and Mr Ernest Cady (co-
applicant) at UCL in 1982 in an infant with NE (1); this and later studies (2,3) were 
significant landmarks in the understanding of neuroprotection for the newborn and 
demonstrating the existence of a therapeutic window after hypoxia-ischaemia (see 
Figure 1). In 2010, the National Institute of Health and Clinical Excellence (NICE) 
endorsed therapeutic hypothermia as standard care for infants with moderate to severe 
encephalopathy (4). Currently with this treatment, for every 7 infants treated with 
cooling, one will escape an adverse outcome (5). More work is on-going at UCL and 
elsewhere to develop adjunct therapies that can further improve outcomes.  
Surrogate outcome measures or biomarkers are important as their use can expedite the 
translation of new therapies to the clinic. In 2002, Robertson et al., demonstrated that 
brain intracellular pH (pHi) was alkaline following perinatal hypoxia-ischaemia and the 
extent of the alkalosis was associated with neurodevelopmental outcome and brain 
injury severity on conventional MR imaging (MRI) (6). Dr Kendall (co-applicant) 
demonstrated the importance of brain pHi in the rodent brain (7) and Prof Robertson 
has shown that manipulation of brain pHi with amiloride is neuroprotective in the 
newborn piglet (8). Brain pHi is thus likely to be an important marker of injury, but no 
studies have been done in babies since the work done by Robertson et al in 2002 (6).  
An exciting development is that now we have the opportunity to develop and validate 
31P MRS brain biomarkers relative to other sophisticated MR imaging techniques 
developed by Prof Golay. Recently Prof Golay has developed a novel MRI method, 
called GlucoCEST, currently in press in Nature Medicine (9). This method uses the 
principles of chemical exchange to provide information on glucose uptake. We here 
propose to adapt this technique to the measurement of pHi, through the base-catalyzed 
chemical exchange between amide protons and surrounding water in the brain (10). 
This new MRI technique is safe, as it is similar to conventional magnetization transfer 
MRI, but has never been used in newborns.  
UCLH is a regional referral centre for term NE, recruiting around 45 infants per year; all 
infants undergo MRI and proton MRS aged 5-10 days. We have a very successful MRI 
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service (led by Dr Giles Kendall and Prof N Robertson) using a Philips 3T multinuclear 
(i.e. including 31P) MR scanner. 
Near infrared spectroscopy 
 
Another very exciting technique for neuromonitoring is NIRS. It is portable and NIR light 
is safe. It can therefore be used to monitor critically ill patients who cannot be moved 
out of an intensive care environment. NIRS is highly sensitive to both haemoglobin 
concentration, oxygenation and oxygen utilisation and can therefore provide information 
of brain tissue function. Such a system is ideally suited to monitor the brain of patients 
both adults and neonates.  
 
The MultiModal Spectroscopy (MMS) group in the Biomedical Optics Research 
Laboratory (BORL) at UCL, lead by Dr. Ilias Tachtsidis, has developed novel optical 
instrumentation and methods to investigate brain oxygen utilisation and regulation, 
during systemic provocations in infants (11) and adults. Ilias has recently developed 
equipment and methodologies that allow simultaneous NIRS and MRI/MRS 
measurements (12) hence providing novel data on brain tissue haemodynamic patterns, 
oxygenation and mitochondrial metabolism (redox state of cytochrome-c-oxidase). 
 
Between 2004 and 2008 Dr Tachtsidis has used NIRS systems to characterise cerebral 
oxygen delivery and oxygen utilisation in different groups of adult patients. The study in 
eight TBI patients with traumatic brain injury (TBI) has demonstrated, for the first time, a 
correlation between the NIRS monitored oxCCO and the cerebral lactate pyruvate ratio 
(measured invasively with cerebral microdialysis) (13). This study confirms that oxCCO 
may be used as a surrogate marker of cellular oxygen metabolism and help identify 
treatment strategies in brain injured patients (such as hyperoxygenation). 
 
Recently Dr Tachtsidis have completed studies in over 50 volunteers in order to explore 
the applicability of NIRS to monitor brain tissue physiology and metabolism, suggesting 
that physiological challenges (such as hypercapnia and hyperoxia) can be used to 
increase cerebral oxygen metabolism (14,15). In a separate study, during controlled 
isocapnic hypoxia in healthy adults, estimated cerebral oxygen delivery and oxCCO 
were linearly correlated (16). Clearly the combination of brain tissue measurements of 
changes in haemoglobin concentration and intracellular oxCCO can identify 
relationships between brain tissue haemodynamics and tissue oxygen utilisation, which 
can be used to understand the coupling between tissue oxygenation and cell 
metabolism; while also helping us define thresholds for brain wellbeing. 
 
Dr Tachtsidis group in collaboration with Prof Nicola Robertson and Prof Xavier Golay 
have recently developed a novel methodology that combines spectroscopic data from 
broadband NIRS and magnetic resonance spectroscopy (MRS) that provides 
information on the brain vasculature haemodynamics, brain tissue oxygenation, brain 
tissue biochemistry and importantly mitochondrial metabolism. They completed a set of 
experiments investigating in a neonatal preclinical model brain metabolism during and 
following hypoxic-ischemia (HI) and demonstrated for the first time through the 
synchronous measurements of oxCCO (by broadband NIRS) and Lac/NAA (by 1H 
MRS) mitochondrial impairment following hypoxic-ischemia (12). It therefore is a 
potential clinical marker of the balance between mitochondrial oxygen delivery and 
utilization. 
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Outcome following neonatal encephalopathy 
 
Despite improvements in care for babies with encephalopathy and the introduction of 
therapeutic hypothermia, up to 40% of babies with moderate or severe encephalopathy 
will still die or have serious impairment at follow up. For survivors it is critically important 
that we identify babies who will develop disability in neuromotor or cognitive domains, 
as these are the two commonest outcomes.  We currently use a structured neurological 
examination and assessment of General Movements at term and 3 months of age to 
support early diagnosis, but there are no early indicators of cognitive impairments other 
than routine clinical developmental assessment, which is poorly predictive.   
 
Over the past year we have developed a range of infant assessment protocols for very 
preterm children over the first year (UCH Preterm Development Project [Funding 
SPARKS; Sponsor UCL 10/0312; REC approval NW London REC 2 10/H0720/80]).  
We would like now to extend these investigations to include this high-risk group using 
the same protocol at the same ages (preterms are assessed at post-term age 
equivalents).  This includes 3 visits at 3, 6 and 12 months timed to coincide with routine 
follow up evaluations.   
 
 
PLAN OF INVESTIGATION 
 
We will recruit a cohort of term and preterm infants at risk of acute brain injury. These 
infants might have a diagnosis of neonatal encephalopathy, seizures or require a clinical 
MRI study for any indication.  
 
These children will be recruited into a longitudinal follow-up study with routine 
neurodevelopmental assessment using the Bayley Scale of Infants and Toddler 
Development – 3rd edition (BSID – III) at 2 years. 
 
Term and preterm babies at risk of acute neurological injury admitted to the neonatal 
unit will be assessed by the clinical team. A member of the neuro-clinical research team 
will approach the parents for consent for entry into the extended neuromonitoring and 
neuroimaging study within the first 24h.  
 
It is routine for babies at risk of acute neurological injury to undergo EEG monitoring 
immediately after admission and stabilisation. Following the EEG application we will 
request consent for extended neuromonitoring using NIRS. This will involve an 
additional probe to be gently fixed to the side of the scalp and another small machine 
(NIRS system) to be beside the baby's cot. The NIRS monitoring will continue for up to 
5 days and can be done intermittently if the baby requires moving or during routine 
cranial ultrasound scanning. This technique is safe for the newborn as far as we know. 
The application of the probes on the scalp is similar to the EEG electrodes – part of the 
clinical care. 
 
Some infants who, after assessment with EEG, are eligible for entry into the TOBY 
Xenon study will have a further consent for entry into this study. We will make it clear 
that the MR imaging and spectroscopy (MRI/MRS) study is a routine part of the care of 
the baby whether he or she is eligible or ineligible for the TOBY Xenon study. What we 
are requesting in the extended neuromonitoring and neuroimaging study is a slightly 
longer period in the MRI scanner when the scan is done between day 5-14.  
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During the time the baby is in the neonatal intensive care unit, there will be a close 
contact between the nursing, clinical and research staff and the parents. Cranial 
ultrasound imaging and continuous EEG will occur as part of the routine care of the 
baby. The NIRS monitoring will continue alongside these routine investigations.  
 
One to two days before the MRI/MRS scan the clinical research team will discuss the 
consent for the extended imaging study. We will explain again that the routine scan time 
for both clinical or Toby Xenon scans is 45-50min and only if the baby remains settled 
and stable will be acquire more sequences up to 90 minutes time in the magnet.  
 
MRI/MRS assessment is routinely carried out on day 5-14 after birth in infants at risk of 
acute brain injury. At least one hour before the scan, a paediatrician and a nurse 
prepare the baby for the MRI according to our protocol.  We double check all the steps: 
safety checks, metal checks, noise protection and monitoring equipment in the MRI 
conditional Lammers Neonatal incubator. The fluid infusions for the MRI conditional 
Braun system are also prepared. All the babies are monitored throughout the scan with 
similar monitoring equipment to that used in the NICU. 
 
In ventilated babies we will continue their routine sedation (usually intravenous 
morphine). In non-ventilated inpatient babies, we will sedate for the MRI scan if 
necessary with Chloral Hydrate orally 50 mg/kg. This is already our current practice for 
most MR scans in babies with acute brain injury. 
 
If the baby is an outpatient, we prepare him as well at least one hour before the scan. 
We will try to avoid sedation if he goes to sleep through a feed-and-wrap technique. If 
we need to give sedation (Chloral Hydrate), we will need to keep the baby monitored 
until he's awake and he managed to do a good feed. 
 
In case of the baby being unstable in the scanner, there is a safety protocol in place. A 
resuscitation trolley and emergency equipment is in place adjacent to the 3T-MRI suite. 
At least one senior Registrar and a nurse or Advanced Nurse Neonatal Practitioner 
(ANNP) accompany the baby to and from the scanner and are present in the control 
room monitoring the baby throughout the scan. 
 
Parents are welcome to accompany their baby in the Lammers Incubator over to the 
MRI ante-room to see where the scan is going to take place, see the facilities, 
monitoring, etc. They will then be asked to wait in the waiting room until the scan is 
finished. 
 
If the baby wakes up, is unsettled or unstable, we will bring the baby out of the scanner 
and attend to the issue.  
 
If the baby becomes unsettled before the end of the clinical scan, we will try to settle 
him down to be able to complete the sequences that are necessary for clinical 
information.  
 
There are no specific risks for the newborn associated to the extra-sequences that this 
study involves as far as we know. The inconvenience is that the time of the scan 
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becomes slightly longer. If the baby wakes up during the extended scanner sequences, 
we will stop the scan and take the baby back to the neonatal unit. Parents will be kept 
informed at all times. 
 
We will collect all the data acquired clinically as well as the extra neuromonitoring and 
neuroimaging sequences and analyse these.  
 
Babies are routinely followed up and undergo assessment with Dr Angela Huertas-
Ceballos at 3, 6, 12 and 24 months each with a formal Bayley III assessment. At the 
infancy visits we will also evaluate the following outcomes in the BabyLab – based in 
the Clinical Research Facility on the ground floor of the EGA Wing adjacent to 
outpatients: 
 
Outcome Test Age (Corrected)  Examiner Time Location 
Neuropsychology  Visual attention test 3m + Psychologist 20min Baby Lab 
(Memory, attention, 
inhibition, planning 
and/or processing 
speed) 
ERP 6m + Psychologist 15 min Baby Lab 
Delayed-response task 6m + Psychologist 10 min Baby Lab 
A-not-B task 12m + Psychologist 5min Baby Lab 
Means-End task 12m + Psychologist 5min Baby Lab 
 Deferred Imitation task 12m + Psychologist 10min Baby Lab 
Language/motor skills Questionnaire 12m + Parent 20min Baby Lab 
 
Full details are included in the UCH PDP protocol (attached); please note this is a 
restricted set of assessments from the full BabyLab protocol. 
 
The primary outcome is the Bayley composite scores (in Language, Motor and 
Cognition) at two years We will record all this data anonymously and analyse the 
relation between the early NIRS, MRI and MRS biomarkers and outcome. In further 
work we will evaluate our new measures made in infancy against the 2-year outcomes 
to determine if we can improve the predictive value of the neonatally acquired 
biomarkers. 
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The routine scanning protocol will comprise:   
 
Sequence Approx time to acquire 
 
 High-resolution T1weighted 3D anatomical 
scan: MP-RAGE or other standard clinical acquisition for 
structural imaging 
6 minutes 
 T2w imaging anatomical scans: TSE or standard 
clinical acquisition for structural imaging 
7.5 – 15 minutes (single or 
multiple orientations) 
 Multi-direction Diffusion tensor-like imaging: 
standard clinical acquisition. Indices derived from DTI-like 
acquisition are thought to be sensitive to ischemia and to 
be correlated with outcome. 
6-8 minutes 
 Single voxel proton spectroscopy (PRESS): 
allows measurement of lactate in a small localised section 
of tissue. 
6-8 minutes 
 Additional positioning anatomical scans for MRS  1 minute 
 
The total time taken for this is around 40 minutes 
 
 
Additional sequences will include: 
 
Sequence Approx time to acquire 
 
 Localised Phosphorus (31P) MRS (ISIS): 
Measurements of energy metabolites and pH. 
12 min 
 Additional positioning anatomical scans for 31P 
MRS 
1 minute 
 Quantitative measurement of perfusion (ASL): 
standard sequence to measure brain perfusion and/or 
angiography to assess blood delivery to the brain. 
7-10 minutes 
 Quantitative measurement of oxygen extraction 
fraction (e.g. TRUST): assessment of oxygen 
metabolism 
8-10 minutes 
 Long and short T2 mobile proton exchange 
measurements (e.g. CEST): assessment of brain 
maturation (myelin), glucose metabolism and pH 
10-15 minutes 
 
The total time taken for this is around 45 mins 
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Feedback to parents:  All MRI/MRS scans and EEG traces are reported by a 
clinical radiologist/physicists/neurophysiologist respectively.  Feedback of relevant 
clinical information to parents occurs as part of the routine clinical care and is led by the 
attending neonatologist; this is recorded in the clinical case-record.  
 
Outputs: 
These data will be presented at national and international paediatric and 
radiological research meetings and written up for publication in peer-reviewed journals.  
 
Study written and electronic records 
 Each participant will be assigned a study identity code number, for use on all paper 
records, other study documents and the electronic database. The documents and 
database will also use the date of birth as a second identifier.  
 All written records will be treated as confidential documents and held securely in 
accordance with regulations. The investigator will make a separate confidential 
record of the participant’s name, date of birth, local hospital number or NHS number, 
and Participant Study Number, to permit identification of all participants enrolled in 
the study, for the purposes of later follow-up.  
 All paper forms will be completed using black ballpoint pen. Errors shall be lined out 
but not obliterated by using correction fluid and the correction inserted, initialled and 
dated. 
 The person completing each paper form shall sign and date each form. 
 
Quality assurance & audit  
Insurance and indemnity 
 University College London holds insurance against claims from participants for harm 
caused by their participation in this clinical study. Participants may be able to claim 
compensation if they can prove that UCL has been negligent. However, if this clinical 
study is being carried out in a hospital, the hospital continues to have a duty of care 
to the participant of the clinical study. University College London does not accept 
liability for any breach in the hospital’s duty of care, or any negligence on the part of 
hospital employees. This applies whether the hospital is an NHS Trust or otherwise. 
 Insurance and indemnity for clinical study participants and study staff is covered 
within the NHS Indemnity Arrangements for clinical negligence claims in the NHS, 
issued under cover of HSG (96)48. There are no special compensation 
arrangements, but study participants may have recourse through the NHS 
complaints procedures. 
 
Reporting Serious Unexpected Adverse Events 
 All Serious Unexpected Adverse Events to a research subject in the study must be 
reported immediately to the sponsor using the following email address research-
incidents@ucl.ac.uk. 
 A Serious Adverse Event: 
o Results in death  
o Is life Threatening  
o Requires Hospitalisation or prolongation of hospitalisation  
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o Results in persistent or significant disability or incapacity  
o Consists of a congenital anomaly or birth defect  
o Any other serious medical occurrence 
 Serious Adverse Events will be documented from the point of enrolment until the 
patient is exited from study. Information recorded and reported shall include 
o A description of the event  
o The date of event onset 
o The relatedness of the event to the procedure  
o The expectedness of the event  
o The outcome of the event  
o The date the event was first noticed by, or reported to the investigator 
 All ongoing Serious Adverse Events will be followed-up until the last study visit. 
 
Reporting Incidents 
 All incidents must be reported through the appropriate Trust incidents reporting 
system. Where no Trust is involved the incident should be reported by completing 
form at http://www.ucl.ac.uk/jro/postapproval 
 Where the study is being conducted at UCLH then the incidents should be reported 
through Datix.  
 An incident in a research study is:  
o Something that should not have happened OR 
o Something that should have happened but didn't , 
which significantly effects any of the following: 
 the rights and well being of the research subject  
 the scientific value of the study  
 the compliance of the study with all relevant legal rules or ethics 
guidance including the Data Protection Act and the Human Tissue Act 
 The reputation of UCL  
 
Conduct of the Study 
 Study conduct will be subject to systems audit for inclusion of essential documents; 
permissions to conduct the study; CVs of study staff and training received; local 
document control procedures; consent procedures and recruitment logs; adherence 
to procedures defined in the protocol (e.g. inclusion / exclusion criteria, timeliness of 
visits); and accountability of study materials.  
 Monitoring of study data shall include confirmation of informed consent; source data 
verification; data storage and data transfer procedures; local quality control checks 
and procedures, back-up and disaster recovery of any local databases and 
validation of data manipulation. The Study manager, or where required, a nominated 
designee of the Sponsor, shall carry out monitoring of study data as an ongoing 
activity.  
 Data will be effectively double entered using SPSS Data Entry continuous 
comparison techniques to ensure accurate electronic data records 
 Study data and evidence of monitoring and systems audits will be made available for 
inspection by the REC as required. 
 
Data Management and analysis 
 Access to all study documents is limited to the study personnel (see below) 
excepting that the CRF and all source documents will be made be available at all 
times for review by the Chief Investigator, Sponsor’s designee and inspection by 
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relevant regulatory authorities.  
 All study staff and investigators will endeavour to protect the rights of the study’s 
participants to privacy and informed consent, and will adhere to the Data Protection 
Act, 1998. The Assessment procedures will only collect the minimum required 
information for the purposes of the trial. All records will be held securely, in a locked 
room, and a locked cabinet. Access to the information will be limited to the trial staff 
and investigators and any relevant regulatory authorities. Computer held data 
including the study database will be held securely and password protected. All data 
will be stored on a secure dedicated web server. Access will be restricted by user 
identifiers and passwords (encrypted using a one way encryption method). 
 Information about the study in the participant’s medical records / hospital notes 
will be treated confidentially in the same way as all other confidential medical 
information. 
 A Neonatal Fellow and postdoctoral fellow (Physics and Bioengineering Dept), 
will carry out data analysis under supervision from the co-investigators.  Where 
off-line analysis of data is undertaken these data are managed anonymously 
using a unique study identifier.  Summary data are then returned to the main 
study database, which is again anonymised to maintain confidentiality. 
 Electronic data will be backed up every 24 hours to both local and remote media 
in encrypted format. 
 Data will be entered onto study forms and posted back to the study centre where 
they will be encoded for computer analysis using SPSS Data Entry and SPSS for 
Windows 
 Data will be analysed using appropriate categorical and continuous comparisons 
using SPSS and STATA statistical software packages.  Regression analyses will 
be performed. 
 Electronic data will be archived at the completion of the study for a period of 25 
years to allow for later follow up of this unique population. Paper records will be 
kept for 10 years after the last assessment is carried out on the population. 
 
 
24.1.13_ v4.0  
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Project ID: 13/0013 
REC Ref: 13/LO/0225 
 
Patient Identification 
Number for this trial:  __________________ 
 
Name of Researcher: Professor Nicola J Robertson   
 
 
THE UCH BABY BRAIN STUDY 
 
FORM FOR PARENTAL CONSENT 
Please initial  
each box  
1. I confirm that I have read and understand the information sheet dated 15 March 2013 (version. 
4.1) for the above study. I have had the opportunity to consider the information, ask questions 
 
and have had these answered satisfactorily.   
2. I understand that the participation of my baby in this study (NIRS monitoring and extra sequences 
during MRI/MRS) is independent from other studies and I can withdraw from  
 
any of them separately at any time.  
3. I understand that the participation of my baby is voluntary and that I am free to withdraw at any 
time without giving any reason, without the medical care or legal rights of my baby being  
 
affected.  
4. I understand that relevant sections of my baby’s medical notes and data collected during the 
study may be looked at by individuals from regulatory authorities or from the NHS Trust from the  
 
sponsor’s representative from UCL, where it is relevant to my baby taking part in this research. I 
give permission for these individuals to have access to my baby’s records. 
 
5. I agree that the NIRS, MRI/MRS and other MR sequences data, video recordings and EEG tracings 
can be used for further research and teaching purposes; the material will always be used  
 
anonymously and my child will not be identifiable in the data used.  
6. I understand that I will be invited back for 3 assessments over the first year after my child was 
born and a last assessment will be performed at 2 years of age. 
 
  
  
7. I agree that my baby may take part in the above study.  
 
 
Name of Child: 
 
  
Name of Parent:  Date Signature 
 
Name of Person taking consent: Date Signature  
 
3 copies:  one to be retained by parent, one placed in the clinical notes and one retained by the study office. 
Version 4.1 15 March 2013 
Neonatal Services 
NNU Medical Secretaries 
2
nd
 Floor, North Wing 
250 Euston Road 
London NW1 2PG 
 
Telephone: 0203 456 7890 
Consultants’ PA: 0203 447 8094 
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